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 Astrocytes are a major glial cell type that is crucial for the health and maintenance of the 
Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, 
neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) 
are components of the astrocyte cytoskeleton that support many of these functions in healthy 
individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to 
accumulation and aggregation. These processes are thought to contribute to disease pathogenesis 
of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of 
pharmacological tools to modulate their assembly and disassembly states. Moreover, the 
mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In 
this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in 
astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) 
and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the 
mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post-
translational modifications (PTMs) in this process. In Chapter 1, I introduce fundamental 
information about astrocyte biology, IF proteins and their functions, and specific roles of 
astrocyte IFs in neurodegenerative diseases. In Chapter 2, I present a method to simultaneously 
isolate mammalian IFs from several tissues in order to examine in vivo-relevant PTMs. In 
Chapter 3, I demonstrate the utility of an image-based small molecule screen to identify IF-
 iv 
selective compounds. In Chapter 4, I reveal mechanistic information in AxD and identify a 
specific PTM as a new marker of AxD severity. In Chapter 5, I describe IF proteostasis in neural 
progenitor cells and astrocytes from GAN patients. The work in Chapters 4 and 5 involves 
development of clinically relevant tools for these diseases using induced pluripotent stem cells 
(iPSCs) and CRISPR/Cas9 gene editing technology. In Chapter 6, I summarize and contextualize 
the results of this work, acknowledge the limitations and remaining gaps, and highlight key 
future directions. In summary, these studies provide new methods, tools, disease models, and 
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CHAPTER 1: INTRODUCTION 
1.1 Astrocytes are crucial for the development and maintenance of the Central Nervous 
System  
 
  Astrocytes are one of the major glial cell-types of the mammalian Central Nervous 
System (CNS). Originally called astrocytes because of their striking star-like appearance1, the 
current understanding of astrocyte morphology and identity has become even more complex. 
Astrocytes are classified into many different subtypes based on morphology and brain region, but 
the two major classes are fibrous and protoplasmic astrocytes of the white and grey matter, 
respectively2. Improved imaging techniques have revealed that astrocytes contain many more 
intricate processes than initially suspected, making them poised to survey their environment3,4. 
Astrocytes utilize their long and complex processes to communicate with nearly every cell type 
in the brain (neurons, microglia, oligodendrocytes, pericytes, endothelial cells) and often act as a 
bridge between cells, such as neurons and the vasculature5. Their myriad of cell-cell contacts 
underscores the crucial roles of astrocytes in most CNS functions, including formation and 
function of synapses6, synaptic plasticity7, neurogenesis8, ion and neurotransmitter homeostasis2, 
blood brain barrier formation9, and regulating cerebral blood flow5, among others. The structural 
and functional organization of astrocytes is closely tied to their cell-intrinsic functions as well as 
the ability to coordinate with other cells. Strikingly, a single human protoplasmic astrocyte can 
contact up to 2 million synapses while maintaining completely separate territories from its 
neighbors, so each astrocyte occupies largely its own unique microanatomical region3,4. Despite 
this apparent separation, astrocytes are connected in a syncytium to neighboring astrocytes via 
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gap junctions and are capable of coordination, such as propagation of calcium waves between 
cells10. This type of carefully controlled cell communication with diverse targets requires the 
guidance of a functional and specialized cytoskeleton.  
1.2 Importance of the cytoskeleton in astrocyte structure and function 
The cytoskeleton consists of three major filamentous systems – actin, intermediate 
filaments, and tubulin – as well as their associated proteins. Together, these cytoskeletal systems 
coordinate many fundamental cellular processes, including cell division, cell migration, 
differentiation, cell signaling, mechanotransduction, and maintenance of cell shape. Beyond 
these broad functions, the cytoskeleton is also involved in important astrocyte functions. For 
instance, astrocytes must maintain communication with other cells, such as neurons. The 
cytoskeleton structurally supports this by participating in regulation of cells shape11. Early 
evidence indicates that actin and tubulin are required for the astrocyte stellate shape12,13. 
Furthermore, the actin cytoskeleton localizes subcellularly to the fine perisynaptic astrocyte 
processes (PAPs) and is involved in monitoring and adapting the shape of PAPs in response to 
neuronal signals because it is required for PAP mobility11,14. Similarly, microtubules have been 
observed in perivascular astrocyte processes15. Additionally, the cytoskeleton actively facilitates 
astrocyte glutamate metabolism. In response to extracellular glutamate, astrocyte cell-surface 
expression of glutamate transporters is increased by an actin polymerization dependent 
mechanism16. While actin and tubulin provide essential functions to all cells and also aid in 
astrocyte-specific functions, intermediate filaments offer abundant cell type-specific isoforms 
that allow for customized refinement of astrocyte-specific functions.  
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1.3 Intermediate filaments are cell type-specific components of the cell cytoskeleton 
Intermediate filaments (IFs) are a major component of the cytoskeleton of metazoan 
cells. The IF gene family consists of over 70 genes that are expressed in a cell type- and 
differentiation-specific manner17. IFs are divided into six different types based on subcellular 
localization, sequence homology, net acidic charge, and assembly properties17,18. Nuclear IFs are 
classified as Type V and include Lamin A, Lamin C, Lamin B1, and Lamin B219. The bulk of the 
IF family is encoded by cytoplasmic IFs, which are grouped into types I-IV and VI18. Types I 
and II include the acidic and basic keratins of epithelial cells20. Type III includes vimentin, 
desmin, glial fibrillary acidic protein (GFAP), and peripherin, which are expressed in 
mesenchymal cells, muscle cells, astrocytes, and peripheral neurons, respectively 21. Type IV 
contains neurofilaments, nestin, and -internexin, which are expressed in neurons and neural 
progenitor cells18. Lastly, type VI IFs consist of the beaded filaments of the lens18.  
Regardless of their classification, IFs share unique structural and physical properties. All 
IF proteins have a conserved domain structure consisting of a central -helical rod domain that is 
flanked by N-terminal and C-terminal low complexity domains, which are called the head and 
tail, respectively22,23. Cytoplasmic IF proteins assemble into mature filaments through a step-
wise process whereby individual IF monomers either homo- or heterodimerize, and dimers 
associate in an anti-parallel orientation to form tetramers24. Eight tetramers combine laterally to 
form unit length filaments (ULFs). ULFs join together longitudinally to extend the filament, 
which undergoes radial compaction to achieve the classical 10 nm size that is “intermediate” 
between actin (5-7 nm) and tubulin (25 nm)24. This process is not dependent upon energy from 
nucleotides, such as ATP or GTP, and results in the formation of apolar filaments with unique 
visco-elastic properties compared to other cytoskeletal elements18,25. IF structures are 
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mechanically stable, yet amenable to reorganization in response to different stimuli. This 
property of IFs is strongly linked to their cell-protective properties, particularly under stress 
conditions26. 
Biochemically, IFs are highly insoluble and resistant to detergent extraction27,28. 
Additionally, IFs can have very long half-lives; for example, neurofilament that has a half-life of 
more than 2.5 months29. Remarkably, although IF structures provide cells with mechanical and 
structural integrity, they are dynamic and experience constant remodeling via both severing and 
annealing at the ends as wells as subunit exchange along the length of IF filaments30. IF 
dynamics are primarily achieved through post-translational modifications (PTMs). IFs are highly 
modified by phosphorylation, especially in the head and tail domains, which can affect solubility, 
assembly, subcellular localization, binding partners, and turnover31. These unique properties 
separate IFs from the other major filament networks of the cytoskeleton and contribute to their 
cellular functions.  
The classic and most widely appreciated function of IFs is their role in providing cells 
and tissues with mechanical integrity and resistance to physical strain32. This is exemplified by 
the phenotype of the keratin-14 knockout mice, which exhibit severe skin blistering upon loss of 
this IF that is normally expressed in the basal cells of the stratified epithelium33. IFs support the 
mechanical integrity of cells and tissues by affecting the stiffness of cells and by regulating cell-
cell and cell-environment interactions at desmosomes, hemidesmosomes, and focal 
adhesions18,32. However, as hinted by their dynamic properties, IFs are broadly involved in an 
array of non-mechanical cellular processes, including the cellular stress response, cell signaling, 
transcription, organization of the cellular space, cellular trafficking, and cell migration17,18.  
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IFs are critical players in the stress response, cellular signaling pathways, and 
transcription. Cells increase expression of IFs in response to multiple stressors, including 
heatshock, mechanical stress, aging, alcohol exposure, or infection26. Cellular stress can also 
affect post-translational modifications of IFs, particularly increasing phosphorylation31. It is 
hypothesized that IFs can act as a phosphate sponge to protect the cell from excess activity of 
stress kinases26,31. IF phosphorylation may also contribute directly to cellular signaling pathways 
by promoting binding to signaling components, such as the 14-3-3 family of adaptor proteins, 
which are involved in virtually all major cellular functions34. IFs regulate transcription indirectly 
through cellular signaling and also through direct mechanisms. For example, Keratin 8/Keratin 
18 bind to the cytoplasmic domain of Tumor Necrosis Factor Receptor 2 (TNFR2) and suppress 
TNF-induced Jun NH2-terminal kinase (JNK) signaling35. Nuclear IFs regulate gene expression 
and cell differentiation by controlling the spatial organization of DNA and promoting 
heterochromatin epigenetic modifications36. More recently, it was shown that the cytoplasmic IF 
Keratin 17 can enter the nucleus and regulate gene expression of inflammatory and proliferation 
related genes37,38. In fact, many other cytoplasmic IFs contain one or more nuclear localization 
signals, providing a new possible connection between the cytoplasm and the nucleus that could 
be exploited for diverse cell signaling mechanisms39.  
IFs organize the intracellular space through their interactions with other cytoskeletal 
components and organelles18. For instance, cytoplasmic IFs associate with the nuclear membrane 
through Plectin, an IF linker protein, which binds to Nesprin-3, a member of the Linker of 
Nucleoskeleton Cytoskeleton (LINC) complex40. Cytoplasmic IFs form a cage around the 
nucleus and mediate actin-driven nuclear positioning, a process that is important during cell 
migration and development41. Additionally, cytoplasmic IFs interact with many other organelles, 
 6 
including mitochondria, the Golgi apparatus, and several components of the protein degradation 
pathway, including lysosomes, autophagosomes, and the proteasome18. The function of IF 
interactions with mitochondria may be to serve as an anchor for docking of mitochondria since 
loss of vimentin leads to increased mitochondrial motility and disrupted ATP production42. 
Similarly, evidence from vimentin knockout cell lines indicates that cytoplasmic IFs also dock 
lysosomes and regulate their motility and positioning43. Cytoplasmic IFs are broadly involved in 
cellular trafficking through their interactions with the Golgi apparatus and various exocytic and 
endocytic pathway members44. These interactions contribute to protein trafficking to the 
membrane as well as endocytosis in a very cell type-specific manner44.  
IFs also play an important but context-dependent role in cell migration, which is highly 
dependent upon the particular IF protein and the cellular context. Motile and invasive cells tend 
to upregulate the Type III IF, vimentin, which promotes cell migration in various ways, such as 
cell shape changes, loss of cell-cell contacts, and increased turnover of focal adhesions45-47. Loss 
of vimentin attenuates cell migration in fibroblasts46,48, leukocytes49, astrocytes50, and various 
cancer cells51-53. Vimentin participates in cell migration through interactions with microtubules, 
actin filaments, and focal adhesions. Vimentin filaments aid in maintenance of cell polarity 
during directed cell migration by providing a stable pattern for microtubules54. In support of this, 
vimentin expression positively correlated with persistence time in migration of cancer cells55. 
Additionally, vimentin interacts with actin directly and indirectly through plectin to promote cell 
migration56,57. Transverse actin arcs drive retrograde movement of small vimentin particles to the 
perinuclear space in a plectin-dependent manner where it is suggested that vimentin reciprocally 
restricts retrograde actin flow58,59. Also in concert with actin and plectin, IFs promote focal 
adhesion localization and turnover during collective astrocyte migration, which restricts traction 
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forces to the leading edge of the leader cells60. This multitude of interactions of IFs that is 
involved with cell migration can vary depending on the cell type, as evidenced by the complex 
roles of epithelial keratins in cell migration61. As with cell migration, all of the general IF 
functions and interactions described here depend upon the particular IF protein and the cellular 
context.  
1.4 Introducing the astrocyte cytoplasmic IFs: vimentin, nestin, synemin, and GFAP 
One of the unique aspects of cytoplasmic IFs compared to other cytoskeletal filaments is 
the wide variety of IF genes that are expressed differentially depending on the cell type. Even 
within cell types, unique combinations of IFs are expressed in specific contexts, such as 
development, injury and aging. Astrocytes exemplify this context dependent IF expression.  
Throughout development, astrocytes express four different IFs: vimentin, nestin, 
synemin, and glial fibrillary acidic protein (GFAP)62. Both astrocytes and neurons arise from 
radial glia progenitor cells, which reside in the ventricular zone and express vimentin, nestin and 
synemin63,64. As astrocytes mature, expression of these early IFs typically decreases and is 
replaced by GFAP65. However, while vimentin expression decreases to undetectable levels in 
most astrocytes66, it remains expressed in some astrocytes, such as the Bergmann glia of the 
cerebellum67. While GFAP is considered a classical marker of mature astrocytes, it is appropriate 
to mention that not all astrocytes express GFAP. Further, non-astrocytic cells have been reported 
to express GFAP, including peripheral glia (non-myelinating Schwann cells68 and enteric glia69), 
neurogenic stem cells in the subventricular zone (SVZ) of the lateral ventricles70 and of the 
subgranular layer (SGL) of the hippocampus71 and even speculatively in some cells outside of 
the nervous system (e.g. liver stellate cells72). Likewise, the other astrocytic IFs are not restricted 
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solely to astrocytes since vimentin is expressed in most mesenchymal cells, synemin is expressed 
in muscle cells, and nestin is expressed in neuroepithelial and other adult stem cells73,74. 
When the CNS suffers injury, astrocytes undergo a process called astrocyte reactivity, 
which is generally characterized by hypertrophy of cell branches, increased proliferation, and 
gene expression changes, notably the upregulation of IF genes75,76. Reactive astrocytes express a 
mixture of immature and mature IF proteins, including nestin, vimentin, GFAP, and sometimes 
synemin, but the proportion and timing of gene expression is especially sensitive to the type of 
CNS insult77-79. Interestingly, it was recently reported that aging astrocytes undergo 
transcriptional changes similar to neurotoxic reactive astrocytes80, and IF protein and gene 
expression increase in the aging brain, among other tissues81. 
1.5 The role of astrocytic IFs in development and physiology 
The cell type and developmental specificity of IFs suggests that individual family 
members may hold unique properties and functions that are required in different tissue contexts. 
The function of the astrocytic IF cytoskeleton has been investigated using mutant mouse models, 
which harbor global deletions in vimentin, Gfap, or nestin82-88. Mice lacking vimentin, Gfap, or 
both genes are viable, develop and reproduce normally, and have no gross defects in CNS 
morphology82-86,89. Structurally, GFAP and vimentin can homo-polymerize or co-polymerize 
with each other. Since nestin and synemin cannot homo-polymerize with themselves or co-
polymerize with each other, the vimentin/Gfap double KO animals lack all astrocytic 
cytoplasmic IF filaments90. Importantly, these mice do not upregulate other cytoplasmic IFs to 
compensate for the loss of one or two IF genes, making them a valuable model to tease out 
specific astrocytic IF functions. Although vimentin, Gfap, and vimentin/Gfap double knockout 
(KO) mice do not display major CNS morphological or behavioral deficits, there are subtle 
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defects that reveal astrocytic IF functions in each of these animal models, which are summarized 
in Table 1. Importantly, while some functions are shared amongst all astrocytic IFs, others are 
unique to one particular IF. Of all the astrocytic IFs, only GFAP is uniquely restricted largely to 
astrocytes, making it an especially interesting candidate to execute astrocyte-specific functions65.  
One of the major functions of IFs is to maintain the mechanical integrity of cells and 
tissues. Under basal conditions, the brain does not experience much mechanical strain since it is 
encased within the skull and cerebral spinal fluid. However, astrocytic IFs are still important for 
providing protection from mechanical stressors. In a model of traumatic brain injury, Gfap KO 
mice were hypersensitive to cervical spinal cord injury91. In the retina, vimentin/Gfap KO mice 
had decreased resistance to severe mechanical challenge92. These studies indicate that GFAP and 
vimentin are critical for protecting the CNS from mechanical forces. Nevertheless, astrocytic IFs 
play several non-mechanical roles in the CNS.    
Astrocytic IFs promote cell migration. Primary astrocytes from vimentin KO, Gfap KO, 
and double KO mice displayed decreased individual cell migration speed50. In agreement with 
this, knockdown of nestin, vimentin, and Gfap in primary rat astrocytes revealed a decrease in 
collective cell migration speed60. Mechanistically, astrocytic IFs restrict traction forces of 
collectively migrating cells to the leading edge of leader cells by controlling localization and 
turnover of focal adhesions. Astrocytic IFs also participate in nuclear positioning during 
collective cell migration, which is important for polarization41. In both individual and collective 
cell migration, the difference in speed was additive, with the most significant difference 
occurring between wild-type and completely IF-deficient astrocytes.  
Astrocytic IFs also regulate cell division. IFs are classically known to undergo 
phosphorylation during cell division to facilitate the dynamic reorganizations that take place 
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during this process31. Indeed, phosphorylation of vimentin and GFAP is required for cell division 
in cancer cells93,94. In primary astrocytes, it has been shown that vimentin phosphorylation is 
required for normal cell division95. However, recent studies indicate that the role of astrocytic IFs 
during cell division may extend beyond reorganization. For instance, vimentin maintains cellular 
proteostasis by coordinating asymmetric cell division of proteosomes and aggregated proteins in 
neural stem cells96. Evidence from primary mouse astrocytes indicates that vimentin may play a 
similar role in promoting asymmetric cell division in astrocytes where proteostasis is 
compromised97. Several studies in glioma cells and primary mouse astrocytes suggest that GFAP 
reduces proliferation98-101. These observations are in line with the fact that mature astrocytes 
typically do not divide. However, there is also evidence that GFAP can promote cell division 
under certain circumstances. For instance, Gfap deficient mice display reduced Schwann cell 
proliferation after damage to peripheral nerves, which causes delayed nerve regeneration102. 
Additionally, GFAP-positive astrocytes can regain their proliferative ability during CNS injury, 
possibly achieving proliferation through reorganization of GFAP by PTMs, so GFAP related 
regulation of cell division is very context-dependent.  
Astrocytes are very active secretory cells, and astrocyte IFs play a role in cell trafficking 
to support this function62. Chemical disruption of the astrocytic IF cytoskeleton in primary 
mouse astrocytes decreased the motility, track length, and displacement of exocytotic vesicles 
without affecting the structure of the microtubule and actin networks103. Recycling vesicles are 
also regulated by IFs in a stimulus-dependent manner. Upon stimulation with ATP, endosomes 
and lysosomes decreased mobility in wild-type astrocytes but did not change speed in 
vimentin/GFAP knockout astrocytes104. Recently, nestin deficient primary mouse astrocytes 
showed reduced exocytotic vesicle mobility and altered dynamics of exocytotic vesicles fusing to 
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the membrane105. Nestin also regulates recycling vesicle transport because endocytic vesicles 
were larger and had decreased mobility in nestin deficient astrocytes105. Thus, different astrocytic 
IFs can promote baseline vesicle mobility, alter trafficking to respond to extracellular stimuli, 
and control vesicle-membrane dynamics.  
GFAP plays a unique role in glutamate metabolism. In the Gfap KO mice, cell trafficking 
of glutamate receptors is specifically reduced, leading to a decreased capacity for glutamate 
uptake in Gfap deficient astrocytes106. Surprisingly, in the Gfap KO mice, there is also a decrease 
in neuronal expression of glutamate transporters, suggesting a potential non-cell autonomous 
effect of loss of astrocyte GFAP106. Moreover, GFAP has been shown to interact directly with 
the glutamate transporter GLAST and to preserve its localization to the plasma membrane during 
hypoxic stress107. Further, expression of GFAP has been correlated with inversely with glutamine 
synthetase expression and activity, indicating that changes in GFAP expression can disrupt 
glutamate metabolism108,109.  
These cell biological roles of astrocyte IFs contribute to larger physiological processes, 
such as astrocyte reactivity110. The vimentin/Gfap double KO mice display attenuated astrocyte 
reactivity in multiple injury models, including spinal cord and cortex stab injuries and 
ischemia89,111. Specifically, the loss of both vimentin and Gfap prevents the increased astrocyte 
branch hypertrophy that is typically observed during astrocyte reactivity112,113. While synemin 
and nestin are also upregulated in reactive astrocytes, they cannot polymerize into filaments 
without either vimentin or GFAP, which explains why they cannot compensate structurally for 
the loss of vimentin and Gfap in the double KO mice90. The loss of Gfap alone contributed to 
reduced astrocyte reactivity in other injury models, including an Alzheimer’s disease model, 
Experimental Autoimmune Encephalomyelitis inflammation model, and infectious disease 
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models114-116. This indicates that GFAP may play a unique role in certain contexts besides acute, 
mechanical injury where vimentin is able to compensate.  
Astrocytes are also known to regulate neurogenesis2. The astrocytic IFs vimentin, GFAP, 
and nestin play an important role in this regulation. Vimentin/Gfap double KO mice display 
increased neurogenesis, and nestin KO mice phenocopy this increased neurogenesis117,118. 
Surprisingly, although neural stem cells express nestin, astrocyte-derived nestin inhibits 
neurogenesis non-cell autonomously118. The loss of either Gfap and vimentin or nestin in 
astrocytes reduced endocytosis of Jagged-1, a ligand for the Notch receptor, which contributes to 
neuronal cell fate decisions117,118. Thus, multiple astrocytic IFs inhibit neurogenesis through 
Notch signaling. Loss of astrocytic IFs affects learning and memory since nestin KO mice show 
impaired long-term memory and vimentin/Gfap KO mice show increased memory 
extinction118,119. The inhibitory effect on neurogenesis is further reflected in neural 
transplantation studies in the retina and spinal cord where enhanced transplantation efficiency 
was achieved in the vimentin/Gfap KO mice120,121.  
During development and homeostasis, astrocytes are also key regulators of neuronal 
synapse plasticity and function122. Gfap KO mice displayed changes in synaptic plasticity in 
specific brain regions. In the cerebellum, Gfap KO mice are deficient in long-term depression, 
which coincided with a functional impairment in eyeblink conditioning86. In the hippocampus, a 
region that normally harbors many GFAP positive astrocytes, there are conflicting results with 
one group reporting enhanced long-term potentiation in Gfap KO mice and a separate group 
reporting no difference85,86. Potential explanations for this discrepancy could be the different 
genetic targeting strategies employed to knockout Gfap or heterogeneity of astrocytes in those 
regions. The role of GFAP in glutamate metabolism and vesicle trafficking likely positively 
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contributes to astrocyte support of neuronal function103,106. Conversely, GFAP can also 
negatively regulate neurite outgrowth in primary mouse astrocytes123.  
Beyond neurons, astrocytes interact with many other cell types to support brain 
architecture. Astrocytes are important components of the blood brain barrier (BBB), where they 
ensheath blood vessel endothelial cells and pericytes9. Defects in the BBB structure and function 
were observed in aged Gfap KO mice124. In line with this finding, primary astrocytes from Gfap 
KO mice were unable to promote BBB properties in co-cultures with endothelial cells125. 
Astrocytes also interact with oligodendrocytes and contribute to myelin formation and 
maintenance126. Aged Gfap KO mice display disorganization of myelin and white matter loss, 
indicating that GFAP contributes to astrocyte long-term support of myelin maintenance124,127.  
Table 1: Summary of Astrocytic IFs 
Name Classification Cell types Functions 
Nestin Type IV Astrocytes, neuroepithelial 
stem cells, adult stem cells 
Cell migration, trafficking, 
astrocyte reactivity, 
neurogenesis 
Synemin Type IV Astrocytes, muscle cells Astrocyte reactivity 
Vimentin Type III Astrocytes, mesenchymal 
cells, radial glia, adult neural 
stem cells 
Mechanical stress, cell 
migration, asymmetric cell 
division, docking organelles, 
astrocyte reactivity (injury), 
neurogenesis 
GFAP Type III Astrocytes, neural stem cells 
(SGL and SVZ), non-
myelinating Schwann cells, 
enteric glia, liver stellate cells 
Mechanical stress, cell division, 
cell migration, glutamate 
metabolism, trafficking, 
astrocyte reactivity (injury and 
neurodegeneration), maintenance 
of blood brain barrier, myelin 
maintenance, neurogenesis 
 
1.6 Astrocytic IFs in pathophysiology  
1.6.1 GFAP and vimentin contribute broadly to neurodegeneration through astrocyte reactivity 
Since the 19th century, it has been recognized that glia exhibit changes in pathological 
conditions128. It is now appreciated that reactive astrocytes are nearly ubiquitous in CNS 
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pathology, including neurodegeneration129. Depending on the injury, brain region, age, sex, and 
several other factors, reactive astrocytes can be incredibly heterogeneous and display both 
protective and toxic effects that are not necessarily mutually exclusive129. A characteristic feature 
of reactive astrocytes is the upregulation of astrocytic IFs, including vimentin, GFAP, nestin, and 
in some cases synemin77-79. The role of IFs in reactive astrocytes is complex and likely dependent 
upon the underlying CNS insult. Examination of vimentin/Gfap KO mice subject to stab injury of 
the cortex revealed that IFs are required for astrocyte reactive properties, including 
morphological and gene expression changes89,112. Another study reported an altered 
transcriptional response of vimentin/Gfap KO reactive astrocytes in an Alzheimer’s disease 
mouse model130. Ultimately, this attenuated astrocyte reactivity leads to functional consequences 
since knockout of vimentin and Gfap during stab injury leads to defective glial scar formation89. 
In an Alzheimer’s disease background, loss of vimentin and Gfap decreases the interaction of 
astrocytes with extracellular amyloid  plaques130. Thus, increased astrocytic IF expression 
promotes morphological changes and migratory properties of reactive astrocytes, which can be 
beneficial during wound healing or harmful during regeneration. A better spatial and temporal 
understanding of the role of astrocytic IFs during CNS pathology could make them attractive 
therapeutic targets in a broad range of contexts.  
1.6.2 Mutations in GFAP cause Alexander disease (AxD)  
Since IFs are involved in multiple astrocyte functions, it is unsurprising that filament-
altering mutations or stress-associated dysregulation of these proteins is linked to astrocyte 
dysfunction and disease. In fact, the first disease ever to be attributed primarily to astrocyte 
dysfunction is Alexander disease (AxD), which is caused by autosomal dominant mutations in 
GFAP131. AxD is a rare and fatal neurodegenerative disease and leukodystrophy that is 
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characterized by abnormalities in the white matter132. While the natural history of AxD is still 
being defined, currently cases are divided into two different categories: Type I AxD and Type II 
AxD133. These two forms of the disease impact different brain regions. Type I AxD largely 
affects the frontal lobe, whereas Type II AxD is localized to hindbrain regions, and this 
discrepancy leads to different manifestations of the disease. Type I AxD is characterized by an 
early age of onset usually within the first 4 years of life, macrocephaly, seizures, encephalopathy, 
developmental and motor delays, a general failure to thrive, and distinct MRI features133,134. 
Type II AxD is characterized by a later age of onset ranging across the lifespan, autonomic 
dysfunction, bulbar symptoms, ocular movement abnormalities, and atypical MRI features133. 
Over 90 percent of AxD patients contain mutations in the coding region of GFAP, and there is no 
clear genotype-phenotype correlation except for the hotspot mutations R79H and R239H, which 
account for about a third of AxD cases and tend to cause Type I AxD133. Still, some patients 
harbor the same exact point mutations at these or other GFAP residues but present with very 
different symptoms. Validated molecular markers that distinguish Type I and Type II AxD are 
not currently available.  
Type I and Type II AxD share certain a number of molecular features. First, AxD 
astrocytes undergo a process called astrocyte reactivity. Reactive astrocytes in AxD have altered 
morphology and upregulate nestin, synemin, vimentin, and GFAP110,135. Second, GFAP 
mutations lead to increased expression and accumulation of GFAP within cytoplasmic 
aggregates called Rosenthal fibers (RFs). RFs are amorphous, electron dense inclusions that 
contain predominantly GFAP (both wild-type and mutant136), ubiquitin137, and small heat shock 
proteins136 and are surrounded by normal filaments when examined at the ultrastructural level138. 
While RFs are present in other some contexts where reactive astrocytes are present, such as 
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astrocytic scars, multiple sclerosis plaques, and pilocytic astrocytoma, they are far more 
abundant and widespread in AxD and are considered the pathological hallmark of the 
disorder139,140. Recent mass spectrometry studies have revealed novel components of RFs, 
including receptor for activated protein C kinase 1 (RACK1), cyclin D2 (CCND2), and 
interestingly, several ribosomal proteins and stress granule proteins (40S ribosomal proteins, 
eiF4A, DDX3X)141. Finally, beyond RFs, total GFAP, including soluble subunits are also 
elevated, and it is suggested that the soluble mutant protein may be the most toxic142,143. As with 
many aggregation disorders, it is currently unclear whether RFs are protective, pathogenic, or 
inert.  
To elucidate molecular mechanisms in AxD, multiple model systems and tools have been 
developed. Overexpression of mutant GFAP has been performed to study GFAP aggregation 
both in vitro (purified protein filament assembly reactions) and in different cell types, including 
adrenal carcinoma SW13 cells lacking vimentin (SW13vim-), glioma cell lines, and primary 
astrocytes136,144. These models have been especially helpful in deciphering the effects of GFAP 
mutations on GFAP protein and filament properties and interactions. For example, it has been 
demonstrated both in vitro and in cell culture that AxD-causing GFAP mutations decrease GFAP 
solubility136. Decreased solubility reduces the soluble GFAP pool available for subunit exchange 
along mature filaments, which could ultimately affect turnover and therefore the overall quality 
of the filament network. Further, GFAP filaments can tolerate a small amount of mutant protein 
or assembly-deficient isoforms145. Incorporation of mutant GFAP into the filament network may 
further compound filament-protein interactions, subunit exchange and turnover, and stability. 
Mutant GFAP can also sequester proteins from their typical cellular localizations. One example 
of this is the binding of the chaperones heat shock protein 27 (HSP27) and B-crystallin to 
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GFAP aggregates in cells expressing AxD-causing mutations136. These chaperones normally 
interact with soluble and filamentous GFAP, but their sequestration within aggregates may 
compromise their other functions, such as involvement in the astrocyte stress response136,146.  
Beyond in vitro and cellular models, animal models have helped to identify disease 
mechanisms and reveal crosstalk between astrocytes and other cell types in AxD. Transgenic 
Drosophila models of AxD that overexpress mutant human GFAP in glial cells and are a 
powerful system to examine mechanisms of RF formation in vivo and to perform genetic and 
pharmacological screens147,148. More recently, zebrafish models of AxD have been developed 
that express human GFAP with disease-relevant point mutations from the zebrafish gfap 
promoter149. These zebrafish models also recapitulate cellular pathology and provide another 
system to examine disease mechanisms and perform screens149,150. 
Likewise, transgenic mice have been used to model AxD. Overexpression of wild-type 
human GFAP (Tg) causes accumulation of RFs151. However, mice that overexpress only the 
wild-type protein do not accurately represent the human disease where both wild-type and 
mutant proteins are present. To address this, two knockin mouse models were engineered to 
express AxD-causing point mutations at the Gfap locus142. These mice harbor either the R76H or 
R236H point mutations, which are equivalent to the human R79H and R239H hotspot mutations. 
Even though the knockin mice have increased expression of total, soluble, and insoluble GFAP, 
accumulate RFs, and exhibit reactive astrocytes, their phenotype is fairly mild, displaying only a 
slight weight loss142. Crossing transgenic GFAP overexpressing mice (Tg) with the mutant 
knockin mice (KI) leads to lethality within approximately one month. However, this mouse 
model (Tg+KI) still fails to recapitulate key aspects of AxD – myelin abnormalities, 
macrocephaly, developmental delays, and reduced motor coordination. Most recently, a new rat 
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model of AxD, harboring the R237H point mutation (equivalent to human R239H) was 
generated and recapitulates not only the pathology evident in the mice but also more extensive 
reactive astrocytes, myelin deficits and behavioral abnormalities, including failure to thrive, 
reduced motor coordination, and partial lethality152.  
 Together, these models have revealed many of the downstream effects of AxD-related 
GFAP mutations. A consistent finding across model systems is that the cellular proteostasis 
machinery is altered by mutant GFAP. It has been shown that mutant GFAP impairs proteasome 
activity153. Surprisingly, the soluble mutant GFAP displayed the strongest inhibitory effect on the 
proteasome143. Conversely, mutant GFAP increases autophagy, which promotes degradation of 
accumulated GFAP147,154. There is also evidence that protein folding pathways are impaired 
because chaperones co-localize with RFs and overexpression of chaperone proteins, including 
B Crystallin, HSP27, and HSP70 reduces aggregation and is protective against cell 
death136,147,155. Many stress signaling pathways are activated by mutant GFAP and likely 
coordinate crosstalk between proteostasis networks. Mutant GFAP activates c-Jun N-terminal 
kinase (JNK) signaling, and this occurs through proteasome impairment153. Other members of 
the mitogen-activated protein kinase (MAPK) family are also activated downstream of mutant 
GFAP, including mixed-lineage kinase 3 (MLK3) and p38, which negatively regulates 
mammalian target of rapamycin (mTOR) and promotes autophagy154. Additionally, signal 
transducer and activator of transcription 3 (STAT3) signaling has been implicated148. The Yes-
associated protein (YAP) mechanosensitive signaling pathway is also upregulated in AxD 
Drosophila, mouse and patient tissues, and this is accompanied by increased actin stress fibers 
and brain stiffness in model systems156. AxD mouse models also display increased oxidative 
stress, and suppression of this pathway through knocking out Nuclear factor erythroid 2-related 
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factor 2 (Nrf2) partially attenuates gliosis157. Similarly, overexpression of antioxidant genes in 
the Drosophila AxD model reduced cell death but not GFAP aggregation147. DNA damage 
markers, such as p53 are upregulated in GFAP positive cells in the Drosophila and mouse AxD 
models as well as AxD patient tissue148. Outside of astrocytes, there is also evidence that mutant 
GFAP has non-cell autonomous effects. There is increased inflammation and upregulation of 
cytokines in AxD158,159. The AxD reactive astrocytes show decreased coupling to other 
astrocytes, thereby affecting astrocyte-to-astrocyte communication135. One inflammatory 
molecule, Chitinase 3-like 1 (CHI3L1), is secreted by AxD astrocytes and can impair 
oligodendrocyte development and function, which could contribute to the white matter 
abnormalities seen in AxD patients160. Decreased cell surface expression of glutamate 
transporters is observed in AxD astrocytes along with a decreased ability to buffer potassium 
levels that could contribute to an excitotoxic environment for neurons135,161. Mutant GFAP also 
promotes glial driven nitrous oxide signaling that mediate non-cell autonomous neuronal 
death148.  
Although these AxD models have shed light on the molecular mechanisms of mutant 
GFAP toxicity, the exact effect of IF aggregation on cell-specific functions in astrocytes and 
other cell types is still largely unknown, but with the advent of more sophisticated human cell 
models, there is a growing interest in this field. Several groups have described cell type-specific 
functional alterations in AxD, including compromised glutamate trafficking in astrocytes161, 
reduced intracellular trafficking in neurons and astrocytes162,163, and aberrant glial cell-cell 
interactions160. In order to fully reveal the effects of IF aggregation on these cell functions, a 
better understanding of the dynamics of aggregate formation and disassembly as well as better 
tools to manipulate these dynamics will be required. 
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The dynamics of how RFs form in real time and how stable they are is not known. 
Fortunately, RFs are reversible, since strategies using either antisense oligonucleotides to reduce 
Gfap mRNA or overexpression of the chaperone protein B-crystallin can both clear RFs in 
AxD rodents152,155,164. Proteomic studies in AxD mice have also revealed that even though 
mutant GFAP accumulates in RFs, protein turnover is actually accelerated specifically for total 
mutant GFAP – although it’s not clear what form of GFAP (soluble subunit, filament, or 
aggregate) is being cleared165. Thus, AxD astrocytes maintain a remarkable capacity for GFAP 
proteostasis, and there is therapeutic potential in strategies that tip the scale of proteostasis by 
reducing production, increasing the degradation, or preventing aggregation of GFAP. 
The formation of RFs has been examined at different developmental timepoints. In AxD 
mice, RFs vary considerably in their shapes, sizes, and numbers, but in general, RFs increase in 
number and size in older animals138. Small RFs are often observed surrounding larger RFs, and it 
is speculated that these smaller aggregates coalesce to form the larger aggregates, an idea that is 
supported by live imaging of overexpressed mutant GFAP97. Of particular interest is the presence 
of small 15-30nm granules, which can be labeled by GFAP and B crystallin by immunogold 
EM labeling. These small, dense granules are present as deposits along otherwise normal-looking 
IFs. In fact, RFs of all sizes are always observed among swirls of apparently normal looking 
intermediate filaments, which has led to the hypothesis that IF filaments may provide a scaffold 
upon which new aggregates are seeded138. One possible mechanism for this seeding hypothesis is 
the B-crystallin chaperone protein may act as a linker for mutant GFAP subunits or oligomers 
to tether onto GFAP filaments. Formation of RFs does not require mutant GFAP protein but 
seems to be rooted in an excess amount of GFAP protein, since RFs form upon overexpression 
of human GFAP151 and RFs can be cleared by decreasing Gfap mRNA expression152,164. 
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However, in AxD, mutant GFAP protein clearly plays a pivotal role since the actual mutant 
protein has been identified within RFs136 and mutant GFAP initiates the cascade of events that 
lead to RF accumulation in patients. The mechanism of how exactly GFAP mutations lead to 
impaired proteostasis and excess levels of GFAP is a major focus of this project. We hypothesize 
that mutations in GFAP disrupt post-translational modifications of GFAP and in turn, alter IF 
properties, such as protein-protein interactions, filament dynamics, and protein turnover, 
ultimately leading to compromised GFAP proteostasis and triggering cell stress pathways.  
1.6.3 Giant Axonal Neuropathy (GAN) is caused by defective IF degradation 
Beyond mutations in astrocytic IF genes, mutations in IF regulatory proteins can also 
cause IF accumulation and dysfunction, leading to disease. Giant Axonal Neuropathy (GAN) is a 
rare pediatric neurodegenerative disease associated with IFs, which was originally described in 
1972166,167. It is a length-dependent distal axonopathy affecting both the PNS and CNS, along 
with several other tissues168. Evidence from GAN mouse models also implicates early impacts on 
the Autonomic Nervous System169. GAN patients display a characteristic physical appearance of 
a pale complexion, high forehead, skin abnormalities, and often, but not always, tightly curled 
hair, the lack of which is associated with a milder disease progression170. Individuals with GAN 
experience muscle weakness and ataxia, loss of ambulation, gastrointestinal issues (including 
constipation and regurgitation), and ultimately succumb to respiratory failure by the second or 
third decade of life168.  
One remarkable pathological hallmark of GAN is the presence of IF accumulations in 
several tissues, including vimentin in fibroblasts, desmin in muscle cells, neurofilaments in 
neurons, GFAP in astrocytes, and more recently, GFAP in lens epithelial cells171-174. Other cells 
show IF accumulations of unknown origin, including melanocytes, endothelial cells, and 
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Schwann cells173. Even some keratins appear to be affected, as evidenced by the curly hair, 
which when examined experimentally, displays unusual longitudinal grooves and keratin 
structural abnormalities175,176. While IFs accumulate in multiple cell types and tissues in GAN 
patients171, the most severely affected cells by far are sensory and motor neurons, so these cells 
have attracted the most attention in research studies. In GAN patients, neurons accumulate 
disorganized bundles of neurofilaments in the cell body and axons, causing the characteristic 
axonal swelling from which the name Giant Axonal Neuropathy arises166,167. While many 
neurons express neurofilaments and accumulate IFs in the CNS and Peripheral Nervous System 
(PNS), it is speculated that sensory and motor neurons in particular are so sensitive because of 
the length of their axons. In GAN, axon degeneration starts from the distal axonal compartment 
and progresses proximally towards the cell body166,177. Although these IF accumulations were the 
only early molecular clue as to the pathogenesis of GAN, the disorder is now known to be caused 
by homozygous loss-of-function mutations in the KLHL16 gene178.  
KLHL16 encodes the protein gigaxonin, which is an E3 ubiquitin ligase substrate adaptor 
in the BTB (bric-á-brac, tramtrack and broad-complex)/KLHL (Kelch-like) gene family179. 
Gigaxonin promotes degradation of proteins through the ubiquitin proteasome system, and it has 
been shown that gigaxonin can form a functioning E3 ligase complex with cullin 3 (Cul3) and 
ring box protein 1 (Rbx1) capable of ubiquitination180. Gigaxonin is ubiquitously expressed and 
has also been shown to interact with and promote degradation of many IF proteins, including 
vimentin, epidermal keratins, peripherin, -internexin, neurofilament, and GFAP162,181-184. 
Beyond IFs, gigaxonin has also been reported to target microtubule-related proteins for 
degradation, including MAP1B, MAP8, and tubulin folding cofactor B (TBCB)168. However, 
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microtubules and actin appear normal in GAN primary patient fibroblasts, whereas vimentin 
forms large, perinuclear aggregates183,185.  
As with AxD, the full effect of abnormally accumulated IFs in GAN are unknown. 
Moreover, most examination of the impacts of IF aggregation on cell functions has been done in 
neurons. By ultrastructural examination of GAN patient neurons, it has been suggested that one 
of the main consequences of bundled neurofilaments is steric hindrance172,173. The aggregates are 
thought to disrupt neuronal trafficking and displace mitochondria and other organelles, which are 
often localized either within the bundles of IFs or towards the periphery of the axons171. This 
idea is further supported by evidence from KLHL16 knockout mouse primary neurons, which 
display decreased mitochondrial motility and altered metabolism162. Similar to AxD, GAN 
patients display abundant RFs within astrocytes173. However, the contribution of astrocytes to 
GAN has been underappreciated, and the effects of GFAP aggregates on mitochondrial motility 
and other critical cell functions of astrocytes, which likely contribute to neuronal injury in GAN, 
are unknown.  
1.7 Dissertation scope and objectives 
 The primary objective of this research project is to develop methods, tools, and models to 
investigate mechanisms of IF protein aggregation in astrocytes, which is graphically depicted in 
Figure 1.1.  
 The chapters of this dissertation contain: 1) a novel method to simultaneously isolate IF 
proteins from mammalian tissues for identification of PTMs, including phosphorylation; 2) 
identification of IF-targeting compounds by an image-based small-molecule screen; 3) 
identification and characterization of phosphorylation at serine 13 of GFAP in AxD using 
overexpression, iPSC-astrocytes, and brain tissue from AxD patients; and 4) generation of a 
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cellular model for GAN utilizing 2- and 3-dimensional human iPSC-astrocytes. In Chapter 6, I 
summarize the results from Chapters 2-5, contextualize these findings into the broader fields of 
IF-associated diseases and neurodegenerative diseases, and address the limitations of this work. 
Finally, I provide a brief conclusion and highlight the most outstanding questions emerging from 
this research. 
 The aim of this work is to develop novel methods, tools, and disease models to examine 
IF protein aggregation in the context of human astrocytes. Using a proteomics approach to 
identify candidate IF PTMs that are disrupted during aging and IF-associated disease, I intend to 
highlight the contribution of altered PTMs to defective proteostasis. I also plan to develop iPSC-
based models of AxD and GAN using fibroblasts donated from patients that will allow for 
investigation of mechanisms in the appropriate genetic and species context, and differentiation of 
these cells to astrocytes will provide an invaluable cell type-specific context. I hope to lay a 
foundation of new tools and mechanisms to aid the long-term goals of understanding of the cell 
biological functions of IF proteins and developing IF-targeted therapies to improve the health 




Figure 1.1 Summary of dissertation scope and objectives. Multiple strategies are implemented 
to understand the formation and dissolution of IF aggregates. Methods to identify PTMs are 
demonstrated (Chapter 2). An image-based small-molecule screen is designed and applied to 
generate tools to target IF proteins (Chapter 3). Clinically relevant disease models of AxD and 
GAN are developed to model GFAP aggregation caused by GFAP mutations (Chapter 4) and 
defective IF turnover (Chapter 5). Site-specific phosphorylation (P) is identified as a marker of 
severe AxD and mechanistic information of GFAP aggregation is revealed (Chapter 4). 
Proteostasis in neural progenitor cells and astrocytes from GAN patients is described (Chapter 
5). Together, this work generates new methods, tools, disease models, and mechanisms to 
understand IF aggregation and therapeutically target IFs in human disease. This figure was 





CHAPTER 2: ISOLATION OF INTERMEDIATE FILAMENT PROTEINS FROM 




IFs are a family of proteins that in humans are encoded by 73 genes and categorized into 
six major types: types I-IV are cytoplasmic (e.g. epithelial and hair keratins (K), myocyte 
desmin, neurofilaments, glial fibrillary acidic protein (GFAP), and others); type V are the nuclear 
lamins; and type VI are IFs in the eye lens17. In terms of their molecular organization, IF proteins 
have three common domains: a highly conserved coiled-coil "rod" domain, and globular "head" 
and "tail" domains. IF protein tetramers assemble to form short filament precursors, which are 
ultimately incorporated into mature filaments that shape dynamic cytoskeletal and nucleoskeletal 
structures involved in mechanical protection186, stress sensing187,188, regulation of transcription37 
and growth, and other critical cellular functions17,61,189.  
The functional importance of the IF system is highlighted by the existence of many 
human diseases caused by missense mutations in IF genes, including neuropathies, myopathies, 
skin fragility disorders, metabolic dysfunctions, and premature aging syndromes73. Some IF gene 
mutations do not cause, but predispose their carriers to disease progression, such as the simple 
epithelial keratins in liver disease190. The latter is due to the critical stress-protective functions of 
IFs in epithelia. IFs in general are among the most abundant cellular proteins under basal 
 
1 This chapter previously appeared as an article in the Journal of Visualized Experiments. The 
original citation is as follows: Battaglia, R. A., Kabiraj, P., Willcockson, H. H., Lian, M. & 
Snider, N. T. Isolation of Intermediate Filament Proteins from Multiple Mouse Tissues to Study 
Aging-associated Post-translational Modifications. J Vis Exp, doi:10.3791/55655 (2017). 
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conditions, but are further strongly induced during various types of stress26. For example, recent 
studies evaluating proteome-wide changes in the nematode C. elegans demonstrated that 
multiple IFs are highly upregulated and prone to aggregation during organismal aging191,192. 
Since maintenance of a proper IF structure is essential for cellular resistance to various forms of 
stress26, IF aggregation may also contribute to the functional decline during aging. However, 
organismal-level studies examining multiple mammalian IF proteins across different tissues 
undergoing stress are lacking.  
IFs are highly dynamic structures that adapt to meet cellular demands. Keratins, for 
example, undergo a biosynthesis-independent cycling between soluble (non-filamentous) and 
insoluble (filamentous) protein pool193. Under normal physiologic conditions approximately 5% 
the total K8/K18 pool can be extracted in detergent-free buffer, in comparison to approximately 
20% that can be solubilized in the non-ionic detergent Nonidet P-40, which is biochemically 
comparable to Triton-X100194,195. During mitosis there is a notable increase in the solubility of 
simple-type epithelial K8 and K18194, which is less apparent in epidermal keratins but more 
apparent in vimentin and other type III IF proteins195,196. Solubility properties of IF proteins are 
tightly regulated by phosphorylation, a key post-translational modification (PTM) for filament 
rearrangement and solubility31,197-199. Most IFs undergo extensive regulation by a number of 
PTMs at conserved sites, resulting in functional changes31.  
The purpose of this method is to introduce investigators who are new to the IF field to 
biochemical extraction and analytical methods for the study of IF proteins across multiple mouse 
tissues. Specifically, we focus on isolation of IF proteins using a high-salt extraction method and 
assessment of changes in PTMs via mass-spectrometry and by PTM-targeting antibodies. These 
methods build upon previously published procedures200 but include modifications for extracting 
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different IF protein types to uncover common mechanisms for regulation across the IF family. 
For example, K8 acetylation at a specific lysine residue regulates filament organization, while 
hyperacetylation promotes K8 insolubility and aggregate formation201. Recent global proteomic 
profiling studies have additionally revealed that most tissue-specific IF proteins are also targets 
for acetylation and that most IF acetylation sites are confined to the highly conserved rod 
domain. This highlights the need for methods suitable for global profiling of the IF system. We 
also introduce a rapid method of isolating IF proteins from multiple tissues using automated 
homogenization in optimized lysing matrix. The resulting preparations are suitable for 
downstream PTM analysis via mass spectrometry and other methods.  
2.2 Protocol 
The protocol is approved and performed in accordance with the Institutional Animal Care 
and Use Committee (IACUC) at the University of North Carolina.  
1. Preparations 
1. Prepare Triton-X buffer (1% Triton X-100, 5 mM ethylenediaminetetraacetic acid 
(EDTA), bring up volume in phosphate-buffered saline (PBS), pH 7.4). To make 500 
mL: stir 5 mL each of Triton X-100 and 500 mM EDTA into 490 mL of PBS, pH 7.4. 
Store Triton-X buffer solution at 4 °C.  
2. Prepare High Salt Buffer (10 mM Tris-HCl, pH 7.6, 140 mM NaCl, 1.5 M KCl, 5 mM 
EDTA, 0.5% Triton X-100, bring up volume in double distilled (dd) H2O). To make 500 
mL: stir 10 mL of 0.5 M Tris-HCl (pH 7.6), 14 mL of 5 M NaCl, 55.9 g KCl, 5 mL of 0.5 
M EDTA, and 2.5 mL of Triton X-100, adjust volume to 500 mL using double distilled 
water). Store High Salt Buffer solution at 4 °C.  
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3. Just prior to use, supplement an appropriate amount of Triton-X and High Salt Buffer 
(e.g. 1 mL for each 25 mg tissue sample) with a protease or protease/phosphatase 
inhibitor cocktail and discard any unused buffer containing the inhibitors.  
4. Prepare 5mM EDTA in 1x PBS, pH 7.4. To make 500 mL: stir 5 mL of 0.5 M EDTA into 
495 mL of 1x PBS, pH7.4.  
5. Isolate different mouse organs (brain, heart, lung, liver, pancreas, colon, intestine, kidney, 
spleen) using approved protocols that comply with veterinary guidelines and institutional 
standards202. The tissue collection procedure should take no more than 5 min to preserve 
RNA and protein integrity of protease-rich tissues (e.g. pancreas should be processed 
first).   
6. Cut a small amount of tissue (~5-20 mg) and place in RNA storage solution, for 
subsequent RNA extraction, cDNA synthesis, and quantitative real-time PCR analysis for 
IF gene expression. Place RNA storage solution tubes with tissue at 4 °C overnight and 
follow manufacturer protocol for further storage and isolation steps.  
7. Cut the rest of the tissue into smaller fragments (e.g. 0.5 cm) and place in cryovial. Snap-
freeze and store vials at -80 °C or liquid nitrogen for longer term storage.  
2. IF Gene Expression Analysis  
1. Extract RNA from tissues preserved in the RNA storage solution reagent. Use any 
suitable/preferred RNA extraction method according to manufacturer's protocol.  
2. Quantify RNA concentration and use 2 μg of RNA to generate cDNA using a suitable 
reverse transcription kit according to manufacturer's protocol.  
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3. Using the generated cDNA and mouse IF gene-specific primers set up qPCR reactions, 
including three technical replicates of each sample as well as blank control according to 
manufacturer's protocol.  
4. Quantify IF gene expression as fold change comparing different conditions (e.g. young 
versus old tissue).  
3. Preparation of Total Tissue Lysates for Immunoblot  
1. Homogenize 25 mg of tissue in 1 mL of 2x non-reducing SDS sample buffer. Omit 
bromophenol blue dye from the sample buffer if a colorimetric protein assay is to be 
performed to quantify protein concentration.  
2. Add 5% (v/v) of 2-mercaptoethanol (2-ME) to make reduced samples. To 200 μL of the 
non-reducing samples, add 10 μL of 2-ME.  
3. Determine protein concentration using detergent- and reducing agent-compatible protein 
assay. If dye is already included in the sample buffer, the protein amount can be 
estimated after running a gel via a number of techniques, including Coomassie-stain203. 
4. Vortex all samples and heat at 95 °C for 5 min. 
5. Perform western blotting under both reducing and non-reducing conditions. Expose 
membrane briefly (<1 min) to reveal monomeric species, and longer (>1 min) to reveal 
high molecular mass complexes containing IF proteins. If monitoring aggregation, 
examine entire gel/ membrane (including the bottoms of the gel wells).  
6. Run a parallel gel and stain with a protein stain as a loading control203. In disease models 
or injury experiments total protein stain should be used as a loading control, as opposed 
to immunoblots for 'housekeeping' proteins (e.g. actin, GAPDH) because the latter 
change under different stress conditions.  
 31 
4. Preparation of Detergent-soluble and High-salt Extracts of Tissue-specific IFs  
1. Add 1 mL of ice-cold Triton X-100 buffer into a glass tube homogenizer and place it on 
ice. 
2. Remove a small piece of tissue (~25 mg) from liquid nitrogen storage and place directly 
into the glass homogenizer. Use a polytetrafluoroethylene pestle to homogenize (50 
strokes) and avoid making bubbles. Keep the homogenizer and lysate cold at all times. 
3. Transfer lysate to a 1.5 mL microcentrifuge tube on ice and centrifuge at 20,000 x g for 
10 min in a pre-chilled centrifuge (4 °C).  
4. Collect the supernatant fraction into a separate tube. This is the Triton X-soluble fraction, 
which can be used for immunoprecipitation (i.p.) and analysis of the detergent-soluble 
pool of IF proteins. Note that steps 4.1-4.4 may be repeated to achieve a cleaner IF 
extract from brain tissue.  
5. Add 1 mL of High Salt Buffer to the tissue pellet, transfer to a clean homogenizer and 
dounce 100 strokes. Transfer the homogenate back to the microcentrifuge tube and place 
the tube on a rotating shaker in the cold room for 1 h.  
6. Centrifuge the homogenates at 20,000 x g for 20 min at 4 °C. Discard the supernatant.  
7. Add 1 mL of ice-cold PBS/EDTA buffer to the pellet and homogenize the pellet (20 
strokes) in a clean homogenizer as a final clean-up step*. Transfer to a new tube and 
centrifuge at 20,000 x g for 10 min at 4 °C to obtain the IF protein-rich high salt extract 
(HSE).  
* Optionally, vortex instead of homogenization at this step.  
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8. Discard the supernatant and dissolve the pellets in 300 μL of non-reducing SDS sample 
buffer that has been pre-heated. Break up the pellet initially by pipetting and vortexing, 
and then heat the samples for 5 min at 95 °C.  
9. Vortex and pipet as needed to ensure the pellet is dissolved. It may take several minutes 
to fully dissolve the pellets.  
10. Store all samples at -20 °C until analysis.  
5. Automated Tissue Lysis for IF Protein Extraction in High-volume Experiments  
1. For RNA extraction, place lysis buffer (600 μL buffer per 25 mg of tissue) in a tube 
containing lysing matrix D (uses small ceramic spheres) and pulse twice for 25 s in the 
tissue lyser. Separate lysate from the matrix by centrifugation at 20,000 x g and proceed 
to the next step in isolation.  
2. For protein extraction, place Triton X-100 (or SDS sample buffer if preparing total 
lysate) in a lysing tube with lysing matrix SS (use a single stainless steel bead). After 
testing multiple matrices, this was selected because it produces IF protein extracts that are 
in similar quality as the traditional douncing method. Note that the automated method is 
not optimal for pancreas and spleen, and the standard homogenization protocol should be 
used for these tissues.  
3. To proceed with preparation of High Salt Extract, remove the stainless steel bead from 
the tube using a magnet, and centrifuge the tubes at 20,000 x g for 10 min at 4 °C.  
4. Continue with step 4.4 (above) of the manual protocol.  




6. Immuno-enrichment of Post-translationally Modified IF Proteins  
1. Prepare PBST buffer (0.02% Tween-20 in PBS). To make 50 mL, add 10 μL of Tween-
20 to 50 mL of PBS, pH 7.4.  
2. Prepare PTM antibody solution (1-10 μg of antibody in 200 μL of PBST). In general, 3 
μg of antibody/reaction is a good starting condition that can be further optimized if 
needed.  
3. For each reaction, aliquot 50 μL of magnetic beads into a microcentrifuge tube, place on 
the magnet and aspirate the bead storage solution.  
4. Conjugate the beads to the immunoprecipitation antibody by re-suspending in the 
antibody solution and incubating on rotator (end-over-end, to ensure mixing of small 
volumes) at room temperature for 20 min.  
5. Place the tubes on magnet and aspirate antibody solution.  
6. Rinse the antibody-conjugated beads once in 200 μL PBST and remove wash buffer.  
7. Add 0.6-1 mL of the tissue lysate to the beads, mix by gentle pipetting and incubate for 3 
h on rotator in a cold room.  
8. Place tubes on magnet, remove lysate, and wash the beads five times with 200 μL of 
PBST. After the last washing step, collect the beads in 100 μL of PBS (no Tween-20) and 
transfer to a clean new tube. Place the tube on the magnet.  
9. Aspirate the PBS and add 100 μL of non-reducing sample buffer. Remove 50 μL and add 
2-ME (5%) to make reducing samples. Heat the samples to 95 °C for 5 min.  
10. Separate the i.p. fraction from the beads on the magnet and collect it into a new tube.  
11. Store samples at -20 °C until analysis.  
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7. Preparation of IF Protein Samples for Mass Spectrometry Analysis  
1. Schedule a consultation with a proteomics expert prior to initiating a study since there is 
significant time and cost involved with mass spectrometry analysis.  
2. Take special precautions to avoid contamination. Handle all gels with clean gloves and 
incubate in clean containers, washed only using ddH2O (avoid soap).  
3. Run 20-50 μL of the HSE sample (from Sections 4 and 5) on an SDS-PAGE gel 
according to standard conditions.  
4. Stain with a protein stain for 1 h. Rinse multiple times and de-stain in ddH2O overnight. 
The IF protein bands should be easily visible after de-staining.  
5. Place the gel between plastic sheet protectors, scan and mark the bands that will be 
excised and sent for analysis.  
6. Excise the IF protein bands using a new clean razor.  
7. Place the gel bands in clean microcentrifuge tubes and transfer to a mass spectrometry 
facility.  
2.3 Representative Results 
2.3.1 A new rapid method for high salt-based extraction of IF proteins from multiple mouse 
tissues using lysing matrix.  
 
The traditional method204,205 of isolating the bulk of the intermediate filament protein 
fraction from epithelial tissue was modified here to include 9 different organs and a more rapid 
procedure for tissue lysis. While 3 manual homogenization steps are required for the traditional 
method, the modified procedure only has 1 manual homogenization step, which shortens the 
procedure by several hours, especially when processing more than 6 samples. Figure 2.1A 
shows a typical result of HSEs from 9 mouse tissues, while the table of expected proteins in the 
tissue and the molecular weight of each protein is shown in Figure 2.1B for comparison. Of 
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note, the new automated method does not work well on pancreas and spleen; the traditional 
homogenization procedure works best for these tissues. This method should be useful for 
profiling IF proteins in a universal fashion across several tissues to assess organism-level 
responses to stress. As specific examples here, we show that IF proteins in liver (K8/K18) and 
brain (GFAP) from old mice are highly upregulated and undergo unique PTMs compared to the 
corresponding tissues in young mice.  
2.3.2 Liver K8 and K18 are strongly upregulated and undergo increased phosphorylation and 
lysine acetylation in livers from old mice.  
 
Figure 2.2 shows typical results from several of the analyses described in this protocol. 
Panel A depicts expression analysis of the two major IF genes in the liver, keratin 8 (KRT8) and 
keratin 18 (KRT18), which encode the IF proteins K8 and K18, respectively. Epithelial keratins 
are strongly upregulated under various stress conditions. In the result shown, this occurs during 
aging, since KRT8 is significantly upregulated in the livers of 24 m old mice compared to 3 m 
old mice. The results at the protein level are more striking, as observed by the dramatic increase 
in K8 monomer as well as high molecular mass complexes in the old (24 m) livers. Coomassie-
based protein stain here serves as a loading control to ensure equal loading of protein across 
samples. Note that with total tissue lysates it is easy to overload protein on a gel, as it is in 
this case. Loading a smaller volume or diluting the sample further in sodium dodecyl sulfate 
(SDS) buffer will alleviate this problem (especially if it appears viscous and difficult to pipet). 
Panel C depicts a typical result from a liver High Salt Extract obtained using the automated 
protocol, demonstrating the strong enrichment of keratins 8 and 18 on the gel. The red lines 
demarcate the area that was excised and submitted for mass spectrometry analysis. In panel D the 
results of the mass spec analysis of the samples in panel C shows that K8 and K18 in the old 
liver have multiple phosphorylation and acetylation sites that are not present in the young liver.  
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2.3.3 GFAP is strongly upregulated and lysine acetylated in the brains from old mice.  
Figure 2.3 demonstrates that the methods used to extract IFs from epithelia can also be 
used on non-epithelial tissue. Furthermore, the results reveal a general pattern for aging-
dependent upregulation of IF genes and proteins. The qPCR result in Figure 2.3A reveals a 5-
fold induction of GFAP mRNA in the brains of 24 m old mice compared to 3 m old mice. Figure 
2.3B reveals total proteins present in the Triton X-100 fraction and the IF-enriched HSE. Note 
the increase in the band intensity at 50 kDa marked by the arrow (corresponding to GFAP) in the 
old brain. Western blot analysis in Figure 2.3C further reveals the upregulation of GFAP and 
significant presence of GFAP monomer and potential high molecular mass complex in the Triton 
X-100 fraction (both marked by arrows). Western blot analysis of the same samples with a pan-
acetyl lysine antibody shows that the antibody recognizes a band at ~50 kDa in the HSE of the 
old mouse brain and at ~250 kDa in the Triton X-100 fraction (Figure 2.3D). Immuno-
enrichment of acetylated proteins from the Triton X-100 fractions reveals increased presence of 
GFAP protein in the lysate obtained from the old brain. Reducing and non-reducing conditions 
are shown to highlight GFAP monomer and high molecular mass complexes. Mass spectrometry 
analysis (similar to Figure 2.1) can be performed in this case to determine the site-specificity of 
the acetylated residues on GFAP in the old brain.  
2.4 Discussion 
Methods that enable biochemical characterization of IF proteins can be useful to 
understand numerous pathophysiological phenomena in mammalian systems, since IF proteins 
are both markers and modulators of cellular and tissue stress205. The principle behind the current 
method is based on the initial procedures developed in the 1970s and 1980s to isolate, separate 
and reconstitute IF proteins from cells and tissues, generally employing low and high salt 
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solutions and Triton X-100 detergent204,206-211. For historical insight into the studies that 
supported the biochemical isolation of IF proteins please see recent reviews212,213. The current 
method is based on more recent protocols developed for the study of simple epithelial keratins205. 
The advantage of the method is that it can serve as an initial step to enable investigators who are 
new to the IF field to effectively isolate IF proteins from most mammalian tissues. It represents a 
visual guide of related procedures that are widely used by investigators in the field to study IF 
protein regulation200,214. 
This technique can be used to study the regulation and function of IFs in stress 
communication mechanisms between mammalian tissues215,216. It is becoming well-appreciated 
that stress in one tissue can affect the functioning of other tissues, for example under conditions 
of nutritional stress217, protein misfolding218, metabolic stress219, and other changes. Of note, 
most of the work currently being done in this area is in Drosophila and C. elegans models, while 
studies on widespread stress responses in mammalian systems are lacking. As the major 
regulator of cellular stress190, the IF system can unlock clues to organismal-level stress 
responses, which can have important disease implications. As such, the current protocol can be 
used to study global pathophysiological mechanisms in various mouse models of stress, injury 
and disease.  
One limitation of the current technique is that the high salt extracts are considered 
"crude" IF preparations since they also contain other IF-associated proteins, such as plectin for 
example220. As shown previously, HSEs can be denatured in 8 M urea buffer to obtain highly 
pure IF proteins that are capable of in vitro re-assembly in phosphate buffer220. After two such 
cycles of disassembly and re-assembly, the stoichiometry of IF proteins (isolated from HeLa 
cells) remained the same, whereas the urea treatment removed plectin220. During desmin 
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purification, actin can be removed by solubilization of the HSE in acetic acid221. Whether 
additional purification steps should be included depends on the ultimate goal of the experiment. 
For example, if the goal is to characterize the assembly state and generate in vitro reconstituted 
IFs, the urea step is required to obtain highly pure IF proteins. On the other hand, if the goal is to 
identify context-dependent associations between IFs and other cellular proteins, then the "crude" 
preparations can be used. Interacting proteins can be identified by mass spectrometry using either 
in-gel digest for high abundance targets visible by gel stain, or in-solution digest for low 
abundance targets. Previous studies using immunoprecipitation of detergent-soluble IFs and 
HSEs containing IF proteins identified functionally important specific interaction between 
keratins 8/18 and heat shock protein 70 (HSP70), which is potentiated after heat stress222, the 
adaptor protein 14-3-3 after phosphorylation223, and K8/K18 Raf-1 kinase under normal 
physiologic conditions224 among others. The current protocol can enable similar studies on other 
IF proteins.  
Use of the lysing matrix is a key modification from previous methods and should allow 
for rapid extraction of IFs from multiple tissues, with the exception of pancreas and spleen. The 
automation of the initial steps can be particularly useful for high-volume mouse experiments. For 
example, isolating IF proteins from 3 different tissues from 10 mice per condition (e.g. normal 
and some form of systemic stress or disease) will require processing of 60 individual tissues. 
Using the traditional manual method this would need to be done in batches and can take several 
days. However, using the automated method with lysing matrix, the procedure can be done in 
just a few hours. Critical steps of the procedure include: ensuring the sample stays cold 
throughout the procedure; incubation in high salt buffer for 1 h (step 4.5); using hot buffer and 
extensive vortexing to ensure complete resuspension of the pellet before analysis (step 4.8); and 
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taking all precautions to avoid contamination of samples to be analyzed by mass spectrometry 
(step 7.2).  
The major drawback to mass spectrometry-based identification of PTM sites is that it 
works very well for certain PTMs – phosphorylation and lysine acetylation being prime 
examples – but others, such as sumoylation are much more challenging225. Nevertheless, 
proteomics is a powerful tool for studying protein regulation in normal and diseased tissues. 
Agnetti et al. compiled a comprehensive up-to-date overview of cutting edge proteomic 
techniques currently in use to study various PTMs in the context of tissue-expressed proteins226. 
The purpose of the current method is to generate samples that can be applied for different types 
of analyses. For example, in vitro sumoylation can be performed on immune-precipitated IF 
proteins, and overall sumoylation can be assessed on isolated IFs in HSE preparations using 
sumo-specific antibodies197,200. Therefore, the application of this method is not limited to 
generating samples only for mass spectrometry analysis but can be used to probe multiple IF 
properties using a variety of downstream techniques.   
IF proteins are extensively regulated by numerous PTMs at conserved sites, resulting in 
altered solubility, filament assembly, and protein interactions31. Recent technological advances 
have unveiled the incredible magnitude, complexity, and disease significance of post-
translational modifications (PTMs) on cellular proteins227-229. Improvement in detection methods 
for common PTMs, such as phosphorylation230 and acetylation227, have yielded vast catalogs of 
data, but understanding their biological meaning – cracking the “PTM code” – is a major 
remaining challenge231,232. One way to assess the functional roles and relative significance of 
each PTM is to determine how well it is conserved across multiple members of the IF protein 
family. For example, identification of a novel phospho-tyrosine site on K8 revealed that this site 
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is contained within a QYE motif found in essentially all cytoplasmic IF proteins and critical for 
regulating IF protein solubility and filament dynamics233. Importantly, mutation of the conserved 
tyrosine residue on GFAP to a negatively-charged “phosphomimic” aspartic acid (Y242D) 
causes Alexander Disease234. The representative data shown here demonstrate how two different 
tissue-specific IF protein types (K8 and GFAP) undergo similar pattern of upregulation and 
increased acetylation during aging, which may be an effect of altered metabolism201,227. This 
example illustrates the utility of the method in understanding the function of IF proteins on a 




Figure 2.1 Automated lysis and extraction of IF proteins from multiple mouse tissues. (A) 
Coomassie-based gel stain of HSEs from the designated mouse tissues. The tissues shown were 
obtained from the same adult (3 m old) male CBA mouse. Samples were processed as described 
in Section 5. Brain: note that NFL, NFM, and NFH are heavily phosphorylated27 and migrate 
slower than expected, at ~70, 145, and 200 kDa, respectively. Heart: In addition to the 53 kDa 
band corresponding to desmin and vimentin), heart samples also contain a ~42 kDa band, most 
likely representing actin, which is known to co-purify with desmin28. Large intestine: The 
identity of the prominent bands above 25 kDa that are co-extracted with K8/K18 are not known, 
but these bands are not present if the tissues are processed using the traditional dounce 
homogenizer method. Pancreas and Spleen: Note that the automated homogenization is not 
suitable for isolation of keratins from pancreas and vimentin from spleen, presumably because of 
the sensitivity of the lysate to the slight increase in temperature during the pulse in the tissue 
lyser. (B) Table showing the major IF protein types present in the different tissues and their 





Figure 2.2 Molecular and biochemical differences in liver keratins from young and old 
mice. (A) Analysis of KRT8 and KRT8 mRNA using standard procedure (Protocol 1) reveals 
significant induction in KRT8 transcript in the livers from old mice. n = 6 for each condition (3 
male and 3 female CBA mice were used per group). **p <0.01; one-way ANOVA. (B) Total 
liver lysates were obtained from 3 young (3 months old) and 3 old (24 months old) male CBA 
mice using Protocol 2 and the samples were analyzed under non-reducing conditions. TS1 
antibody was used to probe for K8 expression and Coomassie-based protein stain was used as a 
loading control. (C) High salt extracts from young and old mouse livers, corresponding to mice 
#1 and #4, respectively from panel B. The two arrows point to K8 and K18 on the gel and the red 
box indicates the part of the gel that was excised and submitted for mass spectrometry analysis. 





Figure 2.3 Molecular and biochemical differences in GFAP from brain of young and old 
mice. (A) Analysis of GFAP mRNA using standard procedure (Protocol 1) reveals significant 
induction in the brains from old mice. n = 6 for each condition (3 male and 3 female CBA mice 
were used per group). **p <0.01; one-way ANOVA. (B) Coomassie-based protein stain of Triton 
X-100 and HSE fractions from brain tissue of young (3 months old) and old (24 months old) 
mouse. Note the increase in ~50 kDa GFAP band in HSE from old brain (arrow). (C) GFAP 
immunoblot (mouse monoclonal; GA5 clone) of the same samples as panel B. (D) Acetyl-lysine 
immunoblot (rabbit polyclonal; Abcam ab80178) of the same samples as in panel B. (E) GFAP 
blot after immunoprecipitation with acetyl-lysine antibody. Samples were analyzed under non-
reducing (NR) and reducing (R) conditions and arrows point to increase presence of GFAP in the 






CHAPTER 3: AN IMAGE-BASED SMALL-MOLECULE SCREEN IDENTIFIES 
VIMENTIN AS A PHARMACOLOGICALLY RELEVANT TARGET OF 
SIMVASTATIN IN CANCER CELLS1 
 
3.1 Introduction 
The cytoskeleton, a critical structural element of all cells, is composed of intermediate 
filaments (IFs), actin filaments, and microtubules as its major components. Human IFs are 
encoded by 73 genes and grouped into 6 major types: types I–IV are cytoplasmic and include the 
epithelial and hair keratins, myocyte desmin, neurofilaments, and glial fibrillary acidic protein, 
among others; type V IFs are the nuclear lamins; and type VI are IFs expressed in the lens17. 
Whereas pharmacologic agents that target actin filaments and microtubules are available and 
widely used in research, there are presently no known chemical probes that target IFs selectively. 
The importance of developing IF-targeting chemical probes is clear in light of what actin- and 
tubulin-targeting drugs have done for our fundamental understanding of cell biology and for 
patients with cancer. There are more than 70,000 PubMed studies that refer to the use of these 
agents, and microtubule drugs are a major class of chemotherapeutic agents235,236. 
The complexity of IF assembly mechanisms and the limited structural data on individual 
IFs have hindered the development of pharmacologic tools for their targeting. All IF proteins 
share a common domain structure, a conserved coiled-coil rod domain that is flanked by globular 
 
1 This chapter previously appeared as an article in Federation of American Societies for 
Experimental Biology Journal. The original citation is as follows: Trogden, K. P., Battaglia R. 
A., et al. An image-based small-molecule screen identifies vimentin as a pharmacologically 




head and tail domains24. Stable IFs are assembled from tetramers, the basic IF subunits, into 10-
nm-thick mature filaments that are critical for mechanical protection, stress sensing, and the 
regulation of transcription and cell growth. Presently, it is not known if and how the IF 
cytoskeleton mediates desired or untoward effects of clinically used drugs, despite the well-
known functions of IFs in cellular homeostasis and disease. 
Vimentin, the major IF protein of mesenchymal cells, has been used as a prototype for 
elucidating IF structure, assembly, and dynamics237. As such, vimentin can serve as a model IF 
protein to study pharmacologically relevant interactions between IFs and small-molecule 
compounds. Withaferin A, a naturally occurring steroidal lactone, has been used as a vimentin 
inhibitor on the basis of findings that it promotes aggregation of vimentin238; however, withaferin 
A affects numerous cellular targets, including other cytoskeletal components239,240, and, 
therefore, it is not selective for vimentin or IFs in general. On the other hand, examining 
functional associations between IF proteins and compounds with well-defined biochemical 
activities may illuminate signaling networks controlling IF dynamics and set the stage for future 
development of novel first-in-class IF-selective chemical probes. 
In the present study, we hypothesized that a pharmacologic screen using a library of 
compounds with known biochemical activities can provide us with new tools with which to 
manipulate IF structures, uncover signaling pathways that regulate IF dynamics, and potentially 
implicate IFs as biologically significant targets of widely used research compounds and clinical 
agents. We used Tocriscreen, a set of 1120 research compounds and clinical drugs, to screen for 
effects on vimentin filaments in a cell-based assay. This led to the identification of several hits 
that included compounds that target GPCRs, protein-protein interactions, and various classes of 
enzymes. We subsequently characterized a functional direct interaction between one of the hits, 
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simvastatin, and vimentin. Simvastatin and other statins target the rate-limiting step in 
cholesterol synthesis and are among the most commonly used drugs in the world241. In addition 
to lowering cholesterol, clinical use of statins is associated with reduced cancer mortality242 and 
adverse muscle-related effects243 through largely unknown mechanisms. Our identification of 
vimentin as a direct target of simvastatin provides a novel potential mechanism of action that 
extends beyond lowering cholesterol. 
3.2 Materials and Methods 
3.2.1 Abs, plasmids, and chemicals 
Abs used were rabbit anti-vimentin (total), pSer39, pSer56 and pSer83, total poly(ADP-
ribose) polymerase (PARP) and cleaved PARP (Cell Signaling Technology, Danvers, MA, 
USA), mouse anti-vimentin V9, and tubulin DM1α (Sigma-Aldrich, St. Louis, MO, USA). 
Phalloidin (Molecular Probes, Eugene, OR, USA) was used to stain filamentous actin. Control, 
mEmerald-C1, and mEmerald-Vimentin-C-18 vectors were obtained from the Michael Davidson 
fluorescent protein collection (Addgene, Cambridge, MA). All chemicals used were purchased 
from Tocris (Bristol, United Kingdom), including the Tocriscreen screening set (a list of 
compounds is provided in the APPENDIX), in addition to individual lots of lovastatin, 
mevastatin, pravastatin, and simvastatin. 
3.2.2 Cell cultures, immunofluorescence staining, imaging, and viability assay 
Cell lines used in the study, SW13-vim+, SW13-vim−, MCF7, and MDA-MB-231, were 
cultured in DMEM with 10% fetal bovine serum, and 1% penicillin-streptomycin. For the small-
molecule screen, cells were treated as described in the next section, then fixed with methanol and 
stained as previously described201. Cells were imaged on the EVOS-FL auto cell imaging system 
(Thermo Fisher Scientific, Waltham, MA, USA) using a x20 (0.75 NA) objective. For triple 
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staining of actin, vimentin, and tubulin, cells were fixed in 4% paraformaldehyde for 10 min at 
room temperature, washed 3x in PBS, permeabilized in 0.1% Triton X-100 (Tx) for 5 min, 
washed 3x in PBS, and incubated in blocking solution (PBS/2.5% wt/vol bovine serum albumin). 
Primary Abs for vimentin (rabbit) and tubulin (mouse) were added overnight in 4°C. The next 
day, slides were washed 3× in PBS and incubated with Alexa Fluor–conjugated secondary Abs 
and phalloidin for 1 h at room temperature. After overnight mounting in ProLong Diamond 
(Thermo Fisher Scientific) that contained DAPI, cells were imaged on Zeiss 880 confocal laser 
scanning microscope using a x63 (1.4 NA) oil immersion objective (Zeiss, Jena, Germany). 
Live/dead assays were performed by using the Ready Probes Cell Viability Imaging Kit 
(Molecular Probes). One drop of NucBlue (stains all cell nuclei) and NucGreen (stains dead cell 
nuclei) (both from Thermo Fisher Scientific) were added to the cells in 500 μl of culture medium 
15 min before imaging. Cells were imaged in 24-well plates by using the EVOS-FL auto system 
with a x10 (0.3 NA) objective. Quantification of nuclei from all cells (blue) and dead cells 
(green) was performed using the EVOS-FL autorecognition counting software. MTT 
(methylthiazolyldiphenyl-tetrazolium bromide) assay to determine cell viability on the basis of 
mitochondrial function was performed by using a commercial kit (Vybrant MTT; Thermo Fisher 
Scientific) according to the manufacturer’s protocol. 
3.2.3 Small-molecule screen, imaging, and quantification of vimentin filament changes 
SW13-vim+ cells were plated on 96-well glass-bottom plates and treated the following 
day (14 plates, 80 compounds per plate; 10 μM final drug added in serum-free DMEM). Each 
plate in the screen included 8 untreated and 8 vehicle (0.1% DMSO)-treated wells in serum-free 
DMEM as control. After 1 h of treatment, medium was aspirated and cells were fixed, stained, 
and imaged on the same day. Fixation and staining were performed as described in Snider et 
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al.201, and images were acquired on EVOS-FL auto using a x20 objective (0.75 NA). 
Approximately 5% of the compounds caused cell liftoff, and they were not considered for 
additional analysis. The remaining wells were analyzed and scored manually for the appearance 
of the vimentin filament network (diffuse/nonfilamentous, peripheral redistribution, bundling, or 
aggregation). Compounds that produced one or more of these effects were considered positive 
hits, and all other compounds were considered negative hits in this screen. Quantification of 
vimentin-positive areas was performed by using ImageJ (National Institutes of Health, Bethesda, 
MD, USA). Vimentin-positive areas were calculated by using the analyze objects program with a 
size exclusion of <10 pixels2. Raw images were converted to 8-bit images and the threshold was 
applied to remove background signal. Average vimentin area is defined as the total signal area of 
all objects divided by the number of objects in each image. The settings allowed the recognition 
of images >10 pixels2 and the removal of nonspecific signal and signal from the edges. 
3.2.4 Preparation of cell lysates and biochemical analysis of vimentin 
Total cell lysates, Tx-soluble, and Tx-insoluble pellets or high-salt extracts (HSEs) were 
prepared as previously described81. Two-dimensional gel electrophoresis samples were prepared 
in ReadyPrep buffer, which contained: 8M urea, 2% CHAPS, 50 mM DTT, 0.2% Bio-Lyte 3/10 
ampholyte, 0.001% Bromophenol Blue (BioRad, Hercules, CA, USA) and subjected to 
isoelectric focusing: 250 V for 15 min, 8000 V for 2 h, 72,000 V hours, and 500 V hold. Cell 
lysates were resolved on 4–20% SDS-PAGE gels, then transferred to PVDF membranes. 
Membranes were blocked by using 5% milk in 0.1% Tween 20/PBS and incubated with the 
designated Abs in milk, with the exception of phospho-specific Abs, which were incubated in 
3% bovine serum albumin in 0.1% Tween 20/PBS. 
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3.2.5 Electron microscopy 
Recombinant human vimentin was generated as previously described244, and vimentin 
filaments were assembled from tetramer buffer (5 mM Tris-HCL, pH 8.5, 1 mM EDTA, 1 mM 
DTT) using an established protocol245 with an added 5-min preincubation step in the presence of 
vehicle or simvastatin. Vimentin filaments were negatively stained with 2% aqueous uranyl 
acetate (pH 4.5). A small droplet (2.5 µl) of protein suspension was applied to a glow-discharged 
formvar/carbon-coated 400 mesh copper grid and allowed to adsorb for 1–2 min. The grid was 
briefly floated on a droplet of deionized water to remove buffer salts and transferred to a droplet 
of 2% aqueous uranyl acetate for 30 s. Excess stain was removed by blotting with filter paper, 
and the grid was air dried. Grids were observed on a LEO EM 910 transmission electron 
microscope at 80 kV (Zeiss). Digital images were acquired by using a Gatan Orius SC1000 
digital camera with Digital Micrograph software (v.2.3.1; Gatan, Pleasanton, CA, USA). 
3.3 Results 
3.3.1 Image-based small-molecule screen identifies vimentin-targeting compounds 
We selected the Tocriscreen library because it consists of a collection of highly pure 
small molecules that are known to be biochemically active and that affect more than 300 
pharmacologic targets, including GPCRs, kinases, ion channels, nuclear receptors, transporters, 
structural molecules, and protein complexes (a full compound list and known targets are included 
in the APPENDIX). We conducted the screen in SW13 adrenal carcinoma cells because these 
cells are commonly used in IF research and because of the availability of a vimentin-positive 
(SW13-vim+) and a vimentin-negative (SW13-vim−) clone, the latter lacking all cytoplasmic 
IFs246. The pharmacologic screen—conducted as outlined in Materials and Methods—identified 
18 positive hits that produced significant changes in vimentin filament morphology within 1 h of 
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treatment (Figure 3.1 and Table 3.1). As a validation of the screening strategy, some of the 
positive hits we identified were expected on the basis of previous work, including kinase and 
phosphatase inhibitors and microtubule-targeting compounds. Among these, the PKC inhibitor, 
palmitoyl-carnitine chloride (Figure 3.1A), the PP1/PP2A inhibitor, cantharidin (Figure 3.1B), 
and the microtubule depolymerizer, nocodazole (Figure 3.1E), induced bundling and 
redistribution of vimentin filaments. We also identified several unexpected novel hits, such as 
diphenylene iodonium chloride (Figure 3.1H) and LY 2183240 (Figure 3.1I), which, among 
other activities, are known to target GPCR signaling related to cannabinoid actions and 
endocannabinoid signaling247. Some of the most prominent and diverse effects on vimentin were 
observed when cells were treated with compounds that target protein-protein interactions and 
multisubunit complexes (Figure 3.1L-P), which is relevant given the well-known scaffolding 
functions of vimentin and other IF proteins248. We also observed striking vimentin bundling in 
the presence of simvastatin (Figure 3.1Q)and mevastatin (Figure 3.1R), 2 fungal metabolites 
that inhibit HMG-CoA, the rate-limiting enzyme in the cholesterol biosynthesis pathway249. 
Mevastatin is not used in the clinic, whereas simvastatin and 2 related fungal-derived 
compounds, lovastatin and pravastatin (both included in the screening library), are commonly 
used for lowering cholesterol in patients249. To validate and further explore mechanisms of the 
hits from the primary screen, we focused on statins because of their pharmacologic and clinical 
importance.  
3.3.2 Simvastatin and mevastatin, but not lovastatin and pravastatin, cause dose-dependent 
bundling of vimentin IFs 
 
The effects on vimentin filaments that were observed as part of the primary screen were 
confirmed by confocal imaging. Representative images in Figure 3.2A show that simvastatin 
treatment caused the reorganization and bundling of vimentin filaments to one side of the 
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nucleus in most cells (marked by arrowheads). Whereas some cells in the untreated group also 
exhibited a compact perinuclear ball-like vimentin structure, in the majority of untreated cells, 
vimentin filaments surrounded and extended away from the nucleus (Figure 3.2A, arrows). To 
quantify the kinetics of vimentin bundling, we used ImageJ software to calculate the ratio of the 
total vimentin-positive area to the total number of objects (i.e., cells), as described in Materials 
and Methods and shown in the representative images in Figure 3.2B. We used this analysis tool 
to quantify the effects of 4 different statins on vimentin filaments. Simvastatin, mevastatin, 
pravastatin, and lovastatin were tested at concentrations of 1 nM–10 μM and 1 h of treatment. As 
shown Figure 3.3A, total vimentin area decreased significantly and dose dependently in 
response to simvastatin and mevastatin, but not lovastatin or pravastatin. Furthermore, whereas 
simvastatin was active at concentrations that ranged from 10 nM to 10 µM, mevastatin was less 
potent and affected vimentin only at concentrations ≥1 µM (Figure 3.3B); therefore, we 
designed the next experiments to examine specifically the interaction between simvastatin and 
vimentin.  
3.3.3 Simvastatin induces time-dependent vimentin bundling independently of changes on actin 
filaments and microtubules 
 
We next assessed the vimentin bundling effects of simvastatin at several time points 
between 15 and 120 min. As shown in the bar graph in Figure 3.4A, the vimentin-positive area 
was reduced to 80, 67, and 50% of untreated control after 15, 30, and 60 min of simvastatin 
treatment, respectively. The maximal effect appeared after 60 min and was similar to the 120-
min treatment. Representative confocal images in Figure 3.4B indicate that, after 15 min, 
vimentin filaments reorganize and shift to one side of the nucleus (arrowheads), followed by the 
appearance of compact ball-like perinuclear vimentin bundles at 30 and 60 min (Figure 3.4B, 
arrows). The rounded perinuclear bundles were also present in some cells after 120 min, 
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although, at this time point, many cells displayed diffuse nonfilamentous vimentin staining 
surrounding the nucleus (Figure 3.4B, asterisks). It has long been known that the inhibition of 
microtubule depolymerization causes vimentin to collapse to the perinuclear region of cells250, a 
phenomenon we observed in our screen with 2 microtubule depolymerizing compounds—
nocodazole and D-64131 (Figure 3.1E, F). Microtubules act as tracks for the bidirectional 
transport of vimentin filaments to allow for a proper array251. This link between microtubules 
and vimentin prompted us to explore whether simvastatin affected another cytoskeletal network, 
thereby indirectly changing vimentin organization. To answer this question, we simultaneously 
stained for actin, tubulin, and vimentin in cells that were treated with DMSO vehicle or 
simvastatin for 60 min (Figure 3.5). At this time point, we did not observe significant changes to 
actin or tubulin, whereas perinuclear vimentin bundling (arrow) was as prominent as we had 
observed previously. These data indicate that simvastatin exhibits pharmacologic selectivity for 
vimentin over actin and tubulin. 
3.3.4 Simvastatin causes time-dependent changes in vimentin solubility 
We next examined how simvastatin affects the biochemical properties of vimentin. To 
study changes in solubility, we analyzed the presence of vimentin in the Tx-soluble fraction by 
immunoblot (Figure 3.6A), which revealed a 4-fold increase in Tx-soluble vimentin at 15–30 
min after simvastatin treatment that returned to control levels at 60 min, as quantified in Figure 
3.6B. A corresponding 10–20% decrease of Tx-insoluble vimentin was observed after 15 and 30 
min of treatment, with no significant difference at 60 min (Figure 3.6B). The relative change in 
the Tx-insoluble pellet fraction was not as robust as the Tx-soluble fraction, as the bulk of 
vimentin is contained within the insoluble fraction27. Because phosphorylation regulates 
vimentin dynamics198, we examined whether simvastatin treatment altered vimentin 
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phosphorylation at 3 common phosphorylation sites in the vimentin head domain (Ser39/-56/-
83). As shown in Figure 3.6C, we did not detect significant changes in site-specific 
phosphorylation either in the Tx-soluble fraction or in the insoluble high-salt extract; however, 2-
dimensional gel analysis revealed an increase in the abundance of a negatively charged isoform 
of vimentin after 60 min of simvastatin treatment (Figure 3.6D, arrow). This suggests that 
changes in vimentin phosphorylation at sites other than Ser39/-56/-83 or another post-
translational modification accompany the morphologic changes in vimentin after 60 min of 
simvastatin treatment. 
3.3.5 Simvastatin promotes vimentin bundling in vitro 
We next examined the possibility that vimentin is a direct target of simvastatin. To test 
this possibility, we preincubated purified vimentin in tetramer buffer for 5 min in the presence of 
DMSO vehicle or simvastatin, initiated vimentin filament assembly, and allowed the reactions to 
proceed for 15, 30, or 60 min. Upon termination of the reactions, samples were pelleted at 
100,000 g, and pellet fractions were analyzed by vimentin immunoblot, which revealed high-
molecular-mass vimentin complexes (>250 kDa) in the presence of simvastatin (Figure 3.7A). 
Negative stain transmission electron microscopy analysis revealed bundling of vimentin filament 
precursors in the presence of simvastatin as early as 1 min after the initiation of assembly 
(Figure 3.7B). The effect was more apparent on mature vimentin filaments (Figure 3.7C). After 
30 min of assembly, we observed the typical ∼10-nm vimentin filaments, as well as ∼20-nm-
thick filaments in the presence of simvastatin, whereas after 60 min, we observed thick vimentin 
filament bundles that may correspond to the high-molecular-mass vimentin species that was 
detected biochemically upon simvastatin treatment in Figure 3.7A. Of note, DMSO vehicle 
treatment itself promoted some bundling after 60 min, but this effect was relatively minor 
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compared with the effect of simvastatin. Our in vitro studies indicate that vimentin is a direct 
target of simvastatin and suggest that this mechanism most likely accounts for the rapid 
simvastatin-induced reorganization and bundling of vimentin filaments that we observed in 
SW13-vim+ cells. 
3.3.6 Simvastatin, but not pravastatin, promotes vimentin-dependent cell death 
To probe the functional significance of the simvastatin-vimentin interaction, we assessed 
whether simvastatin exerts different effects in SW13-vim+ vs. SW13-vim− cells. After 24 h of 
simvastatin treatment, SW13-vim+ cells became rounded with a corresponding drop off in cell 
number to <30% of control (Figure 3.8A, B). In contrast, simvastatin treatment did not affect the 
morphology or number of SW13-vim− cells (Figure 3.8A, B). Pravastatin, which did not affect 
vimentin filaments (Figure 3.3), also did not alter cell morphology or cell numbers in SW13-
vim+ cells (Figure 3.8C, D). To probe this effect further, we assessed the dose dependency of 
simvastatin-induced cytotoxicity in SW13-vim+ cells after 24 h of treatment. As shown in Figure 
3.9A, simvastatin reduced the total number of SW13-vim+ cells at submicromolar 
concentrations, with a corresponding IC50 of 48 nM (Figure 3.9C). Furthermore, at low 
micromolar concentrations, simvastatin promoted significant induction of SW13-vim+ cell death 
(Figure 3.9B, D). We observed the 89-kDa caspase-3/-7 cleavage product of PARP in the 
simvastatin-treated SW13-vim+ cells (Figure 3.9E, F), which indicated that the cells were dying 
by apoptosis252. Taken together, these results suggest that simvastatin targeting of vimentin may 
promote apoptotic cell death. 
3.3.7 Ectopic vimentin overexpression sensitizes SW-vim- cells to simvastatin 
To determine conclusively whether simvastatin sensitivity of SW13-vim+ cells is directly 
dependent on vimentin expression, we examined the response to simvastatin upon transient 
 55 
transfection of mEmerald-vimentin or mEmerald vector in SW13-vim− cells. Vimentin 
overexpression sensitized cells to simvastatin treatment, which resulted in a 50% drop off in cell 
number when vimentin was transiently overexpressed compared with vector alone (Figure 
3.10A). Similar effects were observed upon stable vimentin overexpression, in which case 
simvastatin treatment caused a significant increase in the number of cells that contained rounded 
perinuclear vimentin bundles or aggregates (Figure 3.10B, C). These effects mirror what we 
observed on endogenous vimentin in SW13-vim+ cells and demonstrate that vimentin is a 
functionally relevant direct target of simvastatin that is critical for simvastatin-induced death in 
SW13 adrenal carcinoma cells. 
3.3.8 Simvastatin targets vimentin filaments and causes cell death in MDA-MB-231 breast 
cancer cells 
 
To determine whether our findings in SW13 cells extended to other cell types in which 
vimentin expression is known to regulate cellular properties, we tested 2 breast cancer cell lines: 
MCF7, which are vimentin deficient, and MDA-MB-231, which are vimentin expressing (Figure 
3.11B). It has previously been shown that vimentin regulates properties that are related to the 
epithelial-mesenchymal transition in these cell lines46. Similar to SW13 cells, vimentin filaments 
in MDA-MB-231 cells reorganized into perinuclear bundles in response to simvastatin (Figure 
3.11A). Furthermore, we observed significant cell death when MDA-MB-231 cells were treated 
with simvastatin, but not pravastatin (Figure 3.11C). These data are also consistent with a 
published study that demonstrated that simvastatin induces cell death in MDA-MB-231 cells 
(IC50 = 9 µM), whereas pravastatin does not253. We also quantified cell viability on the basis of 
the mitochondrial MTT assay, which revealed a ∼40% decrease in viability in MDA-MB-231 
cells (Figure 3.11D). In contrast, vimentin-deficient MCF7 cells were not sensitive to either drug 
(Figure 3.11C, D). Taken together, these results demonstrate that the findings in SW13 adrenal 
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carcinoma cells translate to breast cancer cells in which vimentin is known to be functionally 
important. 
3.4 Discussion 
3.4.1 Intermediate filaments as novel drug targets 
In the present study, we conducted a medium-throughput small-molecule screen that 
identified vimentin as a target for several known biochemically active small-molecule 
compounds. By using an image-based screen of the 1120-compound Tocriscreen library, we 
analyzed the effects on vimentin filaments after a relatively short exposure of 1 h to each test 
compound to minimize effects that may be secondary to other major cellular changes (e.g., 
apoptosis or transcriptional reprogramming). With a small compound library, such as that used in 
this study, qualitative scoring for major reorganization of vimentin filaments was possible; 
however, future studies that involve larger compound libraries will necessitate the development 
of computational image analysis tools to monitor and quantify small changes in the IF network 
architecture that may be functionally relevant. A recent study that examined the interactions 
between vimentin filaments and microtubules is one example54. 
3.4.2 Vimentin as a pharmacologically relevant target of statins 
Most of the novel hits we identified through the screen remain to be explored in detail, 
including the regulation of vimentin filaments by compounds that modulate GPCR signaling, 
protein-protein interactions, and enzymes that regulate post-translational modifications. An 
important future aspect of this work will be the subsequent validation studies that involve dose-
response and time-course experiments to discern which of the hits are pharmacologically 
relevant. On the basis of the novelty and potential clinical relevance, we focused here on the 
interaction between statins and vimentin. We demonstrate that simvastatin promotes vimentin 
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filament bundling in the low nanomolar range, which is pharmacologically relevant as serum 
levels in patients who take statins are around 15 nM, with tissue exposure likely being higher254. 
Our data suggest that the mechanism of action involves direct simvastatin-induced 
reorganization of vimentin filaments early on, followed by changes in vimentin post-translational 
modifications, and bundling at later time points, culminating in cell death (Figure 3.12). 
3.4.3 Simvastatin targeting of vimentin 
Statins are taken by millions of people worldwide, and new treatment guidelines may 
significantly increase the number of patients who take them241. The statins we tested are fungal 
metabolites that are related to the original statin (mevastatin), containing a hexahydronaphtalane 
ring249. Simvastatin differs from lovastatin and pravastatin at the dimethylbutyrate ester side 
chain, which suggests that this functional group may be important for the activity on vimentin. 
Crystallographic data reveal that the presence of the additional methyl group on simvastatin 
affects the binding of simvastatin to Aspergillus terreus acyltransferase LovD255,256. Sequence 
alignment of LovD with human vimentin reveals 58% identify between the simvastatin-binding 
LovD peptide sequence, 267FGGQGVFSGPGS278, and vimentin non–α-helical amino terminal 
(head) domain peptide, 15FGGPGTASRPSS26. This suggests that the vimentin head domain may 
potentially mediate binding to simvastatin, although structural and mutagenesis studies will be 
required to elucidate the binding mechanism. Alternatively, the pharmacologic effects may be 
mediated via lipophilic interactions, as vimentin exhibits hydrophobic amino acid clusters and 
has previously been shown to have a high affinity for lipids257. 
3.4.4 Vimentin as a potential determinant of the sensitivity of cancer cells to simvastatin  
Numerous prior studies have reported antiproliferative and proapoptotic effects of statins 
in cancer cells258. Furthermore, previous observations across different cancer cell lines have 
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demonstrated that sensitivity to statin-induced cell death correlates with high levels of vimentin 
expression259. This bears significance as vimentin is a critical component of the epithelial-
mesenchymal transition and regulates cell migration260. Our dose-response studies reveal that 
simvastatin inhibits SW13 cell proliferation with an IC50 of 48 nM in vimentin-expressing, but 
not vimentin-lacking, cells. This demonstrates that the effects we observed at the cellular level 
occur at pharmacologically relevant concentrations and warrant additional investigation using in 
vivo models. It would also be of interest to analyze the effects of synthetic statins, such as 
fluvastatin, atorvastatin, and cerivastatin, on vimentin filament reorganization and vimentin-
dependent cancer cell death. Our findings show that pravastatin differs from simvastatin in terms 
of its lack of effect on vimentin filaments and cell death in the lines tested. In a recent large, 
population-based cohort study, patients who received simvastatin had a 20% reduction in cancer-
specific mortality, whereas use of pravastatin offered no protective benefit261. The LUNGSTAR 
study, a multicenter phase III trial of pravastatin added to standard chemotherapy in small-cell 
lung cancer, concluded that there was no benefit of pravastatin262. Furthermore, simvastatin has 
the most favorable profile on breast cancer prognosis, whereas preclinical and clinical studies 
have not supported a similar protective role of pravastatin263. 
3.4.5 Vimentin as a potential player in statin-associated muscle symptoms 
Although desmin is the major IF in mature muscle fibers, vimentin is expressed during 
myogenesis and is increased during muscle injury264,265. Our results may also provide a potential 
mechanism for statin intolerance, a common clinical problem that limits the use of statins in a 
significant proportion of patients266,267. The molecular mechanisms of statin intolerance are poorly 
understood, and cytoskeletal and other structural or scaffolding proteins have not been implicated 
thus far268; however, a previous study found a significant decrease in skeletal muscle mitochondrial 
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DNA in patients who received simvastatin therapy269. IFs, including vimentin, are critical 
regulators of intracellular organelles, including mitochondria186,270. Vimentin filaments 
specifically are known to regulate structural and functional aspects of mitochondria271,272, and the 
binding of mitochondria to vimentin is regulated by the small GTPase Rac142. Because Rac1 is a 
known target of simvastatin in multiple cell types, including myoblasts, endothelial cells, and 
cancer cells273,274, it is plausible that vimentin may be an upstream mediator of the simvastatin 
effects on this pathway. The prevalence of muscle effects varies depending on the type of statin 
and correlates more strongly with simvastatin. In the Prediction of Muscular Risk in Observational 
conditions study, 18.2% of 1027 patients who received high-dose simvastatin therapy presented 
with muscular symptoms compared with 10.9% of 1901 patients who received high-dose 
pravastatin therapy275. Our finding that simvastatin, but not pravastatin, targets vimentin IFs raises 
the possibility that the simvastatin-vimentin interaction bears potential significance to simvastatin 
action in muscle. Given the high degree of similarity between vimentin and desmin, it would be 
of particular interest to examine the effects of different statins on desmin IFs in future studies. 
3.4.6 The need for pharmacologic tools to probe the function of vimentin and other intermediate 
filaments 
 
Whereas many aspects of basic IF protein function and regulation were elucidated over the 
past 40 years, much remains to be discovered. For example, mechanisms that underlie the crosstalk 
between IFs and other cytoskeletal systems, the identity and function of most IF-regulatory 
proteins, and the signaling pathways that mediate IF associations with the various cellular 
organelles are areas that lack in-depth understanding. Efforts to develop novel tool compounds to 
target IF proteins will accelerate our functional understanding of the IF cytoskeleton, which will 
open up new avenues for its pharmacologic manipulation in the clinic. To this end, the techniques 
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and approaches used in the present study may be generally applicable to future small-molecule 




Figure 3.1 Image-based screen of 1120 biologically active small-molecule compounds for 
effects on vimentin filaments. SW13-vim+ cells, plated on glass-bottom 96-well plates, were 
treated with 1 of 1120 different small-molecule compounds from the Tocriscreen library for 1 h, 
as described in Materials and Methods. Vimentin filaments were visualized in fixed cells by 
indirect immunofluorescence. Shown are untreated (UNT) cells and 18 positive hits. Positive hits 
are defined as those compounds that caused significant vimentin bundling, aggregation, and/or 
peripheral or cytoplasmic redistribution. Palmitoyl-carnitine chloride (A); cantharidin (B); CGP 
52411 (C); m-3M3FBS (D); nocodazole (E); D-64131 (F); KF 38789 (G); diphenylene-
iodonium chloride (H); LY 2183240 (I); carvedilol (J); SB 225002 (K); Ch 55 (L); INCA-6 
(M); JK 184 (N); ivermectin (O); PNU 74654 (P); simvastatin (Q); and mevastatin (R). The 
compounds affect multiple targets and pathways, including: kinases, phosphatases, and lipases 
(A–D); microtubules and adhesion molecules (E–G); GPCRs and GPCR signaling (H–K); 
protein-protein interactions and multisubunit complexes (L–P); and cholesterol biosynthesis 
(Q, R). Note that some hits are expected (e.g., nocodazole), whereas most hits are novel and 





Figure 3.2 Quantification of drug-induced changes in vimentin filaments. (A) Representative 
images of vimentin filaments (red) in untreated (UNT) and simvastatin (SIMVA)-treated SW13-
vim+ cells. Nuclei are stained with DAPI (blue). Vimentin filaments are marked by arrows and 
perinuclear vimentin bundles are marked by arrowheads. (B) Quantification of the vimentin-
positive area in the absence (UNT) and presence of drug; simvastatin is shown as a 
representative example. Shown is a raw image of vimentin staining, threshold of the raw images 
with black representing signal, and outlines of all objects recognized in the threshold image by 
the analyze particles program in ImageJ. The settings allowed for the recognition of images >10 
pixels2 to remove nonspecific signal (purple arrow), fill in holes (red arrow), and remove signal 




Figure 3.3 Dose-response effects of statins on vimentin filaments. (A) Simvastatin, mevastatin, pravastatin, and lovastatin were 
applied for 1 h at concentrations that ranged from 0.001 to 10 μM. Note the dose-dependent decrease in the vimentin-positive area in 
response to simvastatin and mevastatin, but not pravastatin and lovastatin. Shown are representative images of 3 concentrations 
(0.001, 0.1, and 10 μM) from at least 3 independent experiments. (B) Quantification of the total vimentin-positive area in cells that 
were treated with DMSO vehicle and the 4 statins (depicted structurally on the bottom) at different concentrations. Quantification was 
performed as described in Materials and Methods and Figure 3.2B. *P < 0.05, ****P < 0.0001 relative to vehicle control (1-way 







Figure 3.4 Time-dependent effects of simvastatin on vimentin in SW13 cells. (A) Bar graph 
depicting time-dependent effects of simvastatin (gray bars) on the vimentin area relative to 
vehicle control (black bars). Both conditions are expressed as the percent of untreated control 
(n = 3 for each condition). (B) Immunofluorescence images of vimentin (red) and DAPI (blue) at 
different time points after the addition of simvastatin (10 µM) or vehicle control. Vimentin 
filaments reorganize and shift to one side of the nucleus (arrowheads) after 15 min, followed by 
incorporation into ball-like perinuclear bundles at 30 and 60 min (arrows). At 120 min, many 
cells displayed diffuse nonfilamentous vimentin staining around the nuclei (asterisks). *P < 0.05, 
***P < 0.001, ****P < 0.0001 (multiple Student’s t tests). These data were contributed by 




Figure 3.5 Comparison of simvastatin effects on actin filaments, microtubules, and 
vimentin filaments. Quadruple staining for actin (green) tubulin (orange), vimentin (red), and 
DNA (blue) in fixed SW13-vim+ cells that were treated with vehicle (0.1% DMSO) or 
simvastatin (10 μM) for 60 min. Note the simvastatin-induced perinuclear vimentin bundling 
(arrow) and no changes in actin or tubulin. Shown are representative images of at least 3 





Figure 3.6 Biochemical characterization of the simvastatin effect on vimentin in SW13 
cells. (A) Comparison of vimentin levels in the Tx-soluble and -insoluble (pellet) fractions 
relative to total vimentin levels in response to simvastatin treatment for 15, 30, and 60 min. Each 
condition was assayed in triplicate, and shown are representative blots of at least 3 independent 
experiments. (B) Quantification of the band intensity of the blots in panel A. ***P < 0.0001, 
*P < 0.05 compared with control (1-way ANOVA). (C) Immunoblot analysis of common 
vimentin phosphorylation sites in the presence and absence of simvastatin (10 μM; 60 min). (D) 
Two-dimensional gel analysis of vimentin from DMSO vehicle- or simvastatin (10 μM, 60 min)-
treated SW13-vim+ cells. Note the increased abundance of negatively charged vimentin species 
(arrows) in the presence of simvastatin. HSE, high-salt extract. Panel D was contributed by 





Figure 3.7 Effects of simvastatin on in vitro–assembled purified vimentin. (A) Effect of 5-
min, 10-μM simvastatin preincubation on purified vimentin after 15, 30, and 60 min in assembly 
reaction buffer. Note the time-dependent increase in high-molecular-mass (HMM) vimentin 
(>250 kDa) in the presence of simvastatin (S) compared with vehicle (V). (B) Negative stain 
transmission electron microscopy (TEM) images of vimentin filament precursors after 1 min of 
reaction time showing simvastatin-induced vimentin bundling. (C) TEM images of vimentin 
filaments after 30 and 60 min of assembly in the presence of DMSO or simvastatin. Note the 




Figure 3.8 Simvastatin significantly inhibits the growth of SW13-vim+ cells, but not SW13-vim− cells. (A) Phase-contrast images 
(top) and nuclear stain (bottom) of SW13-vim− cells (left 4 panels) and SW13-vim+ cells (right 4 panels). Note the decrease in the 
number of SW13-vim+ cells in response to 24 h of simvastatin treatment (10 μM), appearing smaller and more rounded compared with 
vehicle-treated cells. (B) Quantification of SW13 cell number after exposure to DMSO vehicle or 10 μM simvastatin for 24 h. Double 
immunoblot of actin and vimentin confirms vimentin presence and/or absence in cells. Data are representative of at least 3 
independent experiments. (C) Phase-contrast images and nuclear stain of SW13 vim+ cells in response to 24 h of pravastatin treatment 
(10 μM), which does not affect cell morphology or viability. (D) Quantification of SW13 cell number after exposure to DMSO vehicle 





Figure 3.9 Simvastatin inhibits cell growth and induces dose-dependent apoptotic cell death 
in SW13-vim+ cells. (A) Simvastatin induces dose-dependent reduction in the total number of 
SW13-vim+ cells at pharmacologically relevant concentrations (10 nM–10 µM). Blue stain marks 
the cell nuclei. Cell nuclei were circled (in green) and counted by using the EVOS-FL auto-count 
function. (B) Simvastatin induces dose-dependent cell death in SW13-vim+ cells. Green stain 
marks the nuclei of dead cells. All green nuclei were circled and counted by using the EVOS-FL 
auto-count function. (C) Log dose-response curve for the total number of cells per field as a 
function of simvastatin dose, demonstrating inhibitory effects at low nanomolar concentrations 
(IC50 = 48.1 nM). (D) Quantification of SW13-vim+ cell death in the presence of different 
concentrations of simvastatin (micromolar). **P < 0.01, ****P < 0.0001 compared with vehicle 
control; 1-way ANOVA. (E) Western blot for full-length (∼116 kDa) and cleaved (∼89 kDa) 
PARP showing the presence of cleaved PARP after 24 h of simvastatin treatment. (F) 
Quantification of cleaved PARP band from multiple immunoblots (n = 5). **P < 0.001 (unpaired 




Figure 3.10 Ectopic expression of vimentin sensitizes SW13-vim− cells to simvastatin 
treatment. (A) Transient overexpression of vimentin (24 h), followed by simvastatin treatment 
(10 μM, 24 h), promotes simvastatin-dependent cell death in SW13-vim− cells. (B) Stable 
overexpression of mEmerald-vimentin sensitizes SW13-vim− cells to simvastatin treatment, 
which is accompanied by bundling and aggregation of mEmerald-vimentin. (C) Quantification of 
the number of cells that contained vimentin bundles in the presence of vehicle or simvastatin. 





Figure 3.11 Simvastatin induces vimentin bundling and cell death in the vimentin-positive 
breast cancer cell line, MDA-MB-231. (A) Morphology of vimentin filaments (green) in MDA-
MB-231 cells treated with DMSO vehicle (top) or 10 µM simvastatin for 30 min (middle) or 60 
min (bottom). Note the time-dependent perinuclear bundling of vimentin. Nuclei are stained with 
DAPI. Scale bar, 50 µm. (B) Immunoblot of vimentin in MCF7 and MDA-MB-231 human 
breast cancer cells demonstrating the lack of vimentin in MCF7 cells. (C) Live/dead staining 
showing the nuclei of all cells (blue) and dead cells (green). Note the increase in dead cells in the 
presence of simvastatin, but not pravastatin (10 µM; 24 h), in vimentin-expressing MDA-MB-
231 cells. There is no increase in cell death in the vimentin-negative MCF7 in response to 
simvastatin or pravastatin. Scale bar, 200 µm. (D) MTT assay (absorbance measurement at 570 
nm) of MCF7 and MDA-MB-231 cells that were treated for 48 h in the presence of DMSO 




Figure 3.12 Proposed model for the mechanisms and consequences of vimentin targeting by 
simvastatin. Simvastatin promotes the reorganization of vimentin filaments to one side of the 
nucleus within 15 min of drug addition in SW13-vim+ adrenal carcinoma cells. This timing is 
consistent with the known kinetics of simvastatin uptake in cells276. Combined with the in 
vitro results that demonstrated that simvastatin directly affects vimentin filament assembly, this 
leads us to hypothesize that the early reorganization of vimentin filaments is a direct effect of 
simvastatin binding. Direct binding of simvastatin changes the biochemical properties of 
vimentin, which leads to increased solubility in Tx detergent buffer. At later time points after 
simvastatin addition (30–60 min), vimentin is organized into compact perinuclear bundles. This 
effect is observed in both SW13-vim+ and MDA-MB-231 cells, and correlates with the 
sensitivity of these cells to simvastatin-induced apoptosis at later time points of 24–48 h. 
Cytotoxic effects are directly related to the combination of vimentin expression and simvastatin 
presence, as vimentin-lacking cells are not affected by simvastatin, and statins that do not affect 




















Table 3.1 Positive hits and their corresponding primary targets 
Label Compound Primary target (compound 
activity) 








B Cantharidin PP1 and PP2A (inhibitor) Context-dependent cell 
signaling functions 
C CGP 52411 EGFR (inhibitor) Receptor tyrosine kinase 
regulating multiple 
signaling cascades 
D m-3M3FBS PLC (activator) Numerous cell signaling 
functions, including 
cytoskeletal dynamics 
E Nocodazole Microtubule depolymerizer 
(inhibitor) 
Cell division, movement, 
transport 
F D-64131 Microtubule depolymerizer 
(inhibitor) 
Cell division, movement, 
transport 
G KF 38789 P-selectin mediated adhesion 
(inhibitor) 
Cell adhesion molecule of 




GPR3 (agonist) Orphan GPCR involved in 
aging, metabolism, and 
thermogenesis 
I LY 2183240 FAAH and anandamide uptake 
(inhibitor) 
Endocannabinoid signaling 
J Carvedilol -Adrenergic receptor 
(antagonist) 
GPCR targeted by 
catecholamines 
K SB 225002 CXCR2 chemokine receptor 
(antagonist) 
GPCR targeted by IL-8 
and CXCL1 
L Ch 55 RAR (agonist) Regulation of gene 
expression 
M INCA-6 Calcineurin-NFAT interaction 
(inhibitor) 
Gene regulation in 
response to environmental 
signals 
N JK 184 Hedgehog signaling (inhibitor) Cell survival, 
differentiation, and cancer 
O Ivermectin 7-Nicotinic receptor 
(activator) 
Ligand-gated calcium ion 
channel  
P PNU 74654 -Catenin-TCF4 interaction 
(inhibitor) 
Transcriptional regulation 
of cell adhesion and 
epithelial-mesenchymal 
transition 
Q Simvastatin HMG-CoA reductase (inhibitor) Cholesterol and nonsterol 
isoprenoid biosynthesis 




CHAPTER 4: SITE-SPECIFIC PHOSPHORYLATION AND CASPASE CLEAVAGE OF 
GFAP ARE NEW MARKERS OF ALEXANDER DISEASE SEVERITY1 
 
4.1 Introduction  
Alexander disease (AxD) is a rare and invariably fatal neurological disorder that affects 
primarily infants and small children, but can also manifest later in life277-279. Autosomal 
dominant gain-of-function mutations in GFAP, which encodes glial fibrillary acidic protein 
(GFAP), cause AxD131,279. GFAP is the major component of the intermediate filament (IF) 
cytoskeleton in astrocytes110. The accumulation and incorporation of mutant GFAP within 
cytoplasmic aggregates called Rosenthal fibers (RFs), causes reactive gliosis, leading to 
secondary injury to neurons and non-neuronal cells148,160,163,280. Silencing GFAP via antisense 
oligonucleotide intervention in vivo eliminates RFs, reverses the stress GFAP has been observed 
after various injuries of the central nervous system (CNS) including kainic acid-induced seizures, 
cold-injury, and hypoxic-ischemic models, where phosphorylated GFAP is expressed in reactive 
astrocytes281-283. These observations reveal that phosphorylation of GFAP is important for re-
organization of the astrocyte IF cytoskeleton and plasticity in response to injury. However, it is 
not clear if, and how, abnormal GFAP phosphorylation compromises proteostasis and 
contributes to AxD pathogenesis.  
 
1 This chapter previously appeared as an article in the eLife Journal. The original citation is as 
follows: Battaglia, R. A. et al. Site-specific phosphorylation and caspase cleavage of GFAP are 
new markers of Alexander disease severity. Elife 8, e47789 (2019). 
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Here, we identified a critical phosphorylation site in the GFAP head domain that is 
selectively and strongly upregulated in the brain tissues of AxD patients who died very young, 
independently of the position of the disease mutation that they carried. Further, we show that this 
site-specific phosphorylation promotes GFAP aggregation and is a marker of perinuclear GFAP 
aggregates associated with deep nuclear invaginations in AxD patient astrocytes, but not in 
isogenic control astrocytes. Finally, we demonstrate a correlation between site-specific GFAP 
phosphorylation and caspase cleavage in cells and in post-mortem brain tissue from AxD 
patients. Although our study does not establish a causal relationship between GFAP 
phosphorylation and caspase cleavage, we show that caspase-6 is a new marker for the most 
severe form of human AxD.  
Collectively, our results reveal a new PTM signature that is associated with defective 
GFAP proteostasis in the most severe form of AxD. Future interventional studies targeting these 
PTMs will determine whether they contribute to, or are the consequence of, disease severity.  
4.2 Results  
4.2.1 Phosphorylation of Ser13 on GFAP is a marker of the most aggressive form of AxD 
IFs undergo protein synthesis-independent turnover and re-organization to meet cellular 
demands284. PTMs are key in that process, as they regulate filament polymerization and 
depolymerization, protein-protein interactions, and oligomerization properties of IF proteins31. 
Of all known PTMs that regulate IFs, phosphorylation is the most ubiquitous and can facilitate or 
antagonize other types of PTMs via complex cross-talk mechanisms285. We hypothesized that 
AxD-associated GFAP missense mutations (Figure 4.1A) promote GFAP accumulation and 
aggregation by dysregulating site-specific phosphorylation. We extracted GFAP from post-
mortem brain cortex tissue of 13 AxD patients, representing 10 different mutations 
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(Supplementary Table 4.1) and three non-AxD controls (Supplementary Table 4.2). GFAP 
from the insoluble high salt extracts (HSEs), prepared according to the procedure described in 
Supplemental Figure 4.1, was used in phospho-proteomic analysis, revealing 12 unique 
phosphorylation sites on GFAP in AxD (Figure 4.1B–C). While the AxD-specific phospho-
peptides localized to all three functional domains of GFAP (head, rod, tail), the most abundantly 
phosphorylated residue was a conserved serine (Ser13) in the head domain (Figure 4.1C–D). 
Strikingly, we found that the pSer13-GFAP peptide was selectively elevated in the cortex tissue 
from AxD patients who died very young (median age at death = 1.7 years; range 0.5–14 years) 
(Figure 4.2A). Overall, we did not observe significant phosphorylation of GFAP in the control 
subjects (Figure 4.2—source data 1), or in AxD patients who lived 27–50 years (median age at 
death = 38 years). Further, immunoblot analysis using a phospho-specific antibody (KT13)286 
against pSer13-GFAP validated the mass spectrometry results in the AxD patients (Figure 4.2B–
C). Although there was one notable outlier in each age group (Figure 4.2B lanes 3 and 11), our 
results suggest that pSer13-GFAP is primarily associated with the more aggressive, infantile 
form of AxD. Furthermore, the differences in phosphorylation were not a result of age, since 
pSer13 GFAP was generally not present in the brain lysates from non-AxD control subjects, 
regardless of age (Figure 4.2D).  
4.2.2 Phospho-mimic mutation at Ser13 promotes GFAP aggregation  
To determine the functional significance of pSer13 on GFAP filament organization, we 
analyzed the filament properties of non-phosphorylatable (S13A) and phospho-mimic (S13D and 
S13E) GFAP mutants. We optimized a transient over-expression system in the SW13 vimentin-
negative adrenocarcinoma cells (SW13vim-) for this assay, which resulted in primarily 
filamentous WT GFAP and insoluble aggregated forms of common AxD mutants of GFAP 
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(Supplemental Figure 4.2). Compared to wild-type (WT) GFAP, the S13D and S13E mutants 
assembled primarily into large aggregates, similar to the most common AxD-associated mutant 
R79H-GFAP (Figure 4.3A–B). S13A formed mostly filaments, although they appeared shorter 
compared to WT GFAP. To determine if the phospho-mimic mutation directly promotes 
aggregation, we compared the assembly properties of purified WT, S13A and S13D GFAP 
(Figure 4.3C). Consistent with the phenotype observed in the transfected cells, the S13A mutant 
formed abnormally short filaments in vitro. In contrast, S13D was completely incapable of 
filament assembly, forming globular structures that were homogeneous in size and not 
aggregation-prone. Our results with the phospho-deficient and phospho-mimic mutants reveal 
that S13 is a key site that regulates the assembly properties of GFAP and that its phosphorylation 
status may modulate the dynamics between filaments and aggregates.  
4.2.3 Generation of AxD induced pluripotent stem cells (iPSCs) and isogenic controls 
In order to explore the function of this phosphorylation event in a disease-relevant 
system, we used an in vitro human astrocyte model of AxD. We generated iPSCs using 
fibroblasts from a young AxD patient and characterized their pluripotency by 
immunofluorescence staining (Figure 4.4A). Karyotype analysis showed that there were no 
chromosomal abnormalities due to the reprogramming process (Figure 4—figure supplement 1). 
To generate isogenic control cells, we corrected the heterozygous point mutation in GFAP 
(c.715C > T, p.R239C) using CRISPR/Cas9 mediated gene editing (Figure 4.4B). 
Representative chromatograms are shown for the original patient cells and the isogenic controls 
(Figure 4.4C). We also isolated ‘CRISPR control’ clones, which were edited on the wild-type 
GFAP allele, thereby retaining the AxD-causing mutation and serving as an additional disease 
control for the gene editing procedure. Similar to the original patient cells, the edited cells were 
 78 
karyotyped and characterized for pluripotency (Supplemental Figure 4.3). We confirmed that 
there were no off-target effects due to the editing procedure (Supplementary Table 4.3).  
4.2.4 GFAP accumulation and perinuclear aggregation into RF-like structures in AxD iPSC-
astrocytes 
 
AxD, CRISPR control, and isogenic control iPSCs were differentiated to astrocytes 
(iPSC-astrocytes) via neural progenitor cells (NPCs), as described in the Materials and methods 
and shown schematically in Figure 4D. After 54 days in culture, iPSC-astrocytes express 
classical astrocyte markers287, including alcohol dehydrogenase 1 family member L1 
(ALDH1L1), solute carrier family 1 member 3 (SLC1A3), excitatory amino acid transporter 2 
(EAAT2), Connexin 43 and GFAP (Supplemental Figure 4.4). To assess if our model 
recapitulated key features of AxD, we analyzed total GFAP expression in the iPSC-astrocytes by 
immunoblot, and found that GFAP levels were significantly higher in the cells that carried the 
heterozygous GFAP point mutation (AxD patient and CRISPR control lines) relative to the 
isogenic controls (Figure 4.4E–F). This is consistent with in vivo observations of GFAP levels 
in AxD patients288 and mouse models289. In addition, high-molecular-mass (hmm) GFAP 
oligomers were present in the AxD iPSC-astrocytes, similar to what we observed when we 
ectopically expressed the R239C-GFAP mutant (Figure 4.5A). Finally, we observed by 
immunofluorescence staining that the AxD mutant iPSC-astrocytes formed both GFAP filaments 
and perinuclear aggregates (Figure 4.5B), whereas the isogenic control iPSC-astrocytes formed 
only GFAP filaments (Figure 4.5C). In vivo, GFAP antibodies stain the periphery, while DAPI 
stains the core of RFs136,138. The in vitro-derived AxD iPSC-astrocytes displayed similar 
characteristics, with RF-like perinuclear aggregates staining positively for GFAP at their 
periphery and DAPI in the center (Figure 4.5B).  
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4.2.5 pSer13-GFAP marks the core of perinuclear GFAP aggregates localized within deep 
nuclear invaginations 
 
Next, we determined if pSer13-GFAP was present in the AxD iPSC-astrocytes, similar to 
what we observed in the human brain tissues. As shown in Figure 4.6A, pSer13-GFAP signal 
was detected strongly within the core of the perinuclear GFAP aggregates of AxD iPSC-
astrocytes. Somewhat surprisingly, we also observed pSer13-GFAP signal in the isogenic control 
cells, possibly triggered by the in vitro culture conditions. Nevertheless, unlike AxD astrocytes, 
in the isogenic control astrocytes pSer13-GFAP organization was filamentous and paralleled that 
of total GFAP. Therefore, the in vitro iPSC-astrocyte model revealed that, only in the presence of 
the AxD disease mutation, pSer13-GFAP is incorporated within the core of perinuclear 
inclusions. While in all AxD cells pSer13 signal was detected in the aggregates, we also 
observed cells with pSer13-positive diffuse cytoplasmic staining and filaments, likely reflecting 
different states of the GFAP network (Supplemental Figure 4.5). Furthermore, the pSer13-
positive GFAP aggregates appeared adjacent to prominent nuclear invaginations (Figure 4.6A). 
Nuclear deformations, similar to what we observed in the AxD iPSC-astrocytes, are also present 
in RF-bearing astrocytes in AxD human brain138. To determine whether the perinuclear 
aggregates compromised the nuclear envelope, we examined the AxD iPSC-astrocytes by 
electron microscopy. While we observed filamentous bundles on the cytoplasmic side of the 
nuclear invaginations, the nuclear envelope appeared intact (Figure 4.6B). Thus, pSer13-GFAP 
marks cytoplasmic GFAP aggregates adjacent to nuclear invaginations. It should be noted that 
the perinuclear aggregates containing disorganized GFAP filaments are not identical to the 
electron-dense RFs that are seen in post-mortem patient brain, but that they may reflect an 
intermediate state of GFAP accumulation.  
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4.2.6 Phosphorylation at Ser13 promotes caspase-mediated cleavage of GFAP 
To understand the mechanism for how GFAP phosphorylation may promote GFAP 
aggregation, we conducted a biochemical analysis of the S13A, S13D and S13E GFAP mutants. 
In line with our immunofluorescence result (Figure 4.3A), we observed an increase in high-
molecular-mass ~100 kDa GFAP oligomer in the phospho-mimic mutant by immunoblot 
analysis (Figure 4.7A). However, more strikingly, we observed increased levels of a cleaved 
GFAP fragment (24 kDa) in S13D and S13E, which was significantly lower in WT- and S13A-
GFAP (Figure 7A–B). Cleavage of GFAP by caspase-6 in vitro generates two fragments of 24 
and 26 kDa size290. The 24 kDa C-terminal fragment is recognized by the monoclonal GA5 
antibody290, which was used here. Therefore, we tested the effect of a peptide inhibitor of 
caspase-6 (Ac-VEID-CHO), and found that it significantly reduced the amount of cleaved S13D-
GFAP (Figure 4.7C–D). Furthermore, we observed augmented cleavage of S13D-GFAP when 
combined with an AxD-causing mutation (S13D/R79H double mutant), and this was also 
blocked by the caspase-6 inhibitor (Figure 4.7C–D). Further analysis of the AxD mutant R79H 
in the transfection system revealed phosphorylation not only at S13, but also at nearby Y14, S16, 
and S17 (Supplemental Figure 4.6 and Figure 4.7—source data 1). Of note, mutagenesis of 
S16 and S17 to non-phosphorylatable alanines reduced both the cleavage and oligomerization of 
R79H (Supplemental Figure 4.6). Phospho-motif analysis revealed that S13, S16 and S17 are 
part of a segment in the GFAP head domain that is a potential target for several kinases 
(Supplementary Table 4.4). Candidate kinases include casein kinase 2 (CK2), protein kinase A 
(PKA), PKC, MAP kinase activated protein kinase 2 (MAPKAP2), and glycogen synthase 
kinase 3 (GSK3). These data suggest that phosphorylation of Ser13 (and nearby S16/17) may 
promote caspase-6-mediated cleavage of GFAP in the context of AxD mutations. In line with 
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that, we observed increased levels of cleaved GFAP (upon normalization for total GFAP) in the 
AxD iPSC-astrocytes compared to isogenic control astrocytes (Figure 4.7E), along with intense 
caspase-6 staining within perinuclear GFAP aggregates in AxD iPSC-astrocytes, but not isogenic 
control astrocytes (Figure 4.7F).  
4.2.7 Interference with GFAP cleavage by caspase-6 partially reduces aggregation of the 
phospho-mimic mutant S13D 
 
To determine how blocking GFAP cleavage affects aggregation, we performed site-
directed mutagenesis to block cleavage of GFAP at Asp225. As shown in Figure 4.8A–B, the 
D225E mutation reduced cleavage of S13D GFAP by >90%. This resulted in partial rescue of 
filament structure in S13D, although the D225E mutation on its own caused significant filament 
bundling and perinuclear structures that resembled large aggregates (Figure 4.8C–D). We also 
tested the effect of the caspase-6 inhibitor Ac-VEID-CHO, and found that it reduced both the 
size of the S13D aggregates (Figure 4.8E) and the presence of ~100 kDa hmm GFAP oligomers 
(Figure 4.8F–G). However, similar to the mutagenesis experiment, filament bundles were 
observed in WT and S13D GFAP treated with Ac-VEID-CHO, suggesting that caspase-6 
regulates both aggregation and normal GFAP filament reorganization.  
4.2.8 Caspase-6 expression and GFAP cleavage are upregulated in AxD patients 
Caspase-6 is not expressed highly in the normal human brain, especially after birth291. 
Therefore, we wanted to examine its expression in the context of AxD. Using immunoblot 
analysis of total brain lysates, we found that caspase-6 is expressed in the brain tissue from all 8 
AxD patients who died very young, but is essentially undetectable in the patients who survived 
longer (Figure 4.9A). To ensure caspase-6 expression is not simply more abundant in young 
individuals, we compared brain lysates from young and old AxD patients to non-AxD control 
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brains from age-matched individuals, and observed a significant increase in caspase-6 expression 
selectively in young AxD patients, but not in the other groups (Figure 4.9B–C).  
Next we asked whether AxD patients, particularly young AxD patients that exhibit more 
pSer13-GFAP and caspase-6 expression, also displayed increased GFAP cleavage. To determine 
the extent of caspase-6-cleaved GFAP in AxD patient brains, we utilized an antibody that 
specifically recognizes N-terminally caspase-6-cleaved GFAP (D225)290. We detected cleaved 
GFAP in extracts from AxD patient brains, and we observed a significant increase in the amount 
of D225 signal in young AxD patients, which paralleled the increased pSer13 signal in these 
samples (Figure 4.9D–E). In agreement with the biochemical evidence, brain tissues from young 
AxD patients stained intensely for cleaved GFAP, while the signal was significantly weaker in 
AxD patients who were older (Figure 4.9F; Supplemental Figure 4.7). The signal was 
particularly strong around perinuclear areas and surrounded circular structures that stained 
positive for DAPI (Figure 4.9F, bottom panels), similar to what we observed in the AxD iPSC-
astrocytes. Thus, our results show that caspase-6 expression in AxD patient brain tissue parallels 
the presence of cleaved GFAP, and both are selectively and significantly elevated in patients 
who succumbed to the disease very early in life.  
4.3 Discussion  
Our study reveals that missense mutations, affecting discrete domains on the GFAP 
molecule, share a common PTM signature that is associated with compromised GFAP 
proteostasis in the severe form of AxD. Using patient brain tissue and human iPSC-derived AxD 
astrocytes, we show that head domain phosphorylation promotes defective filament assembly 
and perinuclear accumulation and incorporation of mutant GFAP within nuclear invaginations. 
By taking an unbiased mass spectrometry proteomic approach, we were able to identify GFAP 
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phospho-peptides that were selectively elevated in human AxD brain tissue, and subsequently 
validated these results using a phospho-specific antibody against the most abundant epitope 
(pSer13-GFAP). We demonstrate the importance of the Ser13 site for GFAP assembly in vitro 
and in cells. Phospho-mimetic mutation S13D completely abolished the ability of GFAP to form 
filaments in vitro, without leading to aggregation. In transfected SW13vim- cells, phospho 
mimic S13D-and S13E-GFAP mutants formed highly abnormal perinuclear aggregates that 
correlated with increased cleavage of GFAP by caspase-6. We detected a dramatic increase in 
caspase-6 expression, in association with Ser13 phosphorylation and cleavage of GFAP, in the 
brain tissue of AxD patients who succumbed to the disease very early in life. While the N-
terminal caspase-6 fragment of GFAP promotes filament aggregation in vitro290, presently we do 
not have direct evidence of cause and effect between caspase-6 cleavage and GFAP aggregation 
in AxD patient cells. Nevertheless, our current findings provide a basis for exploring PTM-based 
diagnostic and potential therapeutic strategies in AxD.  
Our study does not address whether Ser13 phosphorylation directly promotes caspase 
cleavage of GFAP, or if these two PTMs are independent markers of an increased cellular stress 
response in AxD. One possibility is that Ser13 phosphorylation destabilizes the filament 
structure, thereby promoting access of caspase-6 to the rod domain Asp225 residue, where the 
cleavage occurs. Another likely possibility is that the increased cleavage of GFAP is an indirect 
result of stress-dependent caspase-6 activation in the more severe form of AxD. This is 
supported by previous studies showing that AxD mutations promote activation and nuclear 
accumulation of p53148, which can directly induce caspase-6 expression292. Future studies in 
AxD iPSC-astrocytes and animal models will be required to determine the timing of GFAP 
phosphorylation and caspase-6 activation in relationship to GFAP cleavage and aggregation.  
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Given our findings that pSer13-GFAP is enriched in the most aggressive form of AxD, 
monitoring the levels of this phospho-epitope (in addition to total GFAP) in AxD patient 
cerebrospinal fluid or blood may provide added sensitivity for disease activity288. 
Phosphorylation of Ser13 by protein kinase C and cAMP-dependent protein kinase was initially 
described in vitro using purified recombinant GFAP293. In the presence of active kinases, Ser-13 
phosphorylation occurred in conjunction with phosphorylation at three additional sites (Thr-7, 
Ser-8, and Ser-34). Phosphorylation of monomeric GFAP at these sites prevented filament 
assembly, while phosphorylation of in vitro assembled GFAP filaments led to their 
disassembly293. Using the same antibody to pSer13-GFAP that we used in this paper (clone 
KT13) it was later shown that Aurora-B and Rho-associated kinase phosphorylate GFAP in 
cultured astrocytoma cells during mitosis294. This may bear relevance to AxD, since human and 
mouse AxD astrocytes with RFs display mitotic abnormalities138. However, it was also shown 
using knock-in mice with the human GFAP head domain that, in vivo, the distribution of pSer13 
localization was not limited to mitotic astrocytes, but that select astrocyte populations within 
multiple regions were pSer13 positive, such as those in the olfactory bulb, subpial regions, and 
subventricular zone159,282. Interestingly, the regional distribution of pSer13 largely overlaps with 
areas that are known to be most enriched in RFs in the AxD mouse model159. Therefore, this 
particular phosphorylation event on GFAP may occur during mitosis, or in phenotypically 
distinct astrocyte populations. This remains to be addressed in the future using the appropriate 
model systems, as over-expression studies in cancer cell lines (such as the SW13vim- cells we 
used here) may not be truly reflective of the signaling that occurs in astrocytes. In particular, it 
remains to be resolved whether phosphorylation of GFAP on Ser13 is part of a sequentially 
priming phosphorylation cascade involving nearby Ser16/17 (as predicted by the kinase motif 
 85 
analysis) or if Ser16/17 phosphorylation is unique to the SW13 over-expression system. 
Importantly, identifying the relevant in vivo kinase(s) that phosphorylate GFAP in human AxD 
may lead to potential novel interventions via kinase inhibition.  
Caspase-mediated proteolysis of IF proteins is an important mechanism by which the 
filament networks re-organize during apoptosis. Although multiple effector caspases are capable 
of cleaving IF proteins, caspase-6 is frequently implicated in cleavage at a conserved motif 
within the linker L12 region of the rod domain, which results in the generation of two fragments 
of similar sizes. This was initially demonstrated to be the case for the type I keratins295, and later 
shown to also occur on vimentin296, desmin297, A-type lamins298, and GFAP110. Caspase-6 
cleavage of GFAP at 222VELD225 in vitro generates an N-terminal 26 kDa fragment and a C-
terminal 24 kDa fragment. The N-terminal fragment directly impairs assembly of full-length 
GFAP and promotes aggregation in vitro290. Using a specific antibody recognizing the N-
terminal GFAP fragment (D225), we show here that GFAP cleavage is significantly increased in 
AxD tissues from patients presenting with an aggressive form of AxD, and that this parallels 
elevated expression of caspase-6. This could suggest that misregulation of caspase-6 may 
contribute to the severity of AxD. However, we were not able to demonstrate in cells that 
inhibition of caspase-6, or mutagenesis of the cleavage site on GFAP, can resolve aggregate 
formation. These results point to a more complex function for caspase-6, likely involving 
cytoskeletal remodeling in response to stress.  
Indeed, caspase-6 upregulation has been reported in other neurodegenerative diseases 
involving protein aggregation, including Huntington’s Disease (HD) and Alzheimer’s Disease 
(AD)299-301. Similar to GFAP, there is a caspase-6 cleavage site on the aggregation-prone 
proteins in both AD (amyloid precursor protein) and HD (huntingtin). Furthermore, in caspase-6 
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cleavage-resistant genetic mouse models of both HD and AD, neuronal dysfunction and 
degeneration are rescued302-304. Caspase-6 can promote neurodegeneration via induction of 
neuronal apoptosis or axon pruning305. However, the functions of caspase-6 in astrocytes are not 
clear. In the context of human AxD it still remains to be determined which astrocyte populations 
express caspase-6, and whether it promotes apoptosis or performs a non-apoptotic role, such as 
sculpting the cytoskeletal architecture in reactive astrocytes. Based on our demonstration that 
caspase-6 localizes within the perinuclear GFAP inclusions in the AxD iPSC-astrocytes, it is 
intriguing to speculate that, similar to keratin inclusions in epithelial cells306, RFs sequester 
active caspases away from other cellular substrates and may protect reactive astrocytes from 
apoptosis.  
Recently, iPSC-derived patient astrocyte models have emerged as an important system 
for dissecting the cellular mechanisms in AxD. For example, these novel tools have revealed that 
AxD astrocytes have defects in the secretory pathway, impaired ATP release, and attenuated 
calcium waves163; that they inhibit oligodendrocyte precursor cell proliferation160, providing a 
potential mechanistic explanation for the degeneration of white matter observed in patients; and 
that they have defects in mechanotransduction signaling pathways156. A novel aspect of the AxD 
astrocyte cell model that we generated in our study is the perinuclear accumulation of pSer13-
GFAP that was associated with prominent nuclear abnormalities. As such, these patient-derived 
cells replicate a key phenotypic characteristic of RF-bearing AxD astrocytes in vivo, since 
nuclear invaginations have been described in electron microscopy studies of AxD mouse models 
and AxD patient cortex138. Another important parallel is that the GFAP inclusions we observe in 
the AxD patient astrocytes in vitro stain positive for DAPI, and it was shown that DAPI is a 
reliable and sensitive marker of RFs in human and mouse brain138. Therefore patient-derived 
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iPSC-astrocytes provide a unique model system to investigate cytoplasmic-nuclear mechanics in 
AxD.  
Invaginations of the nucleus, such as those we observe here, have been described in 
physiological and pathological states307. Control of nuclear shape is critical for regulation of gene 
expression and response to mechanotransduction signals308. The effects of impaired nuclear 
morphology can be very severe, as evidenced by mutations in lamin A that lead to defective 
nuclear morphology in Hutchinson-Gilford Progeria Syndrome (HGPS), where patients 
experience accelerated aging309. An elegant study combining multiple 3D imaging strategies 
established a direct link between intermediate filaments, actin and the nuclear envelope within 
nuclear invaginations, and genetic evidence indicates that filamentous actin may play a role in 
generating these structures310,311. It is hypothesized that nuclear invaginations provide localized 
control of gene expression and nuclear-cytoplasmic transport deep within the nucleus, since they 
have been found to contain calcium receptors and nuclear pores307. Our study provides the first 
link between abnormal cytoplasmic PTM processing and perinuclear accumulation of mutant 
GFAP with nuclear defects, setting the stage to address how nucleo-cytoskeletal coupling is 
adversely impacted by defective IF proteostasis in AxD and related human diseases.  
4.4 Materials and Methods 
4.4.1 Antibodies 
The following antibodies were used: rabbit anti-GFAP (DAKO Agilent, Santa Clara, CA, 
Z0334), rabbit anti-caspase-6 (Cell Signaling Technologies, Danvers, MA, 9762), rabbit anti-
Caspase-6 (abcam, Cambridge, UK, ab185645), rabbit anti-D225290, mouse anti-GFAP (Sigma, 
GA5), mouse anti-pSer13-GFAP (KT13286), mouse anti-pan Actin, mouse anti-Tra-1– 60, mouse 
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anti-SSEA4, rabbit anti-Oct4, rabbit anti-Sox2, and Alexa 488- and Alexa 594-congujated goat 
anti mouse or rabbit antibodies (Thermo Fisher Scientific, Waltham, MA). 
4.4.2 Cell lines  
SW13vim- cells were provided by Dr. Bishr Omary and cultured in DMEM with 10% 
fetal bovine serum and 1% penicillin-streptomycin. Authentication of the cell line was done by 
short tandem repeat (STR) profiling by ATCC. Fibroblasts from a male 6 year old type I AxD 
patient were obtained from the Coriell institute (Camden, NJ). Sanger sequencing was performed 
to confirm the AxD mutation was present in the cells (c.715C > T; p.Arg239Cys). The cell lines 
used tested negative for mycoplasma contamination, as assayed using the Universal Mycoplasma 
Detection Kit (ATCC 30–1012K).  
4.4.3 Human brain tissues  
De-identified post-mortem fresh-frozen and fixed AxD patient and control brain tissues 
were provided by the NIH NeuroBioBank and are described in Supplementary Table 4.1 and 
4.2.  
4.4.4 Mass spectrometry  
Sample Preparation: HSEs from AxD patient post-mortem brain cortex tissue were 
prepared as described previously81,200 and in Figure 1—figure supplement 1, then subjected to 
SDS-PAGE followed by Coomassie stain. Bands corresponding to GFAP were excised and the 
proteins were reduced, alkylated, and in-gel digested with trypsin overnight at 37 ̊C. Peptides 
were extracted, desalted with C18 spin columns (Pierce – Thermo Fisher Scientific) and dried 
via vacuum centrifugation. Peptide samples were stored at -80°C until further analysis. LC-
MS/MS Analysis: The peptide samples were analyzed by LC/MS/MS using an Easy nLC 1200 
coupled to a QExactive HF mass spectrometer (Thermo Fisher Scientific). Samples were injected 
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onto an Easy Spray PepMap C18 column (75 m id x25 cm, 2 m particle size) (Thermo Fisher 
Scientific) and separated over a 1 hr method. The gradient for separation consisted of 5–40% 
mobile phase B at a 250 nl/min flow rate, where mobile phase A was 0.1% formic acid in water 
and mobile phase B consisted of 0.1% formic acid in 80% ACN. The QExactive HF was 
operated in data-dependent mode where the 15 most intense precursors were selected for 
subsequent fragmentation. Resolution for the precursor scan (m/z 300–1600) was set to 120,000 
with a target value of 3 x 106 ions. MS/MS scans resolution was set to 15,000 with a target value 
of 1 x 105 ions. The normalized collision energy was set to 27% for HCD. Dynamic exclusion 
was set to 30 s, peptide match was set to preferred, and precursors with unknown charge or a 
charge state of 1 and ≥7 were excluded. Data Analysis: Raw data files were processed using 
Proteome Discoverer version 2.1 (Thermo Fisher Scientific). Peak lists were searched against a 
reviewed Uniprot human database, appended with a common contaminants database, using 
Sequest. The following parameters were used to identify tryptic peptides for protein 
identification: 10 ppm precursor ion mass tolerance; 0.02 Da product ion mass tolerance; up to 
two missed trypsin cleavage sites; phosphorylation of Ser, Thr and Tyr were set as variable 
modifications. The ptmRS node was used to localize the sites of phosphorylation. Peptide false 
discovery rates (FDR) were calculated by the Percolator node using a decoy database search and 
data were filtered using a 5% FDR cutoff. The peak areas for the identified peptides were 
extracted and used for relative quantitation across samples.  
4.4.5 Site directed mutagenesis, in vitro assembly, transfections, and immunofluorescence 
Mutagenesis of GFAP (Origene, Rockville, MD, in vector CMV6-XL6) was performed 
using the QuikChange II mutagenesis kit (Agilent) to generate the designated point mutants. 
Sanger sequencing of the entire coding sequence of GFAP was performed to confirm the wild-
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type and mutant sequences. We used established procedures for the purification and in vitro 
assembly of GFAP312. For transfections, lipofectamine 2000 was used according to the supplier 
instructions (Invitrogen, Thermo Fisher Scientific, Carlsbad, CA), and experiments were 
performed 20–24 hr after transfection. For immunofluorescence, cells were fixed in methanol at -
20 ̊C for 10 min, washed three times in PBS and incubated in blocking solution (2.5% bovine 
serum albumin, 2% normal goat serum in PBS) for 1 hr at room temperature. Primary antibodies 
were diluted into blocking buffer and incubated overnight at 4°C. The next day, cells were 
washed 3 times in PBS and incubated with Alexa Fluor-conjugated secondary antibodies diluted 
into blocking buffer for 1 hr at room temperature. Cells were washed 3 times in PBS, incubated 
in DAPI for 5 min, washed 3 times and mounted in Fluoromount-G (SouthernBiotech, 
Birmingham, AL) overnight. Cells were imaged on Zeiss 880 confocal laser scanning 
microscope using a 63x (1.4 NA) oil immersion objective (Zeiss, Jena, Germany).  
4.4.6 Preparation of protein lysates and western blotting  
High salt extracts (HSEs) and triton-X (TX) lysates were prepared as previously 
described81. Total lysates were prepared by homogenizing 25 mg tissue directly into hot 2X Tris-
Glycine SDS Sample Buffer (Thermo Fisher Scientific) and heating for 5 min at 95 ̊C. 
Immunoblotting was performed as previously described313. Briefly, samples were resolved on 4–
20% gradient SDS-PAGE gels transferred onto activated polyvinylidene difluoride membranes at 
40V overnight. The transferred gels were routinely stained with Coomassie blue and the 
membranes were blocked in 5% non-fat milk in 0.1% tween 20/PBS (PBST). Post-transfer 
Coomassie-stained gels served as another loading control where the levels of housekeeping 
protein (actin) varied (Figure 4E). For immunoblotting, the membranes were incubated with the 
appropriate primary antibody diluted in 5% milk/PBST, with the exception of KT13, which was 
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incubated in 5% bovine serum albumin/PBST for blocking, primary antibodies and secondary 
antibodies. Antibodies were detected using ECL reagents (PerkinElmer Life Sciences, 
Hopkinton, MA). For 2D gel analysis, HSEs were dissolved in 2-D starter kit rehydration/sample 
buffer (Biorad; 1632106) for separation by isoelectric focusing (IEF). Immobilized pH gradient 
(IPG) strips (Biorad; 11 cm; pH 4–7; 1632015) were passively rehydrated in 2-D starter kit 
rehydration/sample buffer overnight. Cup loading method was employed to load the protein 
samples in cathode side (as isoelectric point of GFAP is 5.2) of the Protean IEF cell tray (Biorad; 
1654020). The IEF separation was done using 72000 vh. After IEF separation the protein 
samples were further separated based on molecular weight using SDS-PAGE gel by applying 
constant 90 volts.  
4.4.7 Cellular reprogramming, characterization and karyotyping of iPSCs  
Skin fibroblasts were reprogrammed under feeder free conditions using Cytotune –iPS 
2.0 Sendai Reprogramming kit and individual iPSC clones were picked for propagation in 
culture for 10 passages. To confirm stemness and differentiation capabilities of reprogrammed 
and edited iPSCs, we used the qPCR based TaqMan human Pluripotent Stem Cell Scorecard 
Panel (Thermo Fisher Scientific). iPSCs were differentiated into all three germ layers using 
STEMdiff Trilineage Differentiation Kit (StemCell Technologies, Vancouver, Canada), and a 
monolayer-based protocol was used to directly differentiate hES cells in parallel into the three 
germ layers (~1 week). Non-differentiated and differentiated cells were lysed and total RNA 
purified using the RNeasy kit (QIAGEN). RNA reverse transcription was performed following 
the Taqman Scorecard’s manufacture guidelines and the qRT-PCR was carried out using the 
QuantStudio 7 Flex Real-Time PCR system. The TaqMan PCR assay combines DNA 
methylation mapping, gene expression profiling, and transcript counting of lineage marker 
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genes314. Reprogrammed and edited iPSCs were submitted to a standard G-band analysis 
consisting of 20 metaphase spreads. The analysis (carried out by Karyologic Inc) can identify 
gender, chromosome number, and detect aberrations that include trisomies, monosomies, 
deletions, insertions, translocations, duplications, breaks, polyploidy, among others. No 
abnormalities were found in our cell lines (Figure 4—figure supplement 2A).  
4.4.8 CRISPR/Cas9 genome editing  
We used the TrueCut Cas9 Protein V2, sgRNAs and the Neon Transfection system 
(Thermo Fisher Scientific) to edit iPSCs. The recombinant TrueCut Cas9 V2 was diluted in 
resuspension buffer R provided in the kit and mixed with 900 ng of sgRNA and 2700 ng of 
single-stranded donor oligonucleotide, incubated 15 min at room temperature and then a total of 
3 x 105 iPSCs were electroporated with the ribonucleoprotein mix. Seventy-two hours after 
electroporation, cells were dissociated into single cells, diluted, and seeded on Matrigel-coated 
96-well plates. Single-cell colonies were selected after two weeks and tested for gene correction. 
Genomic DNA of single clones was extracted and the gene of interest amplified by PCR using 
allele specific primers. Sanger sequencing of positive clones demonstrated single or double allele 
gene correction. Off-target sites within the exons of genes were predicted via selection of the top 
candidates using the MIT software (CRISPR.mit.edu). The analysis was performed via PCR of 
400 bp fragments, which flanked the predicted off-target cut site followed by Sanger sequencing. 
The chromatograms for edited clones were compared to sequences from the original AxD patient 
cells.  
4.4.9 iPSC culture and astrocyte differentiation  
iPSCs were maintained on Matrigel in StemFlex medium (Thermo Fisher Scientific) and 
passaged every 3–4 days with 0.5 mM EDTA dissociation solution. iPSCs were differentiated 
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into neural progenitor cells (NPC) using an embryoid body (EB) protocol. Briefly, iPSCs at 80% 
confluence were collected, resuspended in Neural Induction Medium (NIM, StemCell 
Technologies) and seeded on one well of an Aggrewell 800 plate (StemCell Technologies) at 3 x 
106 cells per well. At day five, EBs were seeded on poly-ornithine and laminin (PLO/LAM)-
coated dishes in NIM. Rosette selection was performed after 12 days using Rosette Selection 
Reagent (StemCell Technologies). NPCs were expanded for 7 days in Neural Progenitor 
Medium (StemCell Technologies). NPCs were then differentiated into astrocyte precursors by 
seeding dissociated single cells at 1 x 105 cells/cm2 density on PLO/LAM dishes in STEMdiff 
astrocyte differentiation medium (StemCell Technologies). Astrocyte precursors were 
maintained for 20 days with medium changes every 48 hr and splitting every week with 
Accutase (Millipore, Burlington, MA). Astrocytes were expanded for up to 120 days in 
STEMdiff astrocyte maturation medium (StemCell Technologies).  
4.4.10 Transmission electron microscopy  
AxD iPSC-astrocytes grown on a polystyrene dish were fixed in 2.5% glutaraldehyde in 
0.1M sodium cacodylate buffer, pH 7.4, for one hour at room temperature and stored at 4 ̊C. The 
cells were washed 3 times in 0.1M sodium cacodylate buffer followed by post-fixation in 1% 
buffered osmium tetroxide for 1 hr. After three washes in deionized water, the cells were 
dehydrated in ethanol, infiltrated and embedded in situ in PolyBed 812 epoxy resin 
(Polysciences, Inc, Warrington, PA). The cell monolayer was sectioned en face to the substrate 
with a diamond knife and Leica UCT Ultramicrotome (Leica Microsystems, Inc, Buffalo Grove, 
IL). Ultrathin sections (70 nm) were mounted on 200 mesh copper grids and stained with 4% 
uranyl acetate and lead citrate. The sections were observed and digital images were taken using a 
JEOL JEM-1230 transmission electron microscope operating at 80kV (JEOL USA, Inc, 
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Peabody, MA) equipped with a Gatan Orius SC1000 CCD Digital Camera (Gatan, Inc, 






Figure 4.1 GFAP is phosphorylated on head domain Ser13 in human AxD brain. 
(A) Schematic displays the frequency and location of AxD patient GFAP mutations. (B) Method 
used to identify GFAP phospho-peptides. (C) Graph of AxD-specific GFAP phospho-peptides 
identified by mass spectrometry and type/position of patient mutations. PSM = peptide spectrum 
match. Green diamonds represent GFAP mutations in young patients (median age at death = 1.7 
years; range 0.5–14 years) and pink diamonds represent older patients (median age at death = 38 
years; range 27–50 years). (D) Amino acid conservation at the N-terminus of human, rat and mouse 
GFAP. The green box indicates the serine corresponding to human Ser13, which is conserved in 




Figure 4.2 GFAP is phosphorylated on head domain Ser13 primarily in AxD brain from 
young patients. (A) Quantification of pSer13-GFAP abundance by mass spectrometry in young 
(green) vs. old (pink) AxD patients (*=p < 0.05 unpaired t-test). (B) Validation of pSer13-GFAP 
by western blot of HSE from AxD patients, using a phospho-specific antibody to pSer13-GFAP. 
The order of samples, by AxD donor ID number, is: 1482, 1070, 885, 5488, 1161, 2768, 338, 613, 
5377, 5517, M3596, 5109, and 4858 (listed in Supplementary Table 1). (C) Quantification of the 
relative intensity of pSer13-GFAP on western blot in young (green) and old (pink) AxD patients 
(*=p < 0.05 unpaired t-test). Signal intensity was normalized to total GFAP in each sample. (D) 
Western blot of pSer13-GFAP in non-AxD control brain lysates of different ages. The order of 
samples, by donor ID number, is: 1547, 5941, 103, 1791, 1670, 4898, 1706, 1711, 1011, 632, 4640, 




Figure 4.3 Effect of phospho-deficient and phospho-mimic S13 substitutions on GFAP 
filament assembly in cells and in vitro. (A) Representative images of immunofluorescence 
staining of DNA (blue) and GFAP (green) in SW13vim- cells transfected with wild-type GFAP 
(WT), R79H mutant GFAP (R79H), non-phosphorylatable GFAP (S13A), and phospho-mimic 
GFAP (S13D and S13E) as single or double mutations, as noted in the images. Scale bar = 5 µm. 
(B) Quantification of percentage of cells containing GFAP filaments, aggregates or both (n = 41–
103 cells per condition). RH = R79H; SA = S13A; SD = S13D; SE = S13E. (C) Electron 
micrographs showing the filament properties of in vitro assembled GFAP (WT, S13A and S13D). 
Bottom three panels represent magnified areas marked by the white boxes in the top panels. Scale 




Figure 4.4 Generation and characterization of AxD patient iPSC-astrocytes and isogenic 
controls. (A) Characterization of iPSC pluripotency. Bright field images of AxD patient 
fibroblasts (top left) and iPSCs (bottom left). Immunofluorescence staining for pluripotency 
markers in AxD iPSCs. (B) GFAP sequence for the AxD mutant allele and the corrected allele. 
Differences between the sequences are indicated by red text. The AxD-causing mutation is 
underlined, and all other changes are silent mutations. The area of gRNA recognition is indicated 
by the red line. (C) Chromatograms showing AxD heterozygous mutation in the original patient 
cells (top), correction of the mutant allele in the isogenic control (middle) and correction of the 
wild-type allele in the CRISPR control (bottom). Red arrows denote presence of the disease 
mutation and green check mark denote genetic correction and presence of silent mutations. (D) 
Schematic representation of astrocyte differentiation protocol. NIM, neural induction medium; 
NPM; neural progenitor medium; ADM, astrocyte differentiation medium; AMM; astrocyte 
maturation medium. (E) Immunoblot of GFAP in iPSC-astrocytes. Pan-actin blot and Coomassie 
stain serve as loading controls. (F) Quantification of band intensities for GFAP from panel E. 




Figure 4.5 Oligomerization and perinuclear aggregation of GFAP in AxD iPSC-astrocytes. 
(A) GFAP blot of AxD iPSC-astrocytes (left) and SW13vim- cells transfected with R239C mutant 
GFAP (right) reveals GFAP monomer and high-molecular-mass GFAP oligomers. Immunoblots 
on the bottom are of the same membranes at lower exposure. (B) Immunofluorescence staining for 
GFAP (magenta) and DAPI (white) in AxD iPSC-astrocytes reveals presence of perinuclear GFAP 
aggregates, marked by the yellow arrows. Scale bars = 10 µm. Boxed area in the merged image is 
shown by the enlarged image on the right. (C) Immunofluorescence staining for GFAP (magenta) 




Figure 4.6 pSer13 marks perinuclear accumulation of GFAP within nuclear invaginations in 
AxD iPSC-astrocytes. (A) Immunofluorescence staining of total GFAP (magenta), pSer13-GFAP 
(green) and DAPI (blue) in isogenic control (top panels) and AxD mutant (bottom panels) iPSC-
astrocytes. Perinuclear GFAP aggregates are indicated by the yellow arrows. Scale bars = 10 µm. 
(B) Electron microscopy images of AxD patient iPSC-astrocytes revealing large, juxtanuclear 
fibrous bundles (boxed area on left), shown at higher magnification on the right. Scale bar = 5 µm 




Figure 4.7 Phosphorylation of Ser13 on GFAP promotes caspase-6 cleavage of GFAP. 
(A) GFAP blot of SW13vim- cells transfected with vector, WT, S13A, S13D and S13E - GFAP. 
Full-length (fl) and cleaved fragment (cf) of GFAP are indicated by arrows. Immunoblot on the 
bottom shows GFAP monomer (fl) from the same membrane at a lower exposure. (B) 
Quantification of panel A by densitometry shows cleaved and full-length GFAP in phospho-
mutants relative to WT GFAP (mean ± SD from three independent experiments; *p<0.05 two-way 
ANOVA). (C) GFAP blot in SW13vim- cells transfected with either S13D or S13D/R79H double 
mutant GFAP and treated for 48 hr with a caspase-6 inhibitor (Ac-VEID-CHO). (D) Quantification 
of GFAP bands in panel C by densitometry (mean ± SD from three biological replicates; **p<0.01; 
****p<0.0001 two-way ANOVA). (E) Immunoblot for GFAP monomer (fl) and cleaved fragment 
(cf) in isogenic control and AxD iPSC-astrocytes. Different amounts of total protein were loaded 
to normalize GFAP monomer levels. (F) Immunofluorescence staining of caspase-6 (magenta), 
GFAP (green) and DAPI (blue) in human AxD and isogenic control iPSC-astrocytes showing 
caspase-6 co-localization within GFAP aggregates in the AxD cells, indicated by the arrowheads. 




Figure 4.8 Inhibition of GFAP cleavage by caspase-6 partially alleviates aggregation due to 
S13D phospho-mimic mutation. (A) Western blot of GFAP total cell lysates from SW13vim- 
cells transfected with empty vector control, WT, S13D, D225E, and double S13D/D225E mutants. 
Shown are GFAP cleaved fragment (cf), full-length (fl) monomer and pan-actin (loading control). 
(B) Quantification of the abundance of cleaved GFAP in the three mutants shown in panel A 
relative to WT GFAP (mean ± SD from three biological replicates; ****p<0.0001 compared to 
S13D; one-way ANOVA). (C) Representative images of immunofluorescence staining of DNA 
(blue) and GFAP (green) in SW13vim- cells transfected with wild-type GFAP (WT), phospho-
mimic GFAP (S13D), and non-cleavable GFAP (D225) as single or double mutations, as noted in 
the images. Scale bar = 10 µm. (D) Quantification of percentage of cells containing GFAP 
filaments, aggregates or both (n = 76–85 cells per condition). (E) Representative images of 
immunofluorescence staining of DNA (blue) and GFAP (green) in SW13vim- cells transfected 
with wild-type GFAP (WT) or phospho-mimic GFAP (S13D) and treated with vehicle (control) 
or the caspase-inhibitor Ac-VEID-CHO (10 µM, 48 hr). (F) Western blot analysis of SW13vim- 
total lysates transfected with S13D GFAP and treated with vehicle (control) or caspase-6 inhibitor 
Ac-VEID-CHO (10 µM, 24 hr), showing the 24 kDa caspase-cleaved fragment (cf), 50 kDa full-
length (fl), and high-molecular-mass ~100 kDa GFAP. (G) Quantification of the relative 





Figure 4.9 High expression of caspase-6 in young AxD patient brain tissue correlates with 
increased levels of cleaved GFAP. (A) Immunoblot for caspase-6 in total lysates from human 
AxD post mortem brain tissue shows that caspase-6 is upregulated in young AxD patients. Pan-
actin is used as a loading control. (B) Immunoblot for caspase-6 in total lysates from young and 
old non-AxD control and AxD patient post-mortem brain tissue. Pan-actin blot serves as a loading 
control. (C) Quantification of band intensities in panel B by densitometry of caspase-6 normalized 
to actin. **p<0.01; two-way ANOVA. (D) Western blotting for full-length GFAP or cleaved 
GFAP (D225 antibody) in HSEs from human AxD post-mortem brain tissue. (E) Quantification 
of band intensities from panel D by densitometry of D225, normalized to total GFAP (**p<0.01, 
unpaired t-test). (F) Immunofluorescence staining showing widespread presence of cleaved GFAP 
(D225; magenta) in cerebral cortex and underlying white matter of 347 day-old child with AxD 
and low expression of cleaved GFAP in a 42 year old AxD patient. Wider fields of view and 
sections from additional patients are shown in Figure 7 – figure supplement 1. DAPI nuclei are 
shown in white in bottom panels, and arrow highlights perinuclear aggregate containing cleaved 
GFAP and staining positively for DAPI in brain tissue from a child with AxD. Scale bar = 100 µm 




Supplemental Figure 4.1 Preparation of brain high salt extracts (HSE) for mass 
spectrometry analysis of GFAP. Isolation of intermediate filament proteins using high salt 
extraction. Shown is an abbreviated version of the protocol referenced in Materials and methods. 
Adopted from Snider & Omary, Methods in Enzymology 2016. In the panel on the right, purified 
GFAP is resolved in parallel with a representative HSE from an AxD patient brain cortex tissue. 




Supplemental Figure 4.2 Optimization of transient expression for WT and AxD-associated 
GFAP mutant proteins in SW13vim- cells. (A) Western blot of SW13vim- cells transfected for 
24 hr with the designated GFAP constructs. NTC, non-transfected control. Top and bottom blots 
show GFAP and pan-actin, respectively, in the Triton X-100-soluble fraction (TX-100). Middle 
blot is a total cell lysate (TCL) blot of GFAP from the same transfections. (B) Corresponding 
immunofluorescence staining of GFAP in SW13vim- cells after 24 hr of transfection. Scale 




Supplemental Figure 4.3 Characterization of pluripotency in AxD and isogenic control 
iPSCs. (A) Karyotype analysis for original AxD patient iPSCs, isogenic control (MDCL11) and 
CRISPR control (MDCL14) iPSCs showing normal karyotypes for all three clones. (B) 
Immunofluorescence staining for iPSC pluripotency markers (red/green) and DAPI (blue). Scale 
bars = 400 µm. (C) TaqMan hPSC Scorecard Panel that compares the gene expression profile of 
the generated iPSCs against nine reference lines. Heat map of the genes that are up-regulated (red), 
have the same expression level (white) or are down -regulated (blue) in the iPSCs. Colors correlate 
to the fold change in expression of the indicated gene relative to the undifferentiated or Day seven 
embryoid body (EB) differentiated reference set. Shown at the bottom are differentiation index 
plots of changes in self-renewal genes (green) and differentiation genes (blue-ectoderm, orange-





Supplemental Figure 4.4 Characterization of astrocyte differentiation. 
(A) Immunofluorescence staining for astrocyte markers ALDH1L1 and SLC1A3 (green) and 
DAPI (blue) in isogenic control, CRISPR mutant and AxD iPSC-astrocytes. Scale bars = 20 µm. 
(B) Immunofluorescence staining for astrocyte markers GFAP (magenta), Connexin-43 (green, 
top), EAAT2 (green, bottom) and DAPI (blue) in AxD iPSC-astrocytes. Scale bars = 10 µm. 
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Supplemental Figure 4.5 Three types of staining pattern observed with the pSer13 GFAP 
antibody in AxD iPSC-astrocytes. Three types of cells were observed with respect to pSer13 
signal: Type I: primarily aggregates (arrows); Type II: aggregates and soluble cytoplasmic GFAP 




Supplemental Figure 4.6 Analysis of major sites of phosphorylation on R79H GFAP 
expressed in SW13 vim- cells. (A) Coomassie stain of a HSE extracts from WT and R79H GFAP 
analyzed by 2-dimensional (2D) gel electrophoresis. Red arrow points to a negatively charged 
species that was only present in R79H and analyzed by mass spectrometry. (B) Summary of 
phosphorylation state of the negatively charged GFAP species from panel A. (C) Effect of 




Supplemental figure 4.7 Presence of cleaved GFAP in in post-mortem brain tissue of AxD 
children versus adults. Human brain sections were immunostained with the D225 antibody, 
which recognizes the N-terminal fragment of cleaved GFAP at Asp-225. 
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Supplemental Table 4.1 Donor information for AxD post-mortem human brain specimens. 











Race Cause of Death Other 
refere
nces 
1482 0 244 F D395Y 2 Caucasian Complication of 
disorder 
 














5488 1 0 F R239H 7 Caucasian Complication of 
disorder 
 
1161 2 175 M R239C 4 Caucasian Complication of 
disorder 
 
2768 2 NA F N77S 17 Caucasian Complication of 
disorder 
 
338 6 87 M R239C 12 Caucasian Complication of 
disorder 
 








5377 27 139 F K63E 22 Caucasian Complication of 
disorder 
 












5109 42 217 F D417A 4 Caucasian Complication of 
disorder 
 
4858 50 139 F S247P 17 Caucasian Complication of 
disorder 
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Race Cause of 
Death 





5941 2 0 Male N/A – 
Control 
9 Hispanic Drowning 










4670 4 237 Male N/A – 
Control 
17 Caucasian Commotio 
Cordis 
4898 7 272 Male N/A – 
Control 
12 Caucasian Accident, 
Drowning 









1670 13 99 Male N/A – 
Control 
5 Caucasian Asphyxia 
By Hanging 
1711* 27 340 Female N/A – 
Control 










632 34 71 Male N/A – 
Control 
6 Caucasian Accident, 
Multiple 
Injuries 
4640 47 124 Female N/A – 
Control 
5 Caucasian Pneumonia 
4915 49 160 Male N/A – 
Control 
5 Caucasian ASCVD 
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Supplemental Table 4.3 Summary from off-target sequencing from CRISPR/Cas9 editing. 









MRNIP/SQSTM1 51149/8878 1bp insertion of 
G in 3’UTR 
(chr5. 
179840448) 
1bp insertion of 
G in 3’UTR 
(chr5. 
179840448) 
1bp insertion of 
G in 3’UTR 
(chr5. 
179840448) 










GNB1L/TBX1 54584/6899 No mutations No mutations No mutations 
INPP4B 8821 No mutations No mutations No mutations 
POLD1 5424 No mutations No mutations No mutations 
RABEP2 79874 Mutation outside 
of exon A G 
(chr16.28906323) 
Mutation outside 
of exon A G 
(chr16.28906323) 
Mutation outside 
of exon A G 
(chr16.28906323
) 
SGSM3 27352 No mutations No mutations No mutations 
WNT5B 81029 Mutation outside 
of exon A C 
(chr12.1639668) 
Mutation outside 
of exon A C 
(chr12.1639668) 
Mutation outside 
of exon A C 
(chr12.1639668) 
DMPK 1760 No mutations No mutations No mutations 
  
 114 
Supplemental Table 4.4 GFAP phosphorylation motifs and candidate kinases. 
Position Sequence Motif (red=phospho site) Features of motif 
described in the 
literature 
11-13 RRS RXpS PKA kinase substrate 
motif 
11-13 RRS (R/K)X(pS/pT) PKA kinase substrate 
motif 
11-13 RRS (R/K)X(pS/pT) PKC kinase substrate 
motif 
12-17 RSYVSS X(pS/pT)XXX(A/P/S/T) G protein-coupled 
receptor kinase 1 
substrate motif 
13-16 SYVS (pS/pT)XX(S/T) Casein Kinase I 
substrate motif 
13-16 SYVS pSXX(E/pS*/pT*) Casein Kinase II 
substrate motif 
13-16 SYVS (pS/pT)XX(E/D/pS*/pY*) Casein Kinase II 
substrate motif 
13 - 17 SYVSS pSXXX(pS/pT) MAPKAPK2 kinase 
substrate motif 
13 - 17 SYVSS pSXXXpS* GSK3 kinase substrate 
motif 
16 - 19 SSGE pSXX(E/D) Casein kinase II 
substrate motif 
16 - 19 SSGE (pS/pT)XX(E/D) Casein Kinase II 
substrate motif 
16 - 19 SSGE (pS/pT)XX(E/D) Casein Kinase II 
substrate motif 
17 - 19 SGE pSX(E/pS*/pT*) Casein Kinase II 
substrate motif 
 
*indicates the residue that has to be phosphorylated already for the enzyme to recognize 
the motif 
PhosphoMotif Finder was used to generate the motif predictions315.  
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Identifiers Additional Information 
Gene 
(human) 
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CHAPTER 5: INTERMEDIATE FILAMENT PROTEOSTASIS FAILURE IN 
ASTROCYTES AND ASTROCYTE PROGENITORS WITH NATURALLY-
OCCURRING KLHL16 (GAN) MUTATIONS 
 
5.1 Introduction 
Giant Axonal Neuropathy (GAN) is a rare pediatric neurodegenerative disease and 
length-dependent distal axonopathy that affects the Central, Peripheral, and Autonomic Nervous 
Systems166-169. Individuals with GAN experience a range of symptoms, including muscle 
weakness, gait abnormalities, and gastrointestinal issues, and usually succumb to respiratory 
failure within the second or third decade of life168. GAN is caused by recessive loss of function 
mutations in the KLHL16 gene (also known as GAN) that encodes gigaxonin, an E3 ubiquitin 
ligase adaptor protein178. Gigaxonin promotes degradation of many members of the intermediate 
filament (IF) gene family, which are cell type-specific cytoskeleton components181,183,184. Thus, 
without proper IF turnover, GAN patients accumulate IF aggregates in cell types where 
gigaxonin targets are expressed, including neurons, melanocytes, endothelial cells, lens epithelial 
cells, Schwann cells and astrocytes171-174. However, the defining pathological characteristic of 
GAN, from which the name is derived, is the swollen, giant axons that are filled with bundles of 
intermediate filaments. For the past several decades, neurons have been the predominant focus of 
GAN research. While sensory and motor neuron function is significantly impacted in GAN 
patients and can directly lead to loss of sensation and ambulation, the contribution of non-
neuronal cells should also be examined, especially when considering therapeutic approaches, 
such as gene therapy.  
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Astrocytes, in particular, are important to consider in GAN because they likely contribute 
directly to neuronal dysfunction. When the Central Nervous System (CNS) suffers injury, 
astrocytes undergo a process called reactive astrogliosis, which is generally characterized by 
hypertrophy of cell branches, increased proliferation, and gene expression changes, notably the 
upregulation of IF genes75,76.  Depending on the injury, reactive astrocytes can exert a wide 
spectrum of effects on surrounding cells ranging from toxic to beneficial316-318. Recently, reactive 
astrocytes have gained notoriety as an important factor in many neurodegenerative disorders 
since they contribute to disease progression through loss of neuroprotective functions and/or gain 
of neurotoxic functions76,319-324. Like most neurodegenerative diseases, GAN is characterized by 
the presence of reactive astrocytes172. In GAN, reactive astrocytes overwhelmingly display a 
characteristic feature referred to as Rosenthal fibers (RFs)173. RFs are aggregates containing glial 
fibrillary acidic protein (GFAP), the major IF of mature astrocytes, as well as ubiquitin, B-
crystallin, and small heat shock protein 27136-138. RFs can also arise upon GFAP overexpression 
or in Alexander disease (AxD) where there are autosomal dominant GFAP mutations, and they 
coincide with astrocyte dysfunction and non-cell autonomous neuronal death131,151. While RFs 
are not completely unique to GAN and AxD, the widespread nature of RFs in these two pediatric 
neurodegenerative diseases is unparalleled. Therefore, it is important to determine the effect of 
altered IF proteostasis and reactivity on GAN astrocyte function. 
Astrocytes are a major glial cell type in the CNS that regulate complex brain functions, 
including memory, learning, sleep, and injury response2,325. At the molecular level, astrocytes 
orchestrate this control through intricate cell processes that communicate with an array of 
different cell types: other astrocytes, neurons, oligodendrocytes, microglia, and perivascular 
cells325. While rodent and human astrocytes share many fundamental properties, human 
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astrocytes are larger and more complex than their rodent counterparts4. With a diameter 
measuring 2.6-fold larger, human astrocytes can initiate more cell-cell interactions than rodent 
astrocytes4. For example, it is estimated that a single human astrocyte can contact up to 2x106 
neuronal synapses compared to only 1.2x105 for rodent astrocytes4. Beyond size, the morphology 
of human astrocytes is also more sophisticated. Based on their unique branching patterns and 
shapes, human astrocytes have been divided into several different classes, two of which have not 
been identified in rodents4. These morphological and size differences are accompanied by 
functional differences in astrocytes between species4. With these important caveats in mind, we 
sought to generate a human astrocyte model of GAN in order to identify novel disease 
mechanisms.  
In this work, we use induced pluripotent stem cell (iPSC) technology and directed 
differentiation to develop a patient-derived human astrocyte model of GAN. We show that all 
GAN iPSC lines lack gigaxonin protein, which can be restored upon genetic correction of the 
KLHL16 mutation. This model reproduces astrocyte intermediate filament aggregation 
comparable to RFs that accumulate in GAN and AxD. The RF-like inclusions observed in GAN 
iPSC-astrocytes accompany deep nuclear invaginations, similar to those observed previously in 
AxD iPSC-astrocytes, suggesting possible shared mechanisms326. Finally, we identify vimentin 
as a key player in promoting aggregation in astrocytes and astrocyte progenitor cells in GAN. 
Together, our results highlight species differences in the KLHL16 gene and astrocyte 
physiology that may contribute to disease pathology of GAN. Future studies will apply this 
model to characterize the role of vimentin and post-transcriptional mechanisms in RF formation. 
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5.2 Results 
5.2.1 Unique properties of the human KLHL16 gene necessitate development of a human disease 
model of Giant Axonal Neuropathy 
 
Knowing that there are key differences between rodent and human astrocytes, we also 
wondered if there were also molecular differences in the KLHL16 gene itself that could 
contribute to GAN pathology. The KLHL16 gene is ubiquitously expressed in humans, and 
orthologous genes exist in many other vertebrates, including canines, rodents, and even the 
zebrafish model organism. The presence of KLHL16 orthologs in other species has allowed for 
the identification of a spontaneous case of GAN in canines and the generation of GAN models in 
rodents and zebrafish327-331. However, as depicted in Figure 5.1A, the human KLHL16 gene has 
unique properties compared to other species, most notably the unusually long 3’UTR. 
Conspicuously, the canine KLHL16 gene also contains a lengthy 3’UTR whereas the rodent 
KLHL16 genes have shorter 3’UTRs. This is especially interesting considering that canine GAN 
recapitulates many features of GAN while rodent GAN models fail to demonstrate the full 
spectrum of GAN symptoms327-330. When compared to other KLHL gene family members, 
KLHL16 alone harbors an unusually long 3’UTR even though the resulting KLHL16 protein 
contains a similar number of amino acids to its related proteins (Figure 5.1B). This is 
noteworthy because the 3’UTR can regulate several aspects of mRNA biology, including 
degradation, translation, and localization, yet the human KLHL16 3’UTR is not represented in 
current animal models332. We found that Van Nostrand et al. previously reported significant 
associations between KLHL16 mRNA transcript and 18 RNA Binding Proteins (RBPs) through 
the high-throughput ENCODE eCLIP project (Figure 5.1C)333. Considering the growing 
appreciation for the role dysregulation of RBPs and RNA metabolism in neurodegenerative 
disease334, this new information motivated us to develop a human model for GAN in which we 
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could investigate the effect of KLHL16 mutations in a context with the human 3’UTR (Figure 
5.1D, E).  
5.2.2 Generation and characterization of mutant KLHL16 induced pluripotent stem cells (iPSCs) 
and isogenic controls 
 
To examine the effect of KLHL16 mutations in a range of human cell types, we first 
obtained fibroblasts from seven different GAN patients (Supplemental Table 5.1). The GAN 
cell lines contained unique KLHL16 mutations that span all functional domains of gigaxonin, 
including null mutations (patients 3, 4) as well as mutations in the BTB (patient 2), Back (patient 
3), or Kelch (patients 1, 5, 6, 7) domains (Figure 5.1D). Then we reprogrammed these 
fibroblasts to induced pluripotent stem cells (iPSCs). Pluripotency was evaluated by the 
ThermoFisher Scorecard314, which compares gene expression of various self-
renewal/pluripotency genes to that of genes distinct to the three germ layers (Supplemental 
Figure 5.1A). The pluripotency was also assessed in each cell line via immunofluorescence 
staining for several markers of pluripotency (Supplemental Figure 5.1B). Finally, karyotyping 
was performed to ensure that no genomic abnormalities had arisen during reprogramming 
(Supplemental Figure 5.1C).  
Next, we used CRISPR/Cas9 gene editing in iPSCs to correct the point mutation and 
generate isogenic controls for patient 7 (G332R). This cell line was selected because it represents 
a strong levels of disease severity and harbors a point mutation which is especially amenable to 
gene editing using our methods in iPSCs326. We used an allele-specific PCR screen to select for 
edited clones, which were verified by Sanger sequencing (Supplemental Figure 5.2A). 
Chromatograms from the target region are shown for the parental line as well as the corrected 
clones (Supplemental Figure 5.2B). We confirmed that there were no off-target mutations via 
Sanger sequencing of the top 20 off-target regions within exons (Supplemental Table 5.2). 
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Since KLHL16 mutations deplete gigaxonin protein expression335, we performed immunoblotting 
for gigaxonin in our isogenic control iPSCs to determine whether genetic correction of KLHL16 
mutation could rescue gigaxonin expression. As expected, GAN iPSCs showed little to no 
gigaxonin expression while isogenic control iPSCs displayed gigaxonin expression that was 
comparable to control stem cell lines (Figure 5.2A). Interestingly, although gigaxonin protein is 
reduced in GAN iPSCs, there is no difference in KLHL16 gene expression (Supplemental 
Figure 5.2C).  
5.2.3 KLHL16 mutant stem cells display aberrant expression of select cytoskeletal intermediate 
filaments (IFs) 
 
KLHL16 is not an essential gene and mutations do not cause embryonic lethality, 
suggesting that there are not major deficiencies in stem cell function. As expected, GAN iPSCs 
divide and differentiate normally. However, knowing that iPSCs express various cytoskeletal and 
nuclear IFs, we asked whether proteostasis of IFs was disrupted in GAN stem cells. Starting with 
iPSCs, we examined nuclear IFs, and did not detect any visible differences in lamin B1 
expression or morphology by biochemical and immunofluorescence analysis (Figure 5.2A, B). 
We did not detect much lamin A/C expression by immunofluorescence in any of the iPSC lines 
(data not shown), in agreement with previous findings that undifferentiated cells express low 
levels of lamin A/C 336,337.  
Next, we examined cytoplasmic IFs that are known to be expressed in iPSCs by 
immunofluorescence: keratin 8 (K8) and vimentin. While we observed no difference in K8 
expression or morphology, we noticed a striking upregulation of vimentin in iPSCs from GAN 
patient 7 compared to isogenic controls (Figure 5.2C). By western blot, we observed an increase 
in vimentin expression in iPSCs from GAN patients 2, 5, 6, and 7 (vim-high). In contrast, 
isogenic controls and GAN patient 1, 3, and 4 (vim-low) iPSCs did not display any detectable 
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vimentin expression (Figure 5.2D). Further examination of the morphology revealed that 
vimentin accumulated in abnormal bundles in the vim-high GAN iPSCs (Figure 5.2E, arrows). 
Importantly, the observation of vimentin expression in GAN patient 7 but not the isogenic 
controls for patient 7 suggests that this phenotype is dependent upon the KLHL16 mutation and 
not variability between stem cell lines. However, gene expression of IFs can also become 
upregulated during cellular stress. To test whether the upregulation of vimentin protein was due 
to an increase in gene expression, we performed qRT-PCR in GAN and isogenic control iPSCs. 
We observed a slight but nonsignificant increase in VIM expression in the vim-high iPSCs. Thus, 
the increase in vimentin protein likely involves a combination of transcriptional and 
posttranscriptional mechanisms. The specificity of abnormalities in vimentin expression and 
morphology suggests that dysregulation of IF proteostasis in GAN iPSCs is selective and unique 
to bona fide gigaxonin targets.  
We next generated neural progenitor cells (NPCs), and since NPCs contain the type IV 
IF, Nestin, we examined Nestin morphology and expression in these cells (Figure 5.3A, B). 
Although Nestin IF morphology looked normal by immunofluorescence analysis, it was apparent 
that there were fewer Nestin positive cells in GAN NPCs (Figure 5.3A). This was supported by 
western blotting for Nestin in the NPCs, which revealed about two-fold less Nestin expression in 
GAN NPCs compared to isogenic controls (Figure 5.3B, C). Future experiments will aim to 
understand whether vimentin expression in iPSCs persists in NPCs and impacts NPC production 
since vimentin has been shown to inhibit neurogenesis in the mouse hippocampus120.  
5.2.4 KLHL16 regulates the astrocyte IF cytoskeleton 
We further differentiated the GAN and isogenic control NPCs to astrocytes (iPSC-
astrocytes) using our previously established protocol326. Throughout development, astrocytes 
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express a variety of IF proteins, first expressing vimentin, which is gradually replaced by GFAP. 
To capture these different developmental time points, we examined the cells at 32 days and 64 
days and classified them as early and late iPSC-astrocytes, respectively (Figure 5.4A, arrows). 
As expected, immunofluorescence analysis showed that early iPSC-astrocytes express vimentin. 
Early GAN iPSC-astrocytes display large, perinuclear accumulations of vimentin among 
vimentin filaments while isogenic control iPSC-astrocytes exhibit mostly normal vimentin 
filaments (Figure 5.4B, C). Vimentin aggregation often coincides with a collapse of the filament 
network and accumulation of vimentin in the perinuclear space, which can be measured by 
quantifying the vimentin area. Indeed, in early iPSC-astrocytes, GAN cells exhibit decreased 
vimentin area compared to isogenic control cells (Figure 5.4D). The decrease in vimentin area is 
even more striking in late iPSC-astrocytes (Figure 5.4E). Thus, we show that correction of the 
KLHL16 mutation rescued vimentin morphology.  
Late iPSC-astrocytes express either vimentin or both vimentin and GFAP (Figure 5.5A). 
While late isogenic control iPSC-astrocytes show mostly normal GFAP and vimentin filaments, 
late GAN iPSC-astrocytes present with IF filaments that are accompanied by large GFAP 
aggregates that co-localize with vimentin (GFAP+/Vim+) (Figure 5.5A). Beyond cytoskeletal 
abnormalities, we noted irregular nuclear morphology in the late GAN iPSC-astrocytes 
expressing GFAP. Early or late GAN iPSC-astrocytes expressing only vimentin displayed mostly 
normal nuclei even in the presence of large vimentin aggregates. In contrast, late GAN iPSC-
astrocytes expressing both vimentin and GFAP contained misshapen nuclei that occur alongside 
GFAP+/Vim+ aggregates (Figure 5.5B). The GFAP aggregates in late GAN iPSC-astrocytes 
also co-localized with three different RF markers, including heat shock protein 27 (HSP27), B-
crystallin (CRYAB), and ubiquitin (Figure 5.5C).   
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5.2.5 Vimentin interacts with GFAP to promote its aggregation 
The iPSC-astrocyte system was useful for examining GFAP aggregation and detecting 
nuclear abnormalities. However, few late iPSC-astrocytes expressed GFAP, so we sought a 
system to generate a greater number of mature astrocytes. We differentiated iPSCs to brain 
organoids using an established protocol (Figure 5.6A)338. Based on this protocol, we expected 
that 20 percent of the cells will be GFAP+ astrocytes after 9 months in culture. Indeed, we saw 
robust GFAP expression in both the isogenic control and GAN brain organoids (Figure 5.6B). 
Similar to the 2-dimensional system, the GAN brain organoids display large, perinuclear GFAP 
aggregates that are adjacent to nuclear deformations (Figure 5.6B). We observed a similar 
phenomenon of deformed nuclei bordered closely by perinuclear aggregates in our iPSC-
astrocyte model of AxD. To investigate other similarities with AxD, we asked whether 
phosphorylation of GFAP played a role in GFAP aggregation in GAN where there is an absence 
of GFAP mutations. Previously, we showed that phosphorylation of GFAP at serine 13 (pSer13-
GFAP) promotes cleavage and aggregation of GFAP and is a marker of aggressive AxD. We 
found that pSer13-GFAP co-localized with total GFAP in GAN brain organoids, suggesting a 
possible shared mechanism of GFAP aggregation (Figure 5.7A).  
To better understand the role of pSer13-GFAP in GFAP aggregation, we utilized 
validated phosphomimetic mutants of GFAP at serine 13 (S13D)326. We hypothesized that 
vimentin promotes aggregation of pSer13-GFAP, perhaps by acting as a scaffold, as proposed 
previously138. To test this, we overexpressed S13D in both SW13vim- and SW13vim+ cells 
(Figure 5.7B-C). As expected, in SW13vim- cells, S13D forms aggregates or localizes diffusely 
to the cytoplasm. In SW13vim+ cells, however, S13D can be seen colocalizing with vimentin 
filaments, an observation that is in line with the finding that GFAP filaments can tolerate up to 
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10% of assembly-defective mutant IFs145. We also noted small GFAP foci of S13D in both the 
SW13vim- and SW13vim+ cells. However, while the foci were dispersed throughout the 
cytoplasm in the SW13vim- cells, they often colocalized with vimentin in the SW13vim+ cells. 
Finally, we observed large GFAP aggregates that colocalize with vimentin in the SW13vim+ 
cells (Figure 5.7B). Biochemically, we found that S13D formed significantly more GFAP 
oligomers in the presence of vimentin, supporting the idea that vimentin promotes GFAP 
aggregation (Figure 5.7C).  
5.3 Discussion  
In this study, we develop a model to examine intermediate filament proteostasis failure in 
human astrocytes. We find that the human KLHL16 gene contains unique properties compared to 
other species that uncover the possibility of novel posttranscriptional disease mechanisms. 
Utilizing GAN patient-derived iPSCs and genetically engineered isogenic controls, we show that 
KLHL16 mutations deplete gigaxonin protein and compromise vimentin and nestin IFs in stem 
cells and astrocyte progenitors. We also detect similarities between GAN and AxD iPSC-
astrocytes, particularly the presence of pSer13-GFAP and deep, nuclear invaginations that 
accompany GFAP+/Vim+ aggregates. Finally, we show that vimentin promotes oligomerization 
of assembly deficient GFAP. Thus, our findings confirm that GAN iPSC-astrocytes and brain 
organoids are a useful model to examine uniquely human disease mechanisms in GAN and 
strongly implicate vimentin as an underappreciated contributor to RF formation. 
Species differences in the clinical symptoms of GAN are apparent when comparing 
humans to canines, rodents, and zebrafish. Spontaneous canine GAN most closely mirrors the 
human clinical symptoms of GAN with some affected animals having curly hair and all affected 
animals showing symptoms early in life (~15 months)327,339,340. The affected GAN animals 
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display with ataxia, paresis, and muscle weakness resulting in death due to complications by 
approximately 2 years327,341. In contrast, while rodent models demonstrate similar pathology, 
they have normal lifespans and have only mild motor and sensory deficits that are late onset328-
330. The zebrafish model of GAN does have locomotion defects but also displays developmental 
defects in motor neurons that are not seen in other models, making the motor phenotype difficult 
to compare to other species331. Here, we highlight unique properties in the 3’UTR of the 
KLHL16 gene in humans that may, at least partly, address some of these differences. 
Importantly, the finding that canine KLHL16 also contains a long 3’UTR provides correlative 
evidence to support the idea that the 3’UTR may contribute to GAN pathogenesis. The discovery 
that numerous RBPs bind to human KLHL16 mRNA suggests several new avenues of 
investigation333. Importantly, these interactions must be examined in the context of GAN to 
understand whether KLHL16 mutations crosstalk with RBPs. It is possible that KLHL16 
mutations promote enhanced RBP binding to the KLHL16 transcript. Such interactions could 
affect RBP subcellular localization, create a seed to promote aggregation or disrupt RNA 
metabolism. TARDP43 is an especially attractive target, as it has been implicated in different 
neurodegenerative diseases dubbed “TDP43 proteinopathies”, as well as AxD342,343. However, 
we acknowledge that other factors surely contribute to disparities in GAN severity among 
species, including lifespan, length differences in axons and differing complexity of cells (e.g. 
astrocyte complexity), and the involvement of the 3’UTR in GAN must be tested experimentally.   
The recessive nature of GAN and the absence of detectable gigaxonin protein has led to 
the understanding that the disorder is caused primarily by loss of function of gigaxonin. In the 
case of null mutations, the cause of gigaxonin depletion is clear, but for missense mutations, it is 
not fully understood why gigaxonin protein is lost. Is has been proposed that the defect occurs 
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posttranslationally because missense mutations could destabilize the gigaxonin protein335. 
However, this hypothesis is yet to be tested experimentally, and we suggest that a key 
intermediate step – translation – should be examined. Perhaps KLHL16 is transcribed and stalled 
at the mRNA transcript stage, an idea that is supported by the finding that KLHL16 mRNA can 
be stored in stress granules in human cells344. The possibility that posttranscriptional mechanisms 
may contribute to GAN opens up the question: Can GAN be caused by mutations outside the 
coding region? Although some mutations have been identified in splicing sites, sequencing is not 
routinely performed on non-coding regions of KLHL16 in suspected GAN patients, which is 
understandable considering the remarkable length of the KLHL16 gene345. This patient-derived 
iPSC model will provide a useful tool to address the mechanism of loss of gigaxonin in GAN. 
Our model expands upon a previous iPSC model of GAN by focusing on the 
contributions of astrocytes346. The human iPSC-astrocyte and organoid models used in this work 
offer several advantages in the study of GAN and other neurodegenerative diseases. Broadly, 
iPSC-derived patient astrocytes have the potential to provide a platform for drug development 
and novel cell-based therapies. Here, we utilize this technology to model GAN and understand 
disease mechanisms in astrocytes. As discussed, human astrocytes differ from their rodent 
counterparts in size, shape, and function4. To fully examine astrocyte-related disease 
mechanisms, it is necessary to complement animal models with a model system that has these 
unique human properties. Advances in directed differentiation methods in combination with 
iPSC technology provide a minimally invasive option to generate human astrocytes338,347. 
Further, organoid-derived astrocytes have demonstrated several astrocyte functions, and thus, our 
model can be utilized in the future to determine astrocyte functional deficits in GAN348. The use 
of patient-derived cells also allows for consideration of background genetics. This is especially 
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helpful in our studies of AxD and GAN where there is variability in disease severity likely due to 
genetic modifiers, but more broadly has also allowed for the study of other neurodegenerative 
disease where the underlying genetic cause is not known, such as spontaneous amyotrophic 
lateral sclerosis. Finally, the ability to generate isogenic controls is a powerful tool and is 
important for any transcriptomic and proteomic studies since iPSCs are known to show 
variability in gene expression and differentiation capacity349,350. It should be noted, however, that 
gene editing by homology-directed repair in iPSCs is especially difficult and requires costly 
reagents and a lengthy screening process for often low-frequency events351. Because of these 
limitations, we were only able to generate isogenic controls for one patient cell line (patient 7) 
and resorted to the use of iPSCs from a healthy donor as an alternative option for more controls.  
Using our iPSC-astrocyte models, we reveal similarities between GAN and AxD that 
indicate these two disorders may share molecular mechanisms, opening the door to the 
possibility of drug repurposing. We previously showed that pSer13-GFAP is a marker of 
aggressive AxD326. Here, we observe pSer13-GFAP in GAN iPSC-brain organoids which lack 
GFAP mutations, suggesting that this may be a common modification of GFAP under 
proteostasis failure. Our previous findings showed that phosphorylation at serine 13 promotes 
oligomerization and caspase cleavage of GFAP. Future work will focus on identifying the 
kinase(s) that promote phosphorylation of this residue to determine whether inhibiting 
phosphorylation could decrease aggregation and improve astrocyte function in AxD and GAN. 
Another molecular similarity was the presence of deep, nuclear invaginations in the presence of 
GFAP aggregates. Nuclear invaginations are not unique to AxD and GAN and are also observed 
in other neurodegenerative diseases352-354. It will be important to determine the effect of these 
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deformations on nuclear structure and functions, such as transcription, mRNA transport, and 
mRNA processing.  
Finally, our results indicate that under IF proteostasis failure, vimentin and GFAP 
cooperate to promote aggregation. While IF aggregates tend to occur perinuclearly, the presence 
of deep nuclear deformations with GFAP+ aggregates suggests that GFAP could promote 
enhanced and possibly toxic interactions of IF aggregates with the nucleus. One possible cause 
for this could be related to plectin, which is an IF-associate protein that crosslinks IFs to other 
structures, including microtubules, actin, and the nuclear envelope40,355. While both vimentin and 
GFAP are known to bind to plectin, it is possible that each IF develops distinct post translational 
modifications, which can alter plectin binding31,355-357. Another potential mechanism could be 
disrupted nuclear transport. GFAP and vimentin both contain a predicted nuclear localization 
signal in the C-terminal tail domain, but GFAP harbors an additional predicted domain in the N-
terminal head domain39. However, it has yet to be shown that GFAP is transported into the 
nucleus, as has been demonstrated with keratin-17, an epithelial IF39. Using our overexpression 
system, we also show evidence that vimentin promotes oligomerization of assembly 
compromised GFAP. We suspect, as others have posited, that vimentin promotes aggregation by 
providing a scaffold on which aggregates are seeded138. Astrocytes are not the only cell that 
express more than one IF in development and disease. In fact, neurons can express at least 4 IFs: 
neurofilaments light, medium, and heavy, as well as peripherin or -internexin, which are 
assembled into filaments at very specific ratios358,359. It is likely that different IFs cooperate to 
promote aggregation in other IF-associated disorders where IF proteostasis and assembly are 
compromised. The abundance of IF aggregates in varying cell types in GAN makes our iPSC 
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model a powerful tool to broadly address the effects IF proteostasis failure in diverse human 
cellular contexts.  
5.4 Materials and Methods 
5.4.1 Cellular reprogramming, characterization, and gene editing of iPSCs 
iPSCs were generate from GAN (OMIM#256850) patient fibroblasts and characterized 
using the methods described in Battaglia et al. 2019. Gene editing and off-target analysis was 
carried out as previously described in Battaglia et al. 2019.  
5.4.2 iPSC culture and differentiation 
iPSCs were maintained on Matrigel (Corning, Cat. No. 354480) in StemFlex Medium 
(Thermo Fisher Scientific, Cat. No A3349401) and passaged every 3-4 days with 0.5 mM EDTA 
dissociation solution. Astrocytes were differentiated as described in Battaglia et al. 2019. Briefly, 
Aggrewell 800 plates (StemCell Technologies) were used to generate EBs from iPSCs. To 
generate neural progenitor cells (NPCs), EBs were plated on poly-ornithine and laminin coated 
plates in Neural Induction Medium (StemCell Technologies) and rosettes were selected after 12 
days and expanded in Neural Progenitor Medium (StemCell Technologies). NPCs were 
differentiated to astrocytes using the Stem Cell Technologies STEMdiff astrocyte differentiation 
and maturation kits during which they were split weekly with Accutase (Millipore).  
Organoids were generated using the protocol described in Pasca et al. 2015 with the 
following modifications for feeder-free conditions338. The EBs were generated as described above 
on days 0-6. On day 7, the EBs were moved to neural medium (NM, Invitrogen) containing serum-
free Neurobasal medium with B-27 without vitamin A (Invitrogen), GlutaMax (Gibco). NM was 
supplemented with FGF2 (20ng/mL, R&D Systems), and EGF (20ng/mL, R&D Systems). Media 
was changed daily for days 7-16 and every other day for days 17-25. After neural induction, the 
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media was replaced with NM supplemented with BDNF (20ng/mL, Peprotech), and NT3 
(20ng/mL, Peprotech) every other day to promote differentiation. On day 43, NM without growth 
factors was used for medium changes every four days.  
5.4.3 Antibodies 
The following primary antibodies and concentrations were used in this study: rabbit anti-
GFAP (DAKO, Agilent, clone Z0334; IF 1:500, WB 1:10,000), mouse anti-GFAP (Sigma, clone 
GA5; IF 1:300), mouse anti-pSer13-GFAP (gift from Dr. Inagaki, KT13, IF 1:20), mouse anti-
Gigaxonin (Santa Cruz Biotechnology, F3, WB 1:200), rabbit anti-Vimentin (Cell Signaling 
Technology, D21H3, IF 1:100), mouse anti-Vimentin (Thermo Fisher Scientific, V9, WB 1:1000), 
mouse anti-Keratin 8 (Thermo Fisher Scientific, TS1, IF 1:100), rat anti-K8 (Developmental 
Studies Hybridoma Bank, Troma I, WB 1:5000), rabbit anti-Lamin A/C (Santa Cruz 
Biotechnology), rabbit anti-Lamin B1 (Abcam ab16048, IF 1:10,000, WB 1:10,000), mouse anti-
Nestin (Thermo Fisher Scientific, 10C2, IF 1:200), mouse anti-Tra-1-60 (Thermo Fisher Scientific, 
41-1000, IF 1:300), mouse anti-Tra-1-81 (Thermo Fisher Scientific, 41-1100, IF 1:300), rabbit 
anti-Oct4 (Abcam, ab19857, IF 1:40), and rabbit anti-Sox2 (Thermo Fisher Scientific, 48-1400, 
IF 1:125) The following secondary antibodies and concentrations were used: Alexa 488- and Alexa 
594-conjugated goat anti mouse and rabbit antibodies (Thermo Fisher Scientific, IF 1:500), and 
peroxidase-conjugated goat anti-mouse and rabbit antibodies (Sigma, WB 1:5000).  
5.4.4 Preparation of protein lysates and immunoblotting 
Total lysates were prepared from 60-80% confluent iPSCs plated on 6-well plates by 
rinsing cells quickly with 1 mL of 1X PBS and adding 2X NovexTM Tris-Glycine SDS Sample 
Buffer (ThermoFisher, Cat#LC2676) directly to the plate, collected into Eppendorf tubes, and 
heated at 95C for 5 min. Protein lysates were normalized by running Coomassie staining before 
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running western blots. Immunoblotting was performed as in (Trogden et al 2018). Briefly, samples 
were separated on a 4-20% gradient SDS-PAGE gel and transferred either for 1 hour at 110 V or 
overnight at 40 V onto an activated polyvinylidene difluoride membrane. Post-transfer Coomassie 
stained were performed on gels after every transfer to verify normalization for each experiment 
and are shown in the figures. Membranes were blocked in 5% non-fat milk dissolved into 0.1% 
tween 20/PBS (PBST) for 1 hour at room temperature and then incubated in primary and secondary 
antibodies diluted into blocking solution at the concentrations listed above. Antibodies were 
detected via ECL reagents (PerkinElmer).  
5.4.5 RNA isolation and quantitative real-time PCR (qRT-PCR) 
RNA was isolated from iPSCs using the ThermoFisher PureLink RNA mini kit (Thermo 
Fisher Scientific, Cat#12183025) following all manufacturer guidelines and immediately 
converted to cDNA. The High-Capacity cDNA Reverse Transcription kit (Thermo Fisher 
Scientific, Cat#4368814) was used to convert 2g of total RNA to cDNA. To measure gene 
expression, qRT-PCR was performed using PowerUp SYBR Green Master Mix (Thermo Fisher 
Scientific, Cat#A25778) and the Applied Biosystems QuantStudio 6 Flex Real-Time PCR System. 
The primers used to detect gene expression in this study are listed in Table 3.  
5.4.6 Immunofluorescence, imaging, and analysis 
Cells were fixed in methanol at -20C for 10 min, washed three times in PBS, and blocked 
in Buffer B (2.5% Bovine Serum Albumin (Sigma), 2% normal goat serum (Gibco)/PBS) for 1 hr 
at room temperature. Next, cells were incubated in primary antibodies overnight at 4C after which 
they were washed three times in PBS and incubated with Alexa Fluor-conjugated secondary 
antibodies 1 hr at room temperature. Cells were washed three times in PBS, incubated in DAPI 
(Invitrogen), washed twice in PBS, and mounted in Fluoromount-G (SouthernBiotech) overnight. 
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Cells were imaged on Zeiss 880 confocal laser scanning microscope using a 40x oil immersion 
objective or for widefield on the EVOS-FL auto cell imaging system (Thermo Fisher Scientific) 
using a 20x (0.75 NA) objective. National Institute of Health ImageJ software was used to measure 
size and intensity of the vimentin cytoskeleton as shown in figure 3D by using the polygon tool to 
circle the vimentin signal and the measure tool, which provides a measure of area and average 





Figure 5.1 Human KLHL16 mRNA contains unique properties. (A) Conservation of KLHL16 
mRNA amongst species using the NCBI BLAST alignment tool. The human KLHL16 mRNA 
sequence is shown at the top in blue with the coding sequence represented by the black line. 
Conservation is indicated by colors, which represent the alignment scores where high scores 
indicate more conservation. Red bars indicate alignment scores greater than or equal to 200 (high 
conservation), magenta bars are 80-200, green bars are 50-80, blue bars are 40-50, and black 
lines are < 40 (low conservation). (B) Graphs displaying the length of KLHL family member 
proteins (left) and mRNA transcripts (right) where KLHL16 is represented by a pink circle and 
other KLHL family members are represented by blue circles. (C) Graph showing fold 
enrichment of KLHL16 mRNA bound to various RBPs determined experimentally by Van 
Nostrand et al. using eCLIP333. (D) Schematic of KLHL16 mutations mapped to the protein, 
gigaxonin. Numbers 1-7 refer to the patients listed in Supplemental Table 5.1. Asterisks 
indicate compound heterozygous mutations. (E) Schematic diagram of methods used to generate 




Figure 5.2 Gene editing in GAN patient-derived iPSCs restores gigaxonin protein and 
selective IF proteostasis. (A) Immunoblotting for gigaxonin and Lamin B1 in GAN patient and 
control iPSCs. Post-transfer Coomassie stained gel is shown below for a loading control. Patient 
and control samples are loaded in the same order as Supplemental Table 5.1 from left to right. 
(B) Confocal images of immunofluorescence of GAN patient 7 and isogenic control iPSCs stained 
for Lamin B1 (magenta) and DAPI (blue). The scale bar represents 10 m. (C) Confocal images 
of immunofluorescence of GAN patient 7 and isogenic control iPSCs stained for keratin-8 (green), 
vimentin (magenta), an DAPI (blue). The scale bar represents 20 m. (D) Immunoblotting for 
vimentin in GAN and control iPSCs. Post-transfer Coomassie stained gel is shown for a loading 
control. (E) Confocal images of immunofluorescence of GAN patient 7 and isogenic control iPSCs 
stained for keratin-8 (green), vimentin (magenta), an DAPI (blue). The white arrow indicates 
vimentin bundling. The scale bar represents 10 m. 
 
 
Figure 5.3 Nestin is downregulated in GAN Neural Progenitor Cells (NPCs). (A) Confocal images of immunofluorescence of 
NPCs stained for Nestin (magenta) and DAPI (blue). The scale bar represents 10 m. (B) Immunoblotting for gigaxonin and Nestin in 









Figure 5.4 Vimentin filament organization is restored in GAN isogenic control iPSC-
astrocytes. (A) Schematic illustrating iPSC differentiation to astrocytes. (B, C) Representative 
images of immunofluorescence staining for vimentin (green) and DAPI (blue) in GAN and 
isogenic control 32-day old iPSC-astrocytes. (B) White arrows indicate vimentin aggregates. 
Scale bar represents 50 m. (C) Scale bar represents 200 m. (D, E) Quantification of vimentin 




Figure 5.5 GFAP-expressing GAN iPSC-astrocytes exhibit deformed nuclei. All panels show 
confocal images of immunofluorescence staining in 66-day old iPSC-astrocytes. (A, B) GAN 
and isogenic control iPSC-astrocytes were stained in A for Vimentin (green), GFAP (magenta), 
and DAPI (blue) and in B for lamin B1 (green) and GFAP (magenta). The scale bars represent 10 














Figure 5.6 iPSC-organoids develop GFAP+ astrocytes and display GFAP aggregation in 
GAN. (A) Schematic diagram of methods for generating brain organoids from iPSCs. The image 
displays a 9 month old brain organoid in a 24-well plate. (B) Confocal images of 
immunofluorescence staining for total GFAP (cyan), pSer13-GFAP (Magenta), and DAPI (blue) 
in GAN patient 7 and isogenic control iPSC-organoids. The scale bars in the top panels represent 




Figure 5.7 Vimentin promotes aggregation of GFAP. (A) Confocal images of 
immunofluorescence staining in GAN patient 7 iPSC-organoids for total GFAP (cyan), pSer13-
GFAP (Magenta), and DAPI (blue). The scale bars represent 10 m. (B-D) SW13vim+ and 
SW13vim- cell lines were transfected with either wild-type GFAP or serine phosphomimetic 
mutant GFAP (S13D). (B) Confocal images of immunofluorescence staining for vimentin 
(green), GFAP (magenta), and DAPI (blue) in transfected cells. Scale bars represent 20 m. (C) 
Immunoblot for GFAP in total lysates of transfected SW13vim+ (left) and SW13vim- (right) 
cells. Immunoblot for pan-actin is shown as a loading control. (D) Quantification of GFAP 





Supplemental Figure 5.1 Generation of GAN iPSCs from patient fibroblasts. (A-B) 
Pluripotency was assessed via ThermoFisher Taqman scorecard analysis and 
immunofluorescence staining for OCT4, SOX2, TRA1-60, and/or TRA1-81/SSEA4 pluripotency 
markers. (C) GAN iPSCs were characterized for genomic stability via karyotyping as shown by 




Supplemental Figure 5.2 Correction of KLHL16 mutations via CRISPR/Cas9 gene editing. 
(A) Gene editing strategy for GAN Patient 7 iPSCs. The G is the wild-type allele, the green 
shape represents the GAN mutation (G>A), and the yellow stars represent the silent mutations 
introduced by the repair construct. Black arrows depict universal primers, whereas the red arrow 
is an allele specific primer that exclusively binds to the corrected sequence. (B) Chromatograms 
display the original GAN mutant sequence (G332R, GGG>AGG; Y89S, TAC>TCC) and the 
sequence from a corrected clone where silent mutations are indicated by red arrows. (C) GAN 




Supplemental Table 5.1 GAN patient and control information 
Patient * NIH/in-house 
ID 
Mutation Sex Age MFM Score 
Control 0 ISCA N/A F  NA 
Control 1 B3 Isogenic control for patient 7 M  NA 
Control 2 G5 Isogenic control for patient 7 M  NA 
Control 3 2D1 Isogenic control for patient 7 M  NA 
Control 4 2D3 Isogenic control for patient 7 M  NA 
1 B15-56.1 R574C; deletion of G280   94.8 
2 B13-69.1 Y89S (homozygous) M  72.9 
3 B16-64.1 R138L: null (whole gene)   71.9 
4 B16-78 IVS4+1G>A (null, homozygous) M  64.6 
5 B16-74 Deletion of exons 10 and 11   61.5 
6 B15-100.1 E486K; 3.2kb deletion (exons 7-9)   38.5 
7 B16-02 G332R (homozygous) M  30.2 
*Patient numbers were assigned by the authors in order of increasing disease severity, as measured 





Supplemental Table 5.2 Summary of off-target Sanger sequencing from CRISPR/Cas9 
editing of Patient 7 




















BNIP3L 665 N.M. N.M. N.M. N.M. N.M. 
CLRN1-
AS1 
116933 N.M. N.M. N.M. N.M. N.M. 
URI1 8725 N.M. N.M. N.M. N.M. N.M. 
SCN9A 6335 Heterozygous: A>G, 










COL19A1 1310 N.M. N.M. N.M. N.M. N.M. 
RFLNB 359845 N.M. N.M. N.M. N.M. N.M. 
CSN1S2AP 286828 N.M. N.M. N.M. N.M. N.M. 
PDZD2 23037 N.M. N.M. N.M. N.M. N.M. 










DIP2A 23181 N.M. N.M. N.M. N.M. N.M. 
EGFEM1P 93556 N.M. N.M. N.M. N.M. N.M. 
GINS2 51659 N.M. N.M. N.M. N.M. N.M. 
SCN3A 6328 N.M. N.M. N.M. N.M. N.M. 
SGMS1 259230 N.M. N.M. N.M. N.M. N.M. 
RUBCNL 80183 N.M. N.M. N.M. N.M. N.M. 
c11orf58 10944 N.M. N.M. N.M. N.M. N.M. 
BTN1A1 696 N.M. N.M. N.M. N.M. N.M. 
USP50 373509 N.M. N.M. N.M. N.M. N.M. 
IRF4 3662 N.M. N.M. N.M. N.M. N.M. 





Supplemental Table 5.3 qRT-PCR primers 
Primer Name Target Sequence (5’  3’) 
GAN_exon2-3_F GAN TCGGTAATGGTTATGAGAGAGATCC 
GAN_exon2-3_R GAN TAAGGTCCGTCAGTAGCAGC 
GAN_exon10-11_F GAN CCGCCAGTTCCTCTTTTGTT 
GAN_exon10-11_R GAN GTCGGATGGAAGGAGTGGTTT 
LmnB1_F LMNB1 CTCGTCTTGCATTTTCCCGC 
LmnB1_R LMNB1 TGGCGTTTAGAGGAACGGAG 
Vim_F VIM AACGCCAGATGCGTGAAATG 










CHAPTER 6: DISCUSSION 
IFs are a major component of the cytoskeleton that provide both mechanical and non-
mechanical cell type-specific functions to support tissue homeostasis17. Despite the importance 
of IFs in health and disease, our understanding of IF dynamics lag behind those of actin and 
microtubules, the other major cytoskeletal filament systems. IF drastically alter their dynamics 
during diverse cellular processes, such as cell division and cell migration. A better understanding 
of IF dynamics would improve our comprehension of IF function and perhaps our ability to 
modulate and harness those functions. Through the work presented in this thesis, I furthered our 
knowledge of IF dynamics using three strategies. First, I contributed a review article focused on 
the role of vimentin IFs in cell migration, which is of particular importance in astrocytes47. 
Second, since PTMs are critical regulators of IF dynamics, I developed a method to 
simultaneously isolate and profile mammalian intermediate filaments from tissues in order to 
identify new PTMs81. I used this method to study changes in PTMs during aging and detected 
increased phosphorylation and acetylation of K8/K18 from aged mouse liver tissue. This study 
identifies new candidate PTMs that could regulate IF dynamics during development and aging. 
Third, I helped design and apply an image-based small molecule screen to identify drugs that 
target IFs313. We used vimentin as a prototype IF and identified simvastatin as a novel regulator 
of vimentin dynamics that induces rapid reorganization followed by bundling of vimentin, 
resulting in cell death in certain cancer cell lines. This small molecule screen identifies vimentin 
as a probable direct target of simvastatin, offers implications for simvastatin-related muscle pain 
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and cancer mortality, and provides an approach for identifying IF-selective compounds that 
could be applied to other IFs.  
The IF gene family is associated with many different human diseases, including skin 
fragility disorders, myopathies, liver disease, aging, cancer, and neurodegenerative diseases73. 
Although united by their membership in the IF gene family, individual IF genes are associated 
with very different pathophysiological symptoms depending on the cell type in which the 
particular IF gene is expressed. The cell type, tissue, developmental, and species specificity of 
each IF is linked to unique characteristics and properties that can be tuned to specific contexts. 
Many human cell models do not reflect the cellular context of disease because they 1) lack the 
unique patient genetic background and 2) often utilize cancer cell lines for expression of disease-
relevant IFs. Similarly, animal models do not reflect human-specific qualities of the particular 
cell type, such as size and complexity.  
To overcome these challenges, I examined the cell type-specific regulation of IFs in 
neurodegenerative disease in the context of human astrocytes, which are a major but 
underappreciated glial cell type in the CNS. I developed two different human iPSC-astrocyte 
models to investigate disease mechanisms in AxD and GAN. I uncovered a novel mechanism 
whereby phosphorylation at serine 13 of GFAP promotes caspase 6-cleavage and aggregation of 
GFAP326. Additionally, I connect our in vitro findings to brain tissue from AxD patients and 
observe increased phosphorylation at serine 13 of GFAP and cleavage of GFAP in aggressive 
cases of AxD. Finally, I observe a crosstalk between vimentin and GFAP aggregation in GAN. 
The presence of GFAP promotes interactions between vimentin aggregates and the nucleus, and 
conversely, the presence of vimentin promotes GFAP aggregation (Battaglia et al. In 
preparation). We also improve the GAN iPSC-astrocyte model by generating brain organoids in 
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3-dimensional co-culture of iPSC-astrocytes and neurons. These disease models provide tools for 
further exploration of IF-related disease mechanisms and development of IF-targeted 
therapeutics.  
6.1 IF phosphorylation in neurodegenerative disorders 
 IFs are especially enriched in phosphorylation sites, which control their dynamics, 
binding partners, subcellular localization, and biochemical properties31,285. While 
phosphorylation is an important regulator of IFs under homeostasis, it is also associated with 
disease. IF aggregates are often hyperphosphorylated, both in IF-associated disorders and 
broadly in neurodegenerative disease360. For example, phosphorylated neurofilament aggregates 
are observed in many neurodegenerative diseases, including Alzheimer’s disease and 
Amyotrophic Lateral Sclerosis360,361. GFAP phosphorylation is also altered broadly in 
neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and 
frontotemporal lobar degeneration362. In addition to AxD, changes in phosphorylation at serine 
13 of GFAP are observed in frontotemporal lobar degeneration and Parkinson’s disease363,364.  
The significance of GFAP phosphorylation in common neurodegenerative diseases is not 
yet clear. In Parkinson’s disease, enteric glia exhibit decreased phosphorylation at serine 13 of 
GFAP364. The authors hypothesize that decreased phosphorylation at serine 13 leads to an 
increase in filamentous GFAP and a decrease in soluble GFAP in reactive enteric glia. This is in 
direct contrast a different study where the authors observed increased phosphorylation at serines 
8 and 13 of GFAP in reactive astrocytes induced by hypoxia283. It is possible that cell type and 
tissue differences between enteric glia (PNS) and astrocytes (CNS) contribute to these 
differences. In contrast to Parkinson’s disease, we observe increased phosphorylation at serine 13 
in AxD and show that phosphomimetic mutation of this residue promotes aggregation and 
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caspase cleavage in vitro326. However, we observe that blocking phosphorylation by generating a 
nonphosphorylatable mutant at serine 13 in an AxD mutant background is unable to rescue 
aggregation. Therefore, it may be important for IF dynamics to maintain the ability to freely 
phosphorylate and dephosphorylate this key residue. In the future, it will be necessary to identify 
the kinase or kinases that phosphorylate GFAP at this residue in AxD. It is quite possible that 
separate kinases phosphorylate GFAP to promote healthy reorganization versus aggregation. If 
so, this would allow targeting of disease-associated kinases while allowing other kinases to 
phosphorylate GFAP for homeostatic maintenance. Alternatively, perhaps careful dose control 
could be utilized to achieve a low threshold of phosphorylation that is enough to maintain 
filament morphology but reduce the propensity for unhealthy aggregate formation. It will be 
important to understand which kinases regulate this phosphorylation in AxD astrocytes in order 
to pursue therapeutic strategies. 
6.2 Beyond phosphorylation: other PTMs contribute to IF-related disorders 
The abundance of tools to study and manipulate phosphorylation have made it an ideal 
PTM to examine. However, other PTMs also regulate IF properties and dynamics. Caspase 
cleavage of IFs has been observed during apoptosis and also neurodegenerative disease31. 
Caspase-3 is known to cleave GFAP and was recently identified as a candidate genetic modifier 
of disease severity in a whole exome-sequencing study of 31 AxD patients365. Additionally, we 
and others find that caspase-6 cleavage of GFAP promotes aggregation290,326. More broadly, 
caspase-6 cleavage of aggregation-prone proteins also occurs in Alzheimer’s disease (AD) and 
Huntington’s disease (HD)302-304. However, whereas blocking caspase-6 cleavage of amyloid 
precursor protein or huntingtin rescued neuronal dysfunction and neurodegeneration in AD and 
HD, blocking caspase-6 cleavage of GFAP disrupted filament morphology. This suggests that 
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some baseline level of caspase-6 cleavage of GFAP is important for filament organization, and 
like phosphorylation, completely blocking cleavage would be harmful to the cell. Future studies 
using genetic and pharmacological approaches to partially reduce caspase-6 expression or 
function should be performed to determine whether caspase-6 could be an effective therapeutic 
target. 
Other PTMs are altered in IF-related disorders and likely contribute to IF aggregation, 
including sumoylation, transamidation, acetylation, and others previously reviewed31. Genetic 
mutations in KRT8 that predispose to chronic liver disease promote hypersumoylation of K8, 
which has been shown to decreases keratin solubility197. Chronic liver disease also involves 
transamidation of K8, which promotes the formation of K8/K18 aggregates called Mallory-Denk 
bodies through crosslinking lysine and glutamine residues366. Acetylation is another promising 
PTM that should be pursued. Acetylation is directly implicated in AxD since histone 
deacetylases (HDACs) were identified as possible candidates in a whole exome-sequencing 
screen for genetic modifiers of AxD365. We also observe increased acetylation of mouse GFAP 
and K8 during aging81. However, this acetylation may be further enhanced in the context of 
neurodegeneration. GFAP was identified as the dominant differentially acetylated protein in ALS 
versus non-ALS control spinal cord tissue367. The functional consequences of acetylation at these 
residues are unknown. The development of additional tools to study IF protein PTMs besides 
phosphorylation, such as site-specific antibodies, PTM enzyme inhibitors, and mutant transgenic 
animal models will be needed to address the functions of other PTMs in IF functions as well as 
how conserved these PTMs are for different IF proteins.  
The possibility of crosstalk between PTMs is also intriguing. PTMs could inhibit other 
PTMs directly competing for the same amino acid or indirectly preventing binding of PTM 
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enzymes. For instance, lysine is an amino acid that can be modified by ubiquitination and 
acetylation, so hyperacetylation of IFs could negatively impact IF protein turnover. Likewise, 
serine can be modified by phosphorylation or glycosylation, so excess glycosylation of IFs could 
affect IF dynamics. Alternatively, PTMs could promote other PTMs (e.g. phosphorylation 
priming). Deciphering how these modifications regulate each other as well as how mutations 
affect PTMs will be important for understanding the effects of PTMs on IF properties and 
dynamics in health and disease. 
6.3 IFs as biomarkers and drug targets 
IFs are often utilized as biomarkers because they are highly abundant and can often serve 
as cell type specific markers of stress or physiological changes. Two ideal examples of this are 
the growing appreciation of IFs in cancer and CNS injury and disease. Vimentin is significantly 
upregulated during the epithelial to mesenchymal transition associated with cancer metastasis46. 
Furthermore, vimentin has been recently suggested as a biomarker in hepatocellular carcinoma 
and pancreatic cancer368,369. GFAP is detected in blood serum or plasma and has been proposed 
or utilized as a biomarker for many CNS injuries, including multiple sclerosis, neuromyelitis 
optica spectrum disorder, traumatic brain injury, intracerebral hemorrhage, Alzheimer’s disease, 
and glioblastoma370-375. Identifying specific IF isoforms or PTMs could provide an even more 
nuanced interpretation of disease progression or severity.   
In addition to providing a marker for cell stress and disease, IFs are emerging as active 
participants in disease pathogenesis, and thus potential targets. Vimentin is a promising target in 
treating cancer because of its role in metastasis. Several compounds have been identified that 
either reduce expression of vimentin, alter vimentin PTMs, or promote vimentin filament 
collapse376. This list includes many compounds that are being tested in cancer-related clinical 
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trials376. Interestingly, vimentin is also being considered as a potential target for treating COVID-
19 because of its role in viral attachment to cells and viral replication377,378. Both vimentin and 
GFAP are upregulated in reactive astrocytes during neurodegeneration and CNS injury110. 
Deletion of vimentin and Gfap has been shown to attenuate certain reactive astrocyte functions in 
animal models, and recent developments in antisense oligonucleotide methods to reduce Gfap 
expression make this a realistic treatment option for the near future112,152,379. A better 
understanding of the functions of GFAP in different subtypes of reactive astrocytes will lead to 
the strategic use of astrocytic GFAP-targeted therapies. Importantly, since IFs serve important 
homeostatic and stress-related functions, targeting specific PTMs may be a way to salvage 
healthy IFs while targeting toxic IFs. One successful example of an IF PTM-targeted therapy is 
the use of a farnesyltransferase inhibitor to pharmacologically target aberrant farnesylation of 
lamin A/C in Hutchinson-Gilford progeria syndrome380. Future identification of small molecules 
that selectively target IFs, specific IF isoforms, or enzymes that regulate IF PTMs will broaden 
the options for therapeutic strategies in IF-associated disorders.  
6.4 Rosenthal fibers (RFs): toxic or protective? 
Protein aggregates are commonly observed in neurodegenerative disease. Despite the 
correlation between protein aggregates and neurodegenerative disease, there is little consensus 
about whether aggregates cause, accelerate, slow, or simply mark disease progression381,382. IF 
proteins are especially prone to aggregation upon genetic mutations or cellular stress not only in 
neurons and glia but also in muscle cells, hepatocytes, and skin epithelial cells. Using the 
example of RFs, the evidence for protection, epiphenomenon, and toxicity is discussed. 
There is some evidence supporting the idea that RFs could be protective. First, it is 
possible that RF formation is a protective mechanism to sequester toxic mutant GFAP away from 
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the cellular milieu. In support of this, one study found that the soluble mutant GFAP oligomers 
inhibit the proteasome143. Second, RFs could promote proteostasis by spatially bringing together 
mutant GFAP protein with protein chaperones and degradation machinery. Both chaperones and 
proteasome subunits have been shown to colocalize with RF137,143. Third, while animal models of 
AxD and GAN faithfully display RF-like inclusions, mouse models fail to fully recapitulate 
disease symptoms142,328-330. While some assert this as evidence that aggregates are not toxic, 
others argue that the absence of a phenotype relates more to species differences, such as lifespan 
as well as size and complexity of cells. In addition to protective mechanisms, RFs may also 
represent a byproduct of injury in some cases. Outside of AxD and GAN, RFs can arise in cases 
of glial scarring, multiple sclerosis, and pilocytic astrocytoma139,140. Whether RFs contribute to 
disease pathology in these other contexts is unknown.  
While soluble mutant GFAP oligomers are more toxic to the proteasome, large 
aggregates are not necessarily inert and harmless. RFs can also contribute to toxicity in GAN and 
AxD by two potential mechanisms. First, RFs could sequester proteins within these inclusions, 
preventing them from performing a critical cell function. As discussed, RFs colocalize with 
chaperone proteins, including B-crystallin and HSP27137. While it may initially promote IF 
proteostasis, long-term sequestration of chaperone proteins within RFs could negatively affect 
proteostasis of a wide range of other proteins that interact with these chaperones. Mass 
spectrometry revealed that RFs also contain numerous RBPs, and the loss of RBPs could affect 
mRNA trafficking and metabolism141. Second, RFs could cause steric hindrance and disrupt 
subcellular organization of organelles. We observe striking changes in nuclear shape, which are 
discussed in the next section. Additionally, another AxD iPSC-astrocyte model shows structural 
alterations of the endoplasmic reticulum and lysosomes163. In GAN mouse DRG neurons, 
 156 
mitochondria exhibit decreased motility and increased metabolic stress correlating with their 
colocalization with large neurofilament aggregates in axon162. Whether disrupting aggregate 
formation or promoting aggregate clearance improves cellular function has yet to be tested.  
At present, there are no tools to target specific forms of IF proteins (subunits, oligomers, 
or aggregate) within cells. The best evidence involves either cellular fractionations or correlative 
colocalization studies. Until techniques are established to specifically target IF oligomers or 
disassemble IF aggregates, it will be difficult to parse out the protective versus toxic functions of 
different forms of IFs. 
6.5 Interactions between cytoplasmic IFs and the nucleus  
 For decades, it has been noted that mature IFs accumulate in the perinuclear space and 
form a cage around the nucleus193. Cytoplasmic IFs interact with the nucleus during baseline 
conditions to control nuclear positioning and implement mechanotransduction18. However, it is 
not clearly understood why large IF aggregates tend to accumulate in the perinuclear space and 
what impact this may have on nuclear functions.  
We hypothesize that mature IFs act as a scaffold upon which IF aggregates form. Thus, it 
is possible that IF aggregates simply accumulate where there is the highest concentration of 
assembled, mature IFs. In contrast to normal IFs, GFAP aggregates appear to have aberrant 
interactions with the nucleus. Instead of maintaining nuclear shape, GFAP aggregates deform the 
nucleus. Nuclear deformations are also observed in many other neurodegenerative diseases, 
including Huntington’s disease, Alzheimer’s disease, and frontotemporal dementia311,352,354. 
While these invaginations did not rupture the nuclear membrane in AxD, it will be important to 
characterize how they affect nuclear functions, such as gene expression, mRNA processing, and 
mRNA trafficking. We did not carry out any cell migration assays, but it also would be 
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interesting to see how the nuclear positioning was affected by IF aggregates during cell 
migration.  
Some RFs localize in regions besides the perinuclear space, such as astrocyte endfeet, 
which contact blood vessels. The distribution of mature IFs in a morphologically complex cell, 
such as an astrocyte or neuron, may be different than that of basic cellular models utilized for 
live imaging to study IF dynamics. In fact, it is well known that neurofilaments determine axon 
caliber and mature neurofilaments are present within axons383. Neurofilament aggregates often 
located multifocally along axon in GAN as opposed to the perinuclear space in the soma166. It 
would be interesting to examine whether IF aggregates form upon a filament scaffold or by an 
alternative mechanism in different subcellular regions.  
6.6 IFs and the spatial protein quality control system 
Beyond the IF scaffold hypothesis, the spatial protein quality control (PQC) system 
provides another potential explanation for the perinuclear localization of IF aggregates. The 
spatial PQC system includes different subcellular compartments that 1) protect the cell by 
spatially separate misfolded proteins from the remainder of the cytosol and 2) facilitate 
proteostasis by bringing together misfolded proteins with protein folding or degradation 
machinery384. Q-bodies are one spatial PQC compartment that forms very early and usually 
mediate protein degradation through the ubiquitin proteasome system (UPS)385. It is possible that 
the small GFAP foci are observed localizing along IFs are sequestered within q-bodies. 
Intriguingly, one of the major PQC compartments localizes to the perinuclear space and is called 
the juxtanuclear quality control compartment (JUNQ)386. It has been shown that vimentin forms 
a cage around JUNQ and mediates asymmetric cell division of aggregated proteins387. Q-bodies 
that are unable to clear misfolded proteins coalesce to form JUNQ385. We have not performed 
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colocalization studies of JUNQ or other spatial PQC components with IF aggregates, but it will 
be important to examine in order to understand IF aggregate dynamics. Future experiments 
should be done to examine whether normal IFs interact with or scaffold other spatial PQC 
compartments in addition to JUNQ.  
6.7 Limitations of iPSC-astrocyte models 
 Although iPSC-astrocytes provide a human cell type-specific context to examine disease 
mechanisms, it is important to indicate the limitations. The cell culture environment is clearly 
different from in vivo conditions in many ways: substrate stiffness, diversity of cell types, and 
serum in the media. Moreover, a major criticism of iPSC models is that even with careful 
differentiation, it is difficult to generate functionally mature cell types388. With this level of 
developmental immaturity, it can be challenging to identify functional deficits and to model 
neurodegenerative diseases that are progressive and do not show molecular signs or cause patient 
symptoms until later in life. Since we examined two pediatric neurodegenerative diseases for 
which patients demonstrate symptoms within the first few years of life, we do clearly visualize 
the cellular hallmark of RF-like inclusions. Notably, two other groups used 2-dimensional AxD 
iPSC-astrocytes to identify functional defects in organelle positioning, cell trafficking, and cell-
cell communication160,163. Furthermore, in our GAN model, we utilize 3-dimensional iPSC brain 
organoid technology, which yields functionally mature astrocytes348.  
 Additionally, iPSC lines can be incredibly variable in terms of gene expression and 
differentiation capacity349,350. Because AxD is a rare disease we were unable to obtain more than 
the publicly available cell line described in the results section. We did not introduce patient 
mutations into ‘healthy’ controls, as it is often done, because AxD phenotypes are likely 
influenced by patient background genetic modifiers132. Therefore, one limitation is that we only 
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examine one iPSC line from a patient with Type I AxD. Future comparison of our findings in 
iPSC lines derived from patients diagnosed with Type II AxD would support our findings. 
However, we were able to obtain post-mortem brain tissue from biobanks to bolster our 
conclusions from the AxD iPSC-astrocytes. In the future, we will obtain iPSC lines from other 
laboratories that have generated other iPSC lines from AxD patients160,163. Fortunately, because 
of the incredible efforts of patient family advocate groups in the GAN community, we had access 
to seven different iPSC lines, which strengthens our findings.  
 Lastly, iPSC-astrocytes lack the context of other cell types that exists in vivo. Astrocyte 
processes connect to many different cell types, including neurons, microglia, oligodendrocytes, 
endothelial cells, and pericytes325. Importantly, another group performed co-cultures with AxD 
iPSC-astrocytes and oligodendrocytes and discovered that AxD iPSC-astrocytes secrete 
cytokines that inhibit oligodendrocyte progenitor cell function160. While we begin to address the 
issue of co-cultures by generating 3-dimensional brain organoids that contain both neurons and 
astrocytes, there are still several cell types missing. The protocol we utilized to generate the 
iPSC-brain organoids specifically inhibits differentiation of mesoderm and thus, microglia338. 
This is a particularly important limitation for studies involving neurodegenerative disorders that 
do not involve a primary astrocyte defect because microglia can promote astrocyte reactivity 
through cytokines389. Moreover, organoid technology has not advanced to include 
vascularization, so astrocyte interactions with the BBB cannot be examined in the current 
system. On the other hand, simpler systems involving fewer cell types can be very useful for 
identifying basic mechanisms before moving to a more complex in vivo environment. In the 
future, co-cultures and organoids incorporating microglia and vascular cells should be pursued to 
elucidate non-cell autonomous mechanisms in AxD and GAN.  
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6.8 Future outstanding questions 
 In summary, my thesis work introduced new tools, methods, and disease models and 
mechanisms to examine IF dynamics in health and disease. By developing methods to identify 
new IF PTMs, screen for IF-selective small molecules, and model IF-associated diseases in 
human astrocytes, I added to the growing arsenal of tools that can be used to elucidate the 
mechanisms of IF and astrocyte dysfunction in neurodegenerative disorders. In the future, these 
tools should be used to address the following outstanding questions in the field: 
1. Deciphering the PTM code in IF-associated diseases. 
a. Which kinase(s) regulate phosphorylation at serine 13 of GFAP, and is this site 
conserved in other IF aggregates? 
b. Do other PTMs contribute to GFAP aggregation? 
c. Can targeting PTM enzymes that regulate IF proteins improve IF proteostasis in 
AxD and GAN? 
2. Understanding dynamics of IF aggregation. 
a. Are IF aggregates protective, toxic, or both? 
b. What is the mechanism of IF aggregation? What are the differences between 
mutant GFAP (AxD) and wild-type GFAP (GAN) aggregation?  
c. How are astrocytic IF aggregates spatially controlled? 
d. Do GFAP and vimentin enter the nucleus? 
3. Examining the impact of IF aggregation on cellular functions. 
a. How do nuclear invaginations affect transcription, mRNA metabolism, and 
nuclear export? 
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b. Why do GFAP aggregates contain RNA binding proteins (RBPs)? Are RBPs 
involved in RF formation, or simply sequestered as a consequence? 
c. How does astrocytic IF aggregation affect astrocyte functions, especially support 
of other cells? 
4. What genetic modifiers and environmental factors contribute to differences in disease 
severity?  
a. One recent study performs whole exon sequencing of 31 AxD patients (13 young, 
18 adult) to detect genetic modifiers and identify several candidates, including 








Batch specific product 
name 
Brief description Batch Concentration/ 
Solvent 
0114 NMDA Selective NMDA 
agonist 




Group I agonist 4 10mM DMSO 
solution 
0169 (RS)-AMPA Selective AMPA 
agonist 
25 10mM DMSO 
solution 
0180 ZAPA sulphate Agonist at ‘low 
affinity’ GABA 
receptor. More potent 
than GABA muscimol 
3 10mM DMSO 
solution 
0186 cis-ACPD Potent NMDA 
agonist. Also group II 
mGluR agonist 
3 10mM DMSO 
solution 
0188 L-Quisqualic acid AMPA/group I mGlu 
agonist 
31 10mM DMSO 
solution 
0189 DNQX Selective non-NMDA 
antagonist 
12 10mM DMSO 
solution 
0197 Homoquinolinic acid Selective, potent 
NMDA agonist 
7 10mM DMSO 
solution 
0216 L-Cysteinesulfinic acid NMDA and mGlu 
agonist 
18 10mM DMSO 
solution 
0222 Kainic acid Potent excitant and 
neurotoxin 
60 10mM DMSO 
solution 
0223 Kynurenic acid Broad spectrum EEA 
antagonist 
55 10mM DMSO 
solution 
0225 Quinolinic acid Endogenous NMDA 
agonist and 
transmitter candidate 
7 10mM DMSO 
solution 
0234 Guvacine hydrochloride Specific GABA 
uptake inhibitor 






21 10mM DMSO 
solution 
0237 7-Chlorokynurenic acid Potent competitive 
inhibitor of L-
glutamate uptake 
5 10mM DMSO 
solution 
0245 2-Hydroxysaclofen Selective GABAB 
antagonist, more 
potent than Cat. No 
0246 
19 10mM DMSO 
solution 
0246 Saclofen Selective GABAB 
antagonist 
12 10mM DMSO 
solution 
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0254 (S)-AMPA Selective AMPA 
agonist. Active isomer 
of (RS)-AMPA (Cat. 
No. 0169) 
25 10mM DMSO 
solution 
0281 (R)-(+)-HA-966 NMDA partial 
agonist/antagonist, 
acts at glycine site 
11 10mM DMSO 
solution 
0282 (S)-(-)-HA-966 NMDA 
antagonist/partial 
agonist 
6 10mM DMSO 
solution 









Broad spectrum EAA 
ligand 




Highly potent NMDA 
receptor agonist 




















4 10mM DMSO 
solution 
0342 (RS)-3,5-DHPG Selective group I 
mGLu agonist 




Standard κ selective 
antagonist 
9 10mM DMSO 
solution 
0348 2-BFI hydrochloride Potent, selective I2 
ligand. Putative 
agonist 













Nicotinic agonist 2 10mM DMSO 
solution 
0357 N-Acetyltryptamine Melatonin partial 
agonist (MT1/MT2). 
Also MT3 antagonist 






acts ion channel site 
 
1 10mM DMSO 
solution 
0373 NBXQ Potent AMPA 
antagonist. More 
11 10mM DMSO 
solution 
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selective than CNQX 
(Cat. No. 0190) 
0378 A-7 hydrochloride 
 
Calmodulin antagonist 1 10mM DMSO 
solution 
0382 Arecaidine but-2-ynyl 
ester tosylate 
Muscarinic agonist 1 10mM DMSO 
solution 
0383 Arecaidine propargyl 
ester tosylate 
Muscarinic agonist 2 10mM DMSO 
solution 
4231 Nateglinide Kir6 (KATP) blocker; 
displays high affinity 
for SUR1/Kir6.2 
channels 
1 10mM DMSO 
solution 
0386 3-Methyl-GABA Activator of GABA 
amino-transferase 
1 10mM DMSO 
solution 
0387 (RS)-Atenolol β1 antagonist 5 10mM DMSO 
solution 










isomer of atenolol 
(Cat. No. 0387) 
















2 10mM DMSO 
solution 
0411 MDL 73005EF 
hydrochloride 
Potent and selective 5-
HT1A partial agonist 
1 10mM DMSO 
solution 
0412 MDL 72832 
hydrochloride 
Potent 5-HT1A ligand 
 
2 10mM DMSO 
solution 




3 10mM DMSO 
solution 






3 10mM DMSO 
solution 




3 10mM DMSO 
solution 
0421 GBR 12909 
dihydrochloride 
 
Selective DA uptake 
inhibitor. Also σ 
ligand 






1 10mM DMSO 
solution 




2 10mM DMSO 
solution 
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0426 L-693,403 maleate 
 
High affinity σ ligand 
 
1 10mM DMSO 
solution 








Protein kinase C 
activator 
2 10mM DMSO 
solution 
0431 ML 9 hydrochloride 
 
Myosin light chain 
kinase inhibitor 










Protein kinase C 
activator 
2 10mM DMSO 
solution 















Potent and specific 5-
HT3 agonist 
 
















Calpain and cathepsin 
L inhibitor 
3 10mM DMSO 
solution 
0454 Carbetapentane citrate 
 
High affinity σ1 
ligand 

























5-HT1 agonist. Also 
has high affinity for 5-
ht5a and 5-HT7 
7 10mM DMSO 
solution 











activator of ENaCδ 





M1 > M2 




Partial α agonist. Non-
selective 






Partial α agonist. Non-
selective 
 






1 10mM DMSO 
solution 
































Standard selective κ 
agonist 






Standard selective κ 
agonist. More active 
enantiomer of (±)-U-
50488 (Cat. No. 0495) 
5 10mM DMSO 
solution 








Binds to flavoproteins 
and inhibits NOS 
2 10mM DMSO 
solution 
0506 Dimaprit dihydrochloride 
 
Standard H2 selective 
agonist 
2 10mM DMSO 
solution 
0507 Dantrolene, sodium salt 
 Ca2+ release inhibitor 
4 10mM DMSO 
solution 
0511 BD 1008 dihydrobromide 
 
Potent, selective σ 
ligand 
2 10mM DMSO 
solution 






1 10mM DMSO 
solution 






3 10mM DMSO 
solution 








α1, β1 and β2 agonist 
 





















agonist. Also has 
moderate affinity for 
5-HT7 
12 10mM DMSO 
solution 
0535 HEAT hydrochloride 
 
Highly selective α1 
antagonist 
1 10mM DMSO 
solution 








GHB receptor ligand 
 
1 10mM DMSO 
solution 
0541 Fasudil hydrochloride 
 
 
Inhibitor of cyclic 
nucleotide dependent- 
and Rho-kinases 




Protein kinase C 
inhibitor 




Potent σ antagonist 
 
2 10mM DMSO 
solution 





Also σ ligand 






1 10mM DMSO 
solution 




2 10mM DMSO 
solution 




11 10mM DMSO 
solution 






























Acylator of PCP and σ 
receptors 





Potent, standard H3 
agonist 
 
12 10mM DMSO 
solution 









H3 agonist, less active 
enantiomer 
 
3 10mM DMSO 
solution 
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1 10mM DMSO 
solution 






Has moderate affinity 
for 5-ht5 and high 
affinity for 5-ht6 and 
5-HT7. Also 
antagonist at 5-HT1 
and 5-HT2 




K+ channel (KATP) 
opener 
3 10mM DMSO 
solution 












2 10mM DMSO 
solution 
0589 PRE-084 hydrochloride 
 
Highly selective σ1 
agonist 












HT1D ligand. Has 
moderate affinity for 
5-HT6 and high 
affinity for 5-HT7 






3 10mM DMSO 
solution 




4 10mM DMSO 
solution 








Ca2+ channel blocker 
(L-type) 




Ca2+ channel blocker 
(L-type) 












1 10mM DMSO 
solution 





inhibitor; orally active 






Protein kinase C 
inhibitor 




5-HT release inhibitor 
 
11 10mM DMSO 
solution 
0620 4-PPBP maleate 
 
Specific σ ligand, 
NMDA antagonist 
2 10mM DMSO 
solution 
0623 Prazosin hydrochloride 
 
 
α1 and α2B 
antagonist. MT3 
antagonist 










Potent, selective α1 
antagonist 
2 10mM DMSO 
solution 




2 10mM DMSO 
solution 










Potent α2C antagonist 
 





inhibitor of IKK-2 






2 10mM DMSO 
solution 














H3 antagonist and H4 
inverse agonist 
15 10mM DMSO 
solution 
0646 HTMT dimaleate 
 
H1 / H2 agonist 
 
2 10mM DMSO 
solution 








Inhibits ACh transport 
 





Potent, specific ligand 
for mitochondrial DBI 
receptor 





Potent, specific ligand 
for mitochondrial DBI 
receptor 
2 10mM DMSO 
solution 
0600 Mepyramine maleate 
 
Selective H1 inverse 
agonist 
2 10mM DMSO 
solution 













1 10mM DMSO 
solution 









standard H2 agonist 
2 10mM DMSO 
solution 








9 10mM DMSO 
solution 
0671 AH 6809 
 
EP1 and EP2 receptor 
antagonist 
3 10mM DMSO 
solution 




1 10mM DMSO 
solution 




preferential action at 
D2-like autoreceptors 














1 10mM DMSO 
solution 
0685 Diltiazem hydrochloride 
 
Ca2+ channel blocker 
(L-type) 






3 10mM DMSO 
solution 










1 10mM DMSO 
solution 
0695 Retinoic acid 
 
Endogenous retinoic 
acid receptor agonist. 
2 10mM DMSO 
solution 
0699 BRL 52537 
hydrochloride 
Potent and selective κ 
agonist 






1 10mM DMSO 
solution 









Highly potent 5-HT1B 
agonist. Also 5-HT3 
antagonist 





acts glycine site 




Dopamine agonist (D3 
≥ D2 < > D4) 













D3 agonist (D3 > D2) 
 
3 10mM DMSO 
solution 




1 10mM DMSO 
solution 




1 10mM DMSO 
solution 
0725 BU 224 hydrochloride 
 
 
Potent, selective I2 
ligand. Putative 
antagonist 
4 10mM DMSO 
solution 
0726 BU 239 hydrochloride 
 
Potent, highly 
selective I2 ligand 






prevents increase in 
NOS mRNA 
1 10mM DMSO 
solution 




2 10mM DMSO 
solution 
0729 Imetit dihydrobromide 
 
Standard H3 and H4 
agonist (H3 > H4) 





DA release inhibitor 
 
 

















5-HT4 agonist. Also 
5-HT3 antagonist 
 












12 10mM DMSO 
solution 
0741 GF 109203X 
 
Protein kinase C 
inhibitor 




Very potent NMDA 
antagonist 
5 10mM DMSO 
solution 




Inhibitor of histamine 
binding at the 
intracellular binding 
site 











σ ligand, σ1 > σ2 
 
1 10mM DMSO 
solution 




1 10mM DMSO 
solution 









Highly potent H3 
antagonist and H4 
partial agonist 










Na+ channel blocker 
 




Retinoic acid analog; 
RARα agonist 




Retinoic acid analog; 
RAR agonist 





σ1 selective ligand 
 
 
1 10mM DMSO 
solution 
0764 SNC 80 
 
Highly selective non-
peptide δ agonist 




MAO-A and MAO-B 
inhibitor 
2 10mM DMSO 
solution 











acts at ion channel site 
9 10mM DMSO 
solution 




antagonist. D3 partial 
agonist. 




Potent κ agonist 
 




Potent, selective H3 
antagonist 






3 10mM DMSO 
solution 
0781 L-694,247 
 5-HT1D agonist 






Displays some D4 
selectivity 
1 10mM DMSO 
solution 
0783 N-MPPP Hydrochloride 
 
Selective κ agonist 
 
1 10mM DMSO 
solution 
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6 10mM DMSO 
solution 


























α2 agonist. Also I1 
ligand 
4 10mM DMSO 
solution 




1 10mM DMSO 
solution 
0792 Efaroxan hydrochloride 
 
α2 antagonist and I1, 
I3 ligand 
2 10mM DMSO 
solution 
0793 Idazoxan hydrochloride 
 
α2 antagonist. Also I2 
ligand 







inhibitor. Sodium salt 
of 7-nitroindazole 
(Cat. No. 0602) 







Selective group I 
mGlu agonist. Active 
enantiomer of 3,5-
DHPG (Cat. No. 
0342) 
31 10mM DMSO 
solution 








Very selective β2 
antagonist 
1 10mM DMSO 
solution 








Potent, selective H2 
antagonist 
















Potent H2 antagonist, 
active in vivo 






β antagonist. More 
active enantiomer of 
propranolol (Cat. No. 
0624) 







β antagonist. Less 
active enantiomer of 
propranolol (Cat. No. 
0624) 






2 10mM DMSO 
solution 






2 10mM DMSO 
solution 
0839 DHBP dibromide 
 
Ca2+ release inhibitor 
 




High affinity ligand 
(σ1 = σ2) 













Potent inhibitor of 










Group II/group III 
mGlu antagonist. 
More selective for 
group II than group III 
1 10mM DMSO 
solution 










inhibitor (AMPA > 
kainate) 




Potent, selective NK1 
antagonist 





acts glycine site 
3 10mM DMSO 
solution 




2 10mM DMSO 
solution 
0871 AMT hydrochloride 
 
Potent, selective iNOS 
inhibitor 
3 10mM DMSO 
solution 
0876 AM 92016 hydrochloride 
 
KV channel blocker 
 















Also CB1 agonist 







agonist. FAAH and 
PAA substrate 





Selective inhibitor of 
NO-sensitive guanylyl 
cyclase 






1 10mM DMSO 
solution 
0882 ZM 226600 
 
KATP channel opener 
 
1 10mM DMSO 
solution 
0883 BD 1063 dihydrochloride 
 
Selective σ1 ligand, 
putative antagonist 














α2 agonist. Also I2 
selective ligand 






Selective α1 agonist 
 








High affinity I2 
ligand. Highly 
selective 








Na+ channel blocker. 
Also I2 imidazoline 
ligand 














Standard δ2 selective 
antagonist 























melatonin MT3 ligand 






iNOS inhibitor, acts 
arginine binding site 






Standard δ1 selective 
antagonist 























acts glycine site 














K+ channel blocker 
(KATP) 












































































acts at ion channel site 









like antagonist. Also 
5-HT2C agonist 














































Standard H3 agonist. 
Also H4 agonist 


































































β1 selective partial 
agonist 












(-)-MK 801 maleate 
 
NMDA antagonist, 
less active enantiomer 














Agonist at polyamine 
site 























of AMPA receptors 






















Highly selective α2B 
antagonist 




RS 79948 hydrochloride 
 
Potent, selective α2 
antagonist 




RS 56812 hydrochloride 
 
5-HT3 partial agonist 
 




RS 67333 hydrochloride 
 
5-HT4 partial agonist 
 




RS 67506 hydrochloride 
 
5-HT4 partial agonist 
 



































5-HT2 antagonist. Has 
moderate affinity for 
5-ht6 





























function modulator (If 
inhibitor) 






Highly selective D4 
antagonist 
5 10mM DMSO 
solution 
1004 
 L-741,742 hydrochloride 
Highly selective D4 
antagonist 




















QX 314 bromide 
 
Na+ channel blocker 
 








5-HT3 ligand. Also 
shows affinity for 
zacopride binding site 






















Potent group I mGlu 
antagonist 

















α7 neuronal nicotinic 
receptor antagonist 


























































Activator of epithelial 
Kca channels 

















Na+ channel blocker 
 














water soluble form of 
NBQX (Cat. No. 
0373) 












































































β3 partial agonist. 
More active 
enantiomer of 
pindolol (Cat. No. 
0994) 














A3 selective agonist 
 







active H2 antagonist 






I1 selective ligand 
 













agonist. More water 
soluble form of (RS)-
AMPA (Cat. No. 
0169) 







Ca2+ channel blocker 
(L-type) 














σ1 selective agonist 
 








Potent GABA uptake 
inhibitor. Penetrates 
blood brain barrier 




























BU 226 hydrochloride 
 
Potent, highly 
selective I2 ligand 










levels in vivo 























release from mast 
cells 






















Potent β2 agonist 
 






Highly selective A3 
agonist 






















Highly selective D3 
antagonist 












estrogen and PPARγ 
ligand 




















Potent, selective CB1 
antagonist/inverse 
agonist 




































Potent, selective M1 
antagonist 






α1 antagonist, L-type 
Ca2+ channel blocker 
















α1 antagonist, L-type 




























Selective PI 3-kinase 
inhibitor 





















Also MAO inhibitor 














β3 partial agonist. 
β1/β2 antagonist. 































Potent NK1 antagonist 
 







Ca2+ influx inhibitor 














Selective inhibitor of 
p38 MAPK 






Selective EP1 receptor 
antagonist 



































mGlu5 antagonist and 
positive allosteric 
modulator at mGlu4 






Specific inhibitor of 
MEK 








mGlu5 antagonist and 
positive allosteric 
modulator at mGlu4 


























































antagonist. Also TRP 
channel modulator 






























translocation to Golgi 






Inhibitor of SERCA 
ATPase 








Used to characterize 
NR2B-containing 
NMDA receptors 














D3 agonist (D3 ≥ D2 
> D4) 




































































































inhibitor of p38 
MAPK 








p53 inhibitor. Also 
aryl hydrocarbon 
receptor agonist 















Potent, selective κ 
antagonist 























CI 966 hydrochloride 
 
Selective inhibitor of 
GAT-1 






















Selective inhibitor of 
mitotic kinesin Eg5 






































Potent, selective c-Raf 
inhibitor 














Potent, selective α2D 
antagonist 























































PDE4 inhibitor. More 
active enantiomer of 
12 10mM DMSO 
solution 
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PDE4 inhibitor. Less 
active enantiomer of 
rolipram (Cat. No. 
0905) 






α7 neuronal nicotinic 
receptor antagonist 




U 99194 maleate 
 
Potent, selective D3 
antagonist 

















of A1 receptors 




























































GCP II inhibitor 
 







Raf1 kinase inhibitor 









peptide NPY Y5 
antagonist 






Potent, selective CB2 
ligand 









































DCPG (Cat. No. 
1395) 




























Potent, selective Src 
inhibitor 












inhibitor. Also inhibits 
GSK-3 



















Inhibitor of ligand 
binding to G-protein-
coupled receptors 





 Potent PARP inhibitor 





SB 203580 hydrochloride 
 
 
Selective inhibitor of 
p38 MAPK; water-
soluble 








Potent activator of 
Ca2+ channels (L-
type) 






Selective inhibitor of 
BTK 






Potent, selective Src 
inhibitor 







peptide δ antagonist 

























Arrests cell cycle in 
G1 phase 





















Full κ agonist, partial 
μ and δ agonist and 
antagonizes agonist-
induced activation of 
NOP 









conductance and hIK1 
K+ channels 




















































































1 10mM DMSO 
solution 
1448 
 Formoterol hemifumarate 
Potent and selective 
β2 agonist 



























Potent inhibitor of 
VEGFR tyrosine 
kinase 




























Cardiac Na+ channel 
blocker. 
Antiarrhythmic 








GABA mimetic and 
GABA modulatory 
agent 

































Irreversible δ agonist 
 






GPR55 agonist. Also 
PPARα agonist 

















Novel and selective 
JNK inhibitor 






σ2 antagonist. Also 
DAT inhibitor 






















α1 and α2B antagonist 
(α1 > α2B). Orally 
active 









































Potent and selective 
β3 antagonist 


















Positive modulator at 
GABAB receptors 






Positive modulator at 
GABAB receptors 



















High affinity α4β2 
and α6β2 subtype-
selective agonist 











































Activates a novel cold 
receptor. Cooling 
agent 

















































Selective Cdc25 dual 
specificity 
phosphatase inhibitor 






Protein phosphatase 1 
and 2A inhibitor 
























Active metabolite of 
oxcarbazepine (Cat. 
No. 3684) 


























High affinity selective 
A3 agonist 


































Potent 5-HT uptake 
inhibitor. Also inhibits 
dopamine and 
noradrenalin uptake 

























HT7 antagonist. Brain 
penetrant 









inhibitor of TGF-βRI, 
ALK4 and ALK7 




































antitumor and induces 
diabetes 











blocks ion channel 
and allosteric 
modulatory site 

















of AMPA currents; 
selective for non-













Inhibitor of hedgehog 
(Hh) signaling. Also 
inhibits cholesterol 
synthesis 




































Inhibitor of tubulin 
polymerization. 
Antitumor in vivo 


























Active in vivo 









































2 10mM DMSO 
solution 
1663 
 BW 373U86 
Potent, selective non-
peptide δ agonist 
1 10mM DMSO 
solution 
1664 
 GW 1929 
Selective PPARγ 
agonist. Orally active 
3 10mM DMSO 
solution 
1671 
 PD 102807 
Selective M4 
antagonist 









































agonist. Orally active 































Also adenosine uptake 
inhibitor 





























































like agonist. Orally 
active 








Potent, selective A1 
agonist 
 








Potent, selective A1 
agonist 
 









inhibitor; may be 
selective for COX-3 

















adenosine A2 receptor 
agonist 

















Highly potent D2-like 
antagonist. Also 5-
HT1A agonist 






Standard selective β 
agonist 

















Activator of caspase-3 
 






Selective inhibitor of 
myosin II 


































Selective 5-HT uptake 
inhibitor 






















α1 antagonist. Also 5-
HT1A receptor 
agonist 









inhibitor. Also inhibits 
IκBα phosphorylation 






Inhibitor of NF-κB 
activation 





Selective inhibitor of 
GAT-1 









NOP agonist; brain 
penetrant 








Highly potent 5-HT3 
receptor antagonist. 
Also 5-HT4 agonist 






Potent inhibitor of 
anandamide uptake 














kallikrein and plasmin 




















LTD4 /LTE4 receptor 
antagonist 



















blocker; inhibits rapid 
delayed rectifier K+ 
current (IKr) 

























Also inhibits other 
protein kinases 






















Potent ETB antagonist 
 




















































Potent PPARδ agonist 
 

















Restores mutant p53 
activity; induces 
apoptosis 








Potent SOC inhibitor; 
blocks capacitative 
Ca2+ entry 





















Selective inhibitor of 
skeletal muscle 
myosin II ATPase 
activity 






Cdk inhibitor. Also 
inhibits GSK-3 
















Inactive analog of m-
3M3FBS (Cat. No. 
1941) 











































modulator at mGlu5 
















































Potent, selective p38 
MAPK inhibitor; 
orally active 

































Selective facilitator of 
5-HT uptake; 
antidepressant 



































inhibitor; orally active 


































partial inverse agonist 




























Positive modulator at 
GABAB receptors 














Ca2+ channel blocker 
(L-type) 














Selective high affinity 
glucocorticoid agonist 









p38 MAPK inhibitor; 
anti-inflammatory 
agent 








Selective human A2B 
receptor antagonist; 
water-soluble 






















human A3 receptor 
antagonist/inverse 
agonist 

















FXR and displays 
hypolipidaemic 
activity 














HT3, H1 and α2-
antagonist. 
Antidepressant 






Potent and selective 
A1 antagonist 





 Potent RAR agonist 





























selective α2 agonist 























































active enantiomer of 
UBP 296 (Cat. No. 
2078) 








Class III receptor 
tyrosine kinase (RTK) 
inhibitor 

































































tumor cell apoptosis 





















cancer cell apoptosis 
















Highly potent and 
selective 5-HT uptake 
inhibitor 

















KATP channel opener 
and NO donor 






Potent, orally active 5-
HT uptake inhibitor. 












PPARγ partial agonist 























kinase 4 (cdk4) 
inhibitor 
















Potent and selective 
non-peptidic NPY Y5 
antagonist 












Inhibitor of X-linked 














cytochrome c release 








Selective inhibitor of 
Rac1-GEF interaction; 
antioncogenic 




























































































Potent and selective 
CCK1 antagonist 









inhibitor of mitotic 
kinesin Eg5 















acting D2-like agonist 






































Very potent and 
selective β3 partial 
agonist 






Ca2+ channel blocker 
(T-type) 










Highly selective and 
potent non-peptide 
NPY Y5 receptor 
antagonist 







NPY Y1 antagonist 








5-HT2C agonist and 
5-HT2A/2B partial 
agonist 









blocks If pacemaker 
current 







































Potent, selective D4 
partial agonist; 
proerectile 


















potent PPARδ agonist 














Potent, selective TrkA 
inhibitor 












Partial agonist at α7-
containing receptors 
and antagonist at α4β2 
neuronal nicotinic 
receptors 









amine: activates β3 
adrenoceptors 







































Agonist selective for 
estrogen-related 
receptors ERRβ and 
ERRγ 








Highly selective Ca2+ 
channel blocker (T-
type) 

























Inhibits NGF binding 
to p75NTR and TrkA 







































Very selective and 
potent A1 receptor 
agonist 








I1 receptor and α2-
adrenoceptor agonist 
(I1 > α2) 





















Silent antagonist for 
putative abnormal-
CBD (Cat. No. 1297) 
receptor 















affinity M2 antagonist 































analog and potent FP 
receptor agonist 
















Highly potent and 
selective PPARγ 
antagonist 






Selective α7 nAChR 
agonist 








Potent, orally active 
ghrelin receptor 
agonist 



















Potent, orally active 
human glucagon 
receptor antagonist 












soluble salt of DNQX 
(Cat. No. 0189) 




QX 314 chloride 
 
Na+ channel blocker 
 








Potent H3 agonist, 
highly selective over 
H4 








Potent and selective, 
competitive antagonist 
of TRPV1 


















Potent SNRI; active 
metabolite of 
sibutramine (Cat. No. 
2290) 








Novel inhibitor of 
non-apoptotic cell 
death (necroptosis) 






Selective D4 receptor 
partial agonist 








K+ channel blocker 
and potent ACh 
release enhancer 


























Potent PAF receptor 
antagonist 







affinity H4 agonist 










A1, A2B and A3 
antagonist and 
inhibitor of p38 
MAPK and PDE4 




















Selective inhibitor of 
eIF2α 
dephosphorylation 












Potent and selective 
glycine site 
antagonist. Orally 
available and active in 
vivo 







inhibitor; orally active 








Potent liver X 
receptor (LXR) 
agonist 









affinity CB2 receptor 
partial agonist 






Potent 5-HT6 agonist 
 







The first selective 
mGlu7 agonist 
 







Potent and selective 
mGlu5 antagonist 



































































High affinity NK1 
receptor antagonist 






Na+ channel blocker 
 







Inhibitor of Aβ42 
fibril formation 




























Selective inhibitor of 
EGFR-kinase 








Negative control of 
LY 294002 (Cat. No. 
1130) 



















































JNJ 10191584 maleate 
 
 
Selective H4 receptor 
antagonist; orally 
active 






Selective inhibitor of 
PKCβII 










Derivative of mGlu1 
antagonist YM 
298198 (Cat. No. 
2448) 























































Potent cdk4/cyclin D1 
and CaM Kinase II 
inhibitor. Antiviral 
agent (anti-HCMV) 






Inhibits Aurora kinase 
B 












SDZ WAG 994 
 
Potent, selective A1 
agonist 











soluble form of UK 
14,304 (Cat. No. 
0425) 






















Selective agonist for 
the GPR109B (HM74) 
receptor. Antilipolytic 




ER 27319 maleate 
 
Selective Syk kinase 
inhibitor 








Selective farnesoid X 
receptor (FXR) 
agonist 





GW 3965 hydrochloride 
 
 
Orally active liver X 
receptor (LXR) 
agonist 









inhibitor of VEGFR-2 
 








Inhibitor of AP-1 
transcription factor; 
antitumor agent 






H1 receptor agonist 
 




























Inhibitor of human 
telomerase activity 

















Orally active, high 
affinity 5-HT1A 
agonist 

























Potent PARP inhibitor 
 









modulator of α7 
nAChR; active in vivo 








Inhibitor of VEGF 
receptor tyrosine 
kinase 














Potent and selective 
NOP antagonist 

























Inhibits viral DNA 
polymerase; 
antiherpetic agent 






Selective EP4 receptor 
antagonist 

















Broad spectrum MMP 
inhibitor 








Selective inhibitor of 
E-selectin and ICAM-
1 expression 









allosteric modulator of 
GABAA receptors 








Blocker of KV1.5 
channel and IKur 
current 















Selective inhibitor of 
IKK 

























Potent and selective 
RARγ agonist 

















checkpoint kinase 1 
(Chk1) 









farnesoid X receptor 
(FXR) agonist 






Ca2+ channel blocker 
(L-type) 






NTPDase 3 inhibitor 
 










































Also opener of 
KIR2.3 













































Potent FLT3 inhibitor 
 






Na+ channel blocker, 
antiarrhythmic agent 














Selective inhibitor of 
MEK1/2 









kinase 4 (cdk4) 
inhibitor 





 Inhibitor of IKK-2 






Potent ErbB receptor 
family inhibitor 






























sensitive Na+ and 
Ca2+ channels (T-
type) 














Ca2+ channel blocker 
(dual L/N-type) 






Potent and selective 
inhibitor of MMP-13 














Potent and selective 
D3 antagonist 






α2 agonist, putative 
α2C agonist 








Selective inhibitor of 
ATR and ATM 
kinases 






























Also D4 antagonist 






Inhibitor of ubiquitin 
isopeptidase activity 








Potent and selective 
FFA1 (GPR40) 
agonist 






Inhibitor of JNK 
signaling 





















 γ-secretase inhibitor 





























































(PfATP6) of P. 
falciparum 






High affinity σ1 
ligand 


































(SERM), selective for 
ERα 


















Selective CB2 agonist 
 












potentiation and direct 
gating of GABAA 














DNA topoisomerase I 
inhibitor; antitumor 

















DNA topoisomerase I 
inhibitor; antitumor 

















Potent and selective 
MET inhibitor 






Selective inhibitor of 
Chk1 and Wee1 






Vitamin D3 analog 
 






















Selective inhibitor of 
TGF-βRI 






Toll-like receptor 7 
(TLR7) agonist 






Potent and selective 
CXCR2 antagonist 






Selective inhibitor of 
Mnk1 









agonist at α4β2 
receptors 






Inhibitor of vesicular 
monoamine transport 




Caffeic acid phenethyl 
ester 
Specific inhibitor of 
NF-κB activation 




















Selective inhibitor of 
P-selectin-mediated 
cell adhesion 




















Highly selective CB2 
agonist 



















and 5-HT uptake 
inhibitor. 
Antidepressant 










PI 3-kinase inhibitor, 
more potent than LY 
294002 (Cat. No. 
1130) 









inhibitor. Also inhibits 
TGF-βRI 






Selective inhibitor of 
p38α and p38β2 












SCIO 469 hydrochloride 
 
Selective p38 MAPK 
inhibitor 






Selective inhibitor of 
PLK1 and PLK3 




















Also inhibits KIT, 
RET, MET and FLT3 




H 89 dihydrochloride 
 
Protein kinase A 
inhibitor 








Src family kinase 
inhibitor; also inhibits 
c-Abl 



























and mTOR inhibitor 




























PDGFR, VEGFR and 
FGFR inhibitor 

































Potent and highly 
selective EP3 
antagonist 






Potent and selective 
A1 antagonist 






Potent and selective 
MCH1 antagonist 









antagonist and 5-HT 
re-uptake inhibitor 
















EGFR inhibitor. Also 
inhibits Aβ42 fibril 
formation 




















Restores mutant p53 
activity; proapoptotic 






Selective ERβ agonist 
 


















PAR2 receptor agonist 
 
















Potent and selective 
GlyT1 inhibitor 






Pan RXR agonist 
 









nuclear aggregation of 
PKCι; proapoptotic 













inhibitor factor (MIF); 
suicide substrate 




























CaM kinase III (eEF-2 
kinase) inhibitor 
























Orally active, potent 
H1 antagonist. Also 
hERG K+ channel 
blocker. 






Purine analog; inhibits 
DNA synthesis 




























Potent and selective 
ERβ agonist 



















inhibits wnt signaling 





































Potent and selective 
ATM kinase inhibitor 

















agonist at MT1 and 
MT2 






Hec1 inhibitor; causes 
arrest of mitosis 







































Potent and selective 
PLD1 inhibitor 






Highly selective A1 
agonist 






Potent and selective 
GPR30 agonist 






Potent P2X4 receptor 
antagonist 












PIM 1 Inhibitor 2 
 
Pim-1 kinase inhibitor 
 





































Potent and selective 
ErbB2 inhibitor 




















inhibitor. Also inhibits 
CK1 






















































Group I p21-activated 
kinase (PAK) 
inhibitor 









allosteric modulator of 
M5 receptors 






p38 MAPK inhibitor 
 






Dual site Src kinase 
inhibitor 






Potent and selective 
CCR3 antagonist 









in mature skeletal 
muscle cells 









inhibitor of eIF2α 
dephosphorylation 




BAN ORL 24 
 
Potent and selective 
NOP antagonist 






Activator of KCa3.1 
and KCa2 channels 







Potent and selective 
NPY Y5 antagonist 








High affinity and 
selective GPR30 
antagonist 



















 Selective CAR agonist 



















M2 proton channel 
blocker 
 






Potent and selective 
P2X7 antagonist 

















inhibitor. Also JAK2, 
JAK3 inhibitor 





























































































High affinity 5-HT1A 
agonist 














H2 antagonist, I1 
agonist 

























water soluble form of 
CNQX (Cat. No. 
0190) 




PD 168077 maleate 
 
High affinity, 
selective D4 agonist 









inhibitor of MEK1 
and 2 






Potent, selective BTK 
inhibitor 




























KATP channel opener 
 















cromakalim (Cat. No. 
1377) 






IKs blocker. Also 
blocks ICFTR 








Highly potent and 
selective 5-HT uptake 
inhibitor 













(Cat. No. 1412) 






Highly potent ERβ 
agonist 

































































Ca2+ channel blocker; 
binds allosterically to 
distinct site on L-type 
channels 








Inactive analog of 
U0126 (Cat. No. 
1144) 








Selective inhibitor of 
MEK1 and MEK2; 
brain penetrant 














KATP channel opener 
 












Prodrug of KATP 
channel opener Y-
26763 (Cat. No. 
2076); orally active in 
vivo 































High affinity H3 
ligand 












NVP DPP 728 
dihydrochloride 
Potent, orally active 
DPP-IV inhibitor 







Free radical trapping 
agent; neuroprotectant 


















kinesin Eg5 inhibitor 

















allosteric modulator at 
mGlu4 






























Ca2+ channel blocker 
(L- and T-type) 
 






























H3 receptor inverse 
agonist/antagonist 























inhibits wnt signaling 

















modulator of α7 
nAChR 




















of MAO-A, MAO-B 
and LSD1 































































with some D4 
selectivity. Also 5-
HT2A/2C antagonist 
















Highly potent H1 
antagonist. Also binds 
to H4 receptor 








Active metabolite of 
methysergide (Cat. 
No. 1064) 






Dual AChE and BChE 
inhibitor 






















α2 agonist. Also I1 
ligand 






Glucosidases α and β 
inhibitor 








Peripherally acting μ 
agonist. Also Ca2+ 
channel blocker 










antagonist at 5-HT1D 






Antagonist, partly D2 
selective 







































β3 partial agonist 
 





































 Muscarinic agonist 





 Nicotinic agonist 






























































Inhibitor of SERCA 
ATPase 





 Disrupts microtubules 









of α7 nicotinic 
receptors 























Inhibitor of tubulin 
 


















Inhibitor of protein 
synthesis. 
Antileukemic agent 




















antiplatelet agent in 
vivo 























inhibitor (COX-1 > 
COX-2) 

































































Potent 5-HT3 receptor 
antagonist; orally 
active 


























































Selective M1 agonist 
 









inhibitor, acts arginine 
binding site 
1 10mM DMSO 
solution 
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